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1 Zusammenfassung 
Die Fehlpaarungsreparatur (auf englisch, mismatch repair oder MMR) einer Zelle hat die 
Aufgabe, Mutationen, die durch Fehlbasenpaarung in unserem Genom entstehen, zu 
verhindern. Demzufolge korrigiert es biosynthetische Fehler in unserer DNS 
(Fehlpaarung von Basen, Insertionen und Deletionen) die waehrend der Replikation 
eingebaut werden koennen. Ihre Aufgaben umfassen nicht nur die Überprüfung der 
Lesefunktion der Polymerasen waehrend der Replikation, sondern auch die meiotische 
und mitotische Rekombination, die Stabilität von repetitiven Trinukleotiden und die 
Reaktion auf DNS-Schäden. 
SN1-methylierenden Substanzen wie Temozolomid und Dacarbazin und aehnlichen 
nicht-klinischen Substanzen wie N-Methyl-N-nitro-Nitronitrosoguanidin (MNNG) und N-
Methyl-N-Nitrosoharnstoff (MNU) verursachen eine Vielzahl von Addukten. Obwohl die 
meisten davon veraenderte Stickstoffatome von Purin-basen sind, ist die Toxizitaet 
dieser Substanzen nicht darauf zurückzufuehren, sondern auf O6-methylguanin (meG). 
Dieses Addukt ist jedoch fuer weniger als 8% der Methylierungen in der Zelle 
verantwortlich und ist trotz dessen das einzige toxische Addukt. 
Die Fehlpaarungsreparatur spielt eine wichtige Rolle bei den zellulaeren Antworten auf 
diese Wirkstoffe. Inwiefern die Prozessierung der meG-Addukte bei MMR waehrend der 
Replikation für den Zelltod im zweiten Zellzyklus verantwortlich ist, bleibt jedoch eine 
offene Frage.  
Es gibt zwei Hypothesen, die versuchen Klarheit über das Thema zu bringen. Die erste 
besagt, dass die repetitiven Reparatur-versuche der Fehlpaarungsreparatur den 
Schaden zu korrigieren, der sich aber im Eltern-doppelstrang befindet und deshalb nicht 
korrigierbar ist, den Zelltod bringen. Dies wurde die Tatsache erklaeren, dass zellulaere 
Checkpoints erst im zweiten Zellzyklus deutlich aktiviert werden, und nicht gleich nach 
der Fehlpaarungs-erkennung. Das zweite Model behauptet, MMR koenne direkt mit 
zellulaeren Checkpoint-Proteine interagieren und somit auf eine sehr direkte Weise den 
Checkpoint aktivieren. Dieses Model basiert auf wissenschaftlichen Publikationen, die 
Interaktionen zwischen MMR Proteinen und Checkpoint-Proteinen nachgewiesen haben. 
Eierextrakte aus dem Frosch Xenopus laevis sind eine etablierte Methode, um 
Replikationsabhängige Signalkaskaden zu untersuchen. Sie erlauben die in vitro 
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Replizierung von spezifische DNS Vorlagen und dienen dazu, die Dynamik waehrend 
der Replikation unter verschiedenen Bedingungen naeher zu untersuchen. In unserem 
Fall war die Replikation nicht-methylierter und methylierter DNS von Interesse. In dieser 
Studie wurde wissenschaftlich nachgewiesen, dass MMR Proteine und Checkpoint-
Proteine nicht unbedingt gleichzeitig zu meG in der DNS rekrutiert werden. Darueber 
hinaus wurde festegestellt, dass keine MMR-abhänginge Aktivierung eines Checkpoints 
sofort nach Erkennung der meG-Substrate stattfindet. Dabei zeigte sich, dass ein 
transienter Checkpoint nach Erkennung von MMR Substraten zwar zu sehen ist, aber 
dies nicht meG spezifisch ist. Hinzu kommt, dass MMR-abhängige Zwischenprodukte in 
der DNS nachgewiesen werden konnten. Diese entstehen durch die Reparaturversuchen 
des MMR Systems von meGs in der DNS und wirken sich tatsächlich negativ auf eine 
weitere Replikation aus. Zum Schluss sind wir zu der Erkenntnis gekommen, dass die 
Erkennung von meG-Substraten bei der Fehlpaarungsreparatur nicht ausreichend ist, um 
das Phänomen des Zelltodes im zweiten Zyklus zu erklären. 
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2 Abstract 
The mismatch repair system is part of the cellular machinery assigned to obfuscate 
mutations that might perturb canonical base pairing in the genome. As such it corrects 
DNA biosynthetic errors (base-base mismatches and insertion-deletion loops) that arise 
during replication. Its functions extend beyond proofreading errors of replicative 
polymerases, to meiotic and mitotic recombination, triplet repeat stability and the DNA 
damage response. 
SN1-type methylating agents such as temozolomide and dacarbazine and their non-
clinical counterparts N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-
nitrosourea (MNU) generate a variety of lesions. Of these, more than 80% are modified 
purine nitrogen atoms, but their toxicity appears to result from the processing of O6-
methylguanine (meG) despite the fact that this lesion only accounts for up to 8% of the 
generated lesions.  
MMR has been found to be a major player in checkpoint and apoptotic responses 
attributed to this type of damage. To what extent MMR-dependent processing of the 
adducts during replication is the ultimate cause of cell arrest/death remains a topic of 
discussion. Currently, two models tackle the involvement of MMR in the processing of 
methylation-induced damage. The first posits that MMR activates damage signaling 
indirectly through its repetitive attempts at processing meG lesions in the template strand 
during replication. This would accommodate the fact that the MMR-dependent cell cycle 
arrest in G2/M is only observed in the second cycle and not immediately after meG 
recognition by the repair machinery. Alternatively, binding of the MMR system to the 
mismatch is sufficient to trigger kinase activation. This model is mainly substantiated by 
reported interactions between MMR and the ATR checkpoint machinery upon treatment 
with SN1-type alkylators.  
The Xenopus egg extract technique has surfaced as a unique tool for analysis of 
replication-dependent DNA damage signaling. This experimental system initiates 
replication on defined templates within a biochemical setup and is able to closely follow 
the dynamics of template replication. In our case, it enabled the study of MMR activity 
during replication of alkylation damaged and undamaged DNA templates. 
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Here, we show that recruitment of the ATR checkpoint machinery to sites of alkylation 
damage, or more specifically O6-methylguanine, is not simultaneous with that of MMR 
proteins. Furthermore, an accumulation of meG/T mispairs during replication, a preferred 
MMR substrate, is in itself not enough to trigger prolonged checkpoint activation. Finally, 
we show that gaps arise in DNA due to MMR-dependent meG processing behind the fork 
and that they largely escape checkpoint surveillance. In conclusion, these results 
substantiate that mere presence of either meG/C or meG/T in the DNA during a first round 
of replication is an unlikely cause for checkpoint activation and the G2 arrest seen during 
the second cell cycle, and that it is rather the presence of meG-dependent gaps which can 
be deleterious to further replication. 
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3 Introduction 
"Just as physics and chemistry are based on molecules and atoms, even so the 
biological sciences must penetrate to these units in order to explain by their 
combinations the phenomena of the living world" Hugo de Vries (taken from "The 
Century of the gene", Evelyn Fox Keller, Harvard University Press, 2002). 
3.1 Eukaryotic DNA replication 
The sequencing of the human genome, completed in April of 2003, marked a 
breakthrough in 21st century biology. Science has come a long way since Watson, Crick, 
Wilkins and Franklin first identified DNA as a base-paired double-helical structure in the 
1950s. How this information, our genome, is passed on from cell to cell, generation to 
generation, producing identical copies of the original double-stranded DNA is studied in 
the field of DNA replication. Replication is the process by which a cell copies its DNA 
during a synthesis phase (S phase) prior to mitotic cell division (M phase). It is semi-
conservative in the sense that it produces two copies that each contain one of the 
original strands and one new strand. Pertinent to this thesis is a focus on eukaryotic DNA 
replication and the replication machinery made up of a plethora of evolutionarily 
conserved proteins. Although, as in any field of study, there are still open questions 
pertaining to all the steps involved, significant progress has been made in its 
understanding and I will summarize the most crucial aspects and novel discoveries of the 
past years. 
DNA replication requires pre-replication complex (pre-RC) formation just prior to S phase 
and origin firing at the start of it (see Fig. 1). The assembly of the pre-RC starts with the 
origin recognition complex (ORC) complex (ORC1, 2, 3, 4, 5 and 6) recognizing DNA 
origins and the loading of the replicative helicase in late M of the cell cycle. This hexamer 
composed of the minichromosome maintenance (MCM2-7) proteins loads as a double 
hexamer [1, 2] in a manner dependent on ORC, cell division cycle 6 (Cdc6) and Cdc10 
dependent transcript 1 (Cdt1) [3]. Assembly of the pre-RC on origins occurs only during 
late mitosis to early Gap 1 phase (G1) in order to prevent rereplication. Activation of the 
pre-RC and origin firing is not detected until S phase and involves expression and activity 
of two kinases, cell division cycle 7 (Cdc7) and cyclin dependent kinase 2 (Cdk2), as well 
as recruitment of proteins such as DNA topoisomerase 2-binding protein 1 (TopBP1), 
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Cdc45, MCM10 and the GINS (from the Japanese go-ichi-ni-san meaning 5-1-2-3, after 
its four related subunits Sld5, Psf1, Psf2 and Psf3) complex.  
 
Figure 1. Origin unwinding and elongation at eukaryotic replication origins. 
Formation of the pre-RC complex preceeds origin firing. This involves binding of MCM2-7 
proteins in a manner dependent on ORC, Cdt1 and Cdc6 in late M/G1. Activation of DNA 
replication by the Cdk2 and Cdc7 kinases triggers binding of additional factors such as 
Cdc45, MCM10, GINS, RPA and the replicative polymerases (α, ε, δ). Proteins involved 
in elongation of the DNA include RFC, PCNA and MCM10. Adapted from [4] 
 
Recently identified TopBP1 interactors, GEMC1 (geminin coiled-coil domain-containing 
protein 1) and Treslin have a role in loading of Cdc45 onto the chromatin [5-7]. With 
regards to the kinase activity neccessary for initiation, Cdc7 phosphorylates the MCM2-7 
subunits, which is thought to facilitate loading of factors such as Cdc45 and MCM10. 
Cdk2 targets have not been clearly identified although the ReQL4 protein, a homolog of 
ORC
CDT1 TopBP1CDC6
MCM2-7
Cdk2Cdc7
MCM10
Cdc45
GINS
RPA
Pol !
PCNA
Pol " Pol #
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the yeast Cdk2 target Sld2/Drc1 that is required for loading of the RPA heterotrimer after 
origin unwinding, might be a target [8, 9].  
Formation of an active replication fork is achieved through the recruitment of the 
replicative polymerases α, ε, δ. Pol α primase primes DNA synthesis on both strands, 
whereas Pol ε and pol δ elongate the leading and lagging strand, respectively [10]. 
TopBP1 and GINS might cooperate in loading pol ε onto origins, whereas Ctf4/And1 and 
MCM10 were shown to be important for pol α stability and replicative function. In 2011, a 
study recapitulating in vitro replication in yeast observed that MCM10 depletion affects 
leading but not lagging strand polymerase recruitment. This could be observed by 
monitoring pol δ  and pol ε  association with chromatin [11]. 
Although a corelation between replication and histone acetylation had been noted 
previously [12] it is now known that the post-translational modification me2H4K20 
(dimethylated lysine 20 on histone 4) is bound by the BAH (bromo adjacent homology) 
domain in ORC1, directly linking the methylome to DNA replication. me2H4K20 is 
enriched at replication origins and possibly aids selection of replication origins [13]. Also 
of note, although ORC binding sites have been proposed in different eukaryotic 
organisms, there is no consensus as to the nature of the DNA sequence and the way in 
which ORC is recruited to DNA. With regards to this, an ORC interacting protein was 
identified in a mass spectrometric analysis of ORC-interacting proteins. ORC-
associated/leucine rich repeats and WD repeat domain containing 1 (ORCA/LWD1) is 
crucial for ORC association to chromatin and has been shown to be capable of artificially 
recruiting ORC to a specific genomic locus [14]. Other players involved in DNA 
replication have been reported. They can be proteins, for example, MCM8 and MCM9,  
required for replication elongation but not initiation in Xenopus egg extracts [15, 16] or 
perhaps more surprisingly, RNA. 
Small, stem-loop RNAs, Y RNAs, first identified as part of Ro ribonucleoprotein particles 
in higher eukaryotes, interact with ORC and other pre-RC components and seem to be 
accordingly required for replication initiation [17]. Intriguingly, many of these replication 
proteins are known to function outside of replication during S phase. For example, MCM8 
and 9 were shown to also play a role in repair of lesions requiring homologous 
recombination [18], highlighting the crosstalk between the replication machinery and 
DNA repair pathways. 
INTRODUCTION 
 
 
 
10 
 
3.2 Cellular DNA repair pathways 
DNA damage accumulates in a cell through exposure to several types of exogenous and 
endogenous agents such as sunlight, cigarette smoke, reactive oxygen and nitrogen 
species, etc. In response to this asault, cells have developed vital tolerance and repair 
mechanisms to ensure the perpetuity of their DNA. The following chapter of this thesis 
will focus on the description of the main DNA repair pathways of a cell. 
3.2.1 Direct DNA damage reversal 
This pathway refers to repair systems in a cell which lack the broad substrate specificity 
and the requirement for multiple steps to accomplish repair. It is simple and often narrow 
in its substrate choice. The primary type of lesions addressed by direct DNA damage 
reversal are generated by alkylating agents. Endogenously, the metabolite S-
adenosylmethionine (SAM), is known to weakly methylate DNA. Significant alkylation 
damage in DNA is generated upon exposure to agents such as the SN1-type alkylators 
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N-nitrosourea (MNU) or the 
SN2-type alkylator methyl methanesulfonate (MMS). SN1-type alkylators cause a variety 
of N- and O-alkylated products. MNU and MNNG, for example, generate about 70% N7-
methylguanine, 9% N3-methyladenine, 8% O6-methylguanine and 2% N3-
methylguanine, amongst others [19]. While most of these adducts are efficiently repaired 
by the multistep base excision repair (BER), O6-methylguanine (meG) is a well known 
example of a lesion that can be repaired in a single step. In humans, it requires O6-
methylguanine-methyltransferase (MGMT), also referred to as alkylguanine transferase 
(AGT). Both the human and the E. coli version of this protein transfer the methyl group 
from the guanine to an internal cysteine residue in what is known as a suicide reaction 
since it leads to the irrevocable degradation of the enzyme [20]. The E. coli protein, Ada, 
is composed of an N- and C-terminal part separated by a hinge region. The C-terminal 
part repairs meG and O4-methylthymine while the N-terminal part demethylates methyl 
phosphotriester lesions in DNA. This is part of an adaptive response to the increased 
sensoring of damage [21]. A second O6-methylguanine methyltransferase, Ogt, is 
constitutively expressed and handles lower amounts of the modified guanine even 
though it shows preference for O4-methylthymine [22]. In the clinic, inhibition of MGMT 
using pseudosubstrate nucleotide analogs such as O6-(4-bromothenyl)guanine (Patrin-2) 
and O6-benzylguanine (BG) is of particular interest when attempting to sensitize cells to 
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killing by alkylating agents [23]. Another set of lesions generated by alkylators, in this 
case, SN2-type alkylators, are N1-methyladenine and N3-methylcytosine [24]. These are 
repaired via oxidative demethylation by alkB alkylation repair homolog 2 (ABH2) and 
ABH3, human homologues of the E. coli AlkB protein. However, whereas ABH2 prefers 
double-stranded DNA, ABH3 and AlkB favour single-stranded DNA and RNA [25]. 
3.2.2 Mismatch repair 
 
Figure 2. Determinants of replication fidelity. The relative contribution of the three 
main components of replication fidelity, the estimated error rate for different families of 
polymerases and the mutation rate of the in vivo complete replication process. Taken 
from [26]. 
 
The mismatch repair (MMR) framework is designed to improve the replication fidelity of 
replicative polymerases by several orders of magnitude (see Fig. 2), be it by correcting 
base-base mismatches or by counteracting polymerase slippage which leads to the 
formation of insertion/deletion loops in DNA [27]. The accuracy of eukaryotic DNA 
synthesis is estimated to be at least as efficient as that of E. coli or bacteriophage 
replication. That is, with a base substitution error rate ranging from 10-7 to 10-8 or, in other 
words, lower than one error for every billion or more base pairs  [26, 28, 29].  
A better understanding of mismatch repair is aided by a comparison between the 
prokaryotic and eukaryotic mismatch repair machineries, thereby identifying important 
similarities and adaptation from a less evolved to a more evolved organism. A brief 
summary summary of the two systems is offered below and Table 1 provides an 
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For leading strand synthesis, a polymerase then binds and 
extends the primer in a continuous fashion for as long as 
the polymerase is able to stay bound. For replication of the 
lagging strand, a discontinuous mode of synthesis occurs 
in patches of ~250 base pairs called Okazaki fragments, 
each of which must be initiated by pol !-primase activity 
[4]. The complexity of the system is illustrated by the fact 
that five decades after the discovery of the structure of 
DNA, uncertainty still remains as to the identity of major 
leading and lagging strand DNA polymerase(s) [4, 7]. In 
mitochondria, pol " is responsible for all DNA synthesis 
activities [8, 9]. The importance of accurate replication of 
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Figure 1 Determinants of replication fidelity. (A) The relative contribution levels of the three main components of replication 
fidelity are shown above the scale, estimated from the mutation rates of systems defective in one or more of the components. 
The overlapping ovals represent the fact that there is a range of possible increases in the level of fidelity that each mechanism 
provides dependent on many factors. The range of fidelity that a given mechanism is capable of providing is the critical factor 
(i.e. MMR can still provide up to four orders of magnitude increase in fidelity for polymerase errors that occur at a frequency of 10-2). 
The horizontal bars below the graph show the ranges of in vitro determined error rates for the different families of polymerases 
and the estimated mutation rate range of the in vivo complete replication complex. Within each family, the error rates can differ 
widely between polymerases and types of errors. The broken bars at the left and right ends indicate that the rates could be even 
higher and lower than indicated. (B) Graphic depicting the various means by which DNA replication can be modulated. DNA is 
shown as a stylized double helix (backbone is black and gray), with purine-pyrimidine base pairs indicated as red-green and 
blue-purple bars. The single-strand region is meant to depict the unwound DNA at a replication fork, with the kink in the DNA 
representing the bend in the template strand identified by crystallography [119]. Red arrows and text indicate conditions that 
lead to lower fidelity. Green arrows and text indicate conditions that promote higher fidelity, and green bars indicate conditions 
that block mutations. M=Mutation; C=Correct.
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overview of proteins involved in MMR in T. thermophilus, E. coli, S. cerevisiae and H. 
sapiens. 
 
 
Table 1. Distribution of MMR proteins. *1 Involvement has not been confirmed yet. *2 
The endonuclease activity of MLH3 has not been confirmed biochemically. *3 In yeast 
and humans EXO1 has a 5' Flap-endonuclease activity in addition to 5'-3' exonuclease 
activity. Taken from [30]. 
In general, MMR machineries are equipped with the ability to distinguish mismatches in 
DNA, discriminate the parental and daughter strands during replication as well as the 
ability to act bidirectionally. 
3.2.2.1 Prokaryotic mismatch repair 
E. coli MMR has been studied extensively both biochemically and genetically. It has even 
been reconstituted in vitro using recombinant proteins [31]. This system requires the 
following components: MutS, MutL, MutH, DNA helicase II (UvrD), four exonucleases 
(ExoI, ExoVII, ExoX and RecJ), single-stranded DNA binding protein (Ssb), DNA 
Molecular 
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Repair 
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polymerase III holoenzyme and DNA ligase [32]. Mismatches are recognized by the 
MutS homodimer and an interaction with the MutL homodimer [33] is neccessary for 
enhanced activation of the MutH restriction endonuclease. MutH utilizes transient 
hemimethylated dGATC sites to introduce an entry point for excision of the error-
containing daughter strand [34, 35]. This sequence is normally methylated at the N6 
position of adenine in E. coli DNA. Depending on the position of the break relative to the 
mismatch, the aforementioned 5'-3' (ExoVII or RecJ) or 3'-5' (Exo1 or ExoX) 
exonucleases [36] and the UvrD helicase [37] remove this strand, and a new strand is 
synthesized and sealed by DNA polymerase III and DNA ligase. 
3.2.2.2 Eukaryotic mismatch repair 
Several human MMR proteins have been identified based on their homology to the E. 
coli proteins. In this system, however, the main players act as heterodimers and have 
diversified into more substrate-specific proteins. MutS homologue 2 (MSH2) 
heterodimerizes with MSH6 or MSH3 to form MutSα or MutSβ, respectively. Likewise, 
MutL homologue 1 (MLH1)  heterodimerizes with post-meiotic segregation 2 (PMS2) 
(MutLα), PMS1 (MutLβ) and MLH3 (MutLγ). Of the three, only MutLα has a clear function 
during replication. MutLβ is involved in meiotic recombination and MutLγ function remains 
unsolved [38-41]. The minimal human MMR system was reconstituted several years ago 
using recombinant proteins. It is composed of MutSα or MutSβ, MutLα, Exonuclease 1 
(EXO1), replication factor C (RFC), proliferating cell nuclear antigen (PCNA), replicating 
protein A (RPA), polymerase δ and DNA ligase I [42-44]. 
As in E. coli, MMR starts with recognition of a mispaired base in the daughter strand 
during replication (see Fig. 3). How this activity is targeted is not fully clear but, it is 
generally believed that strand breaks in the leading and lagging strand due to damage 
correction by other DNA repair pathways or the presence of 3' and 5' termini at Okazaki 
fragments in the lagging strand, could act as discrimination signals [45]. MutSα  
recognizes base-base mismatches and short insertion/deletion loops. MutSβ binds larger 
IDLs of two to three extrahelical nucleotides [46]. MutLα interacts with the MutS 
heterodimers [47] and this complex coordinates 5'-3' excision by EXO1 [48, 49]. 
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Fig. 3. Schematic representation of eukaryotic mismatch repair (MMR). MutSα 
(MSH2/MSH6) binds a mismatch, recruits MutLα (MLH1/PMS2 heterodimer) and 
translocates along the DNA until it encounters proliferating cell nuclear antigen (PCNA) 
bound at the 3’ terminus of the nick. This ternary complex introduces additional breaks in 
the nicked strand, where exonuclease 1 (EXO1) is loaded. EXO1 generates a long 
single-stranded gap which is stabilized by RPA and then filled in by the PCNA/DNA 
polymerase complex. The remaining nick is then sealed. Adapted from [50]. 
 
Since 3'-5' exonuclease activity in this system has not been identified, the bidirectionality 
of eukaryotic mismatch remained a mystery until it was shown that the PMS2 subunit of 
MutLα and yeast MutLα (MLH1/PMS1) contain a PCNA-activated endonuclease activity 
in their C-termini that can introduce single-strand breaks in the vicinity of the mismatch 
[51-53]. RPA stabilizes the single-stranded DNA region generated by EXO1 excision, 
and resynthesis is taken over by polymerase δ and ligase I [54-57].  
3.2.2.3 Mismatch recognition 
MutS proteins have an ATPase domain that is reponsible for binding and hydrolysis of 
ATP [58]. This enzymatic activity is believed to be important in providing MutS with a 
conformational switch so it may translocate along the DNA attempting to find 
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discontinuities that will support excision of the mismatched nucleotide [59]. MSH2 has 
two distinct interaction regions for both MSH3 and MSH6 (see Fig. 4) at its N- and C-
termini. ATP binding domains are found at its C-terminus of all three proteins. In contrast, 
MLH1 interacts with PMS1, PMS2 and MLH3 only through its C-terminus and has N-
terminal ATP-binding sites. MSH2, MSH3 and MLH1 have been found to interact with 
EXO1 and this interaction is important for the excision step during MMR [60, 61]. A 
further interaction that is important for MMR, at least in vitro, is that between both 
MutSα or MutSβ and PCNA. PCNA is important in mismatch repair as an elongation 
factor for polymerase δ and also in earlier steps of the repair [62, 63]. A conserved motif 
QXX(L/I)XXFF at the N-terminus of MSH6 and MSH3 has been found to be crucial for 
this interaction [64-66]. 
Both bacterial MutS and human MutSα contact the mismatched base through a 
conserved phenylalanine residue (Phe36 in E. coli and Phe432 in human MSH6) that 
intercalates from the minor groove [67]. An adjacent glutamate residue (Glu38 in E. coli 
and Glu434 in human MSH6) forms a hydrogen bond with the mismatched base and is 
also crucial for mismatch recognition. In order for this close contact to be made available 
to the mismatch repair machinery, crystallographic and biochemical data suggest a 
certain a priori flexibility of the DNA at places that contain mismatched nucleotides [67, 
68]. Indeed, mispaired bases weaken base stacking interactions and this, in turn, could 
lead to a propensity toward DNA bending [69]. Paradoxically, although the G:T mismatch 
causes the least amount of double-helix distortion, it remains one of the most efficiently 
repaired MMR substrate [70, 71]. 
Crystal structures of MutS-DNA complexes from E. coli and human cells revealed that 
each MutS protein consists of two DNA-interacting domains, one ATP-interacting domain 
and two connecting domains [72, 73]. Most of the MutS-DNA interactions are with the 
DNA backbone and therefore not nucleotide specific, except for the previously mentioned 
phenylalanine and glutamate residues. 
The ATP-binding cassette is an important factor contributing to mismatch recognition. 
When bound to perfectly matched DNA, ATP is quickly hydrolyzed by MutS, while 
binding to heteroduplex DNA inhibits ATP hydrolysis [74-76]. The ATP-bound dimer has 
greatly reduced affinity for homoduplex DNA, and only marginally reduced affinity for 
heteroduplex DNA [77]. Thus, the MutS-bound ATP complex is released from normal  
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Fig 4.  Interaction among the MMR proteins. Each of the MutS homologues (MSH3, 
MSH6, and MSH2) interacts as a heterodimer with the MutL homologues (MLH1, PMS2, 
PMS1, and MLH3), acting as heterodimers, and the exonuclease, EXOI. Mutations that 
occur in the interactive domains may abrogate the ability of these proteins to interact and 
function in DNA MMR, but, in some instances, the mutations may not lead to 
destabilization and loss of the protein product. The interaction domains among the MutS 
homologues, among the MutL homologues, and between one another are illustrated 
here. Adapted from [78]. 
 
DNA, but not from mismatch-containing DNA, which prolongues the lifetime of the MutS-
DNA-ATP complex. This, together with its inhibited ATPase activity, stabilizes mismatch 
recognition and allows subsequent steps in mismatch repair. 
The current mismatch recognition model [79, 80] suggests a DNA scanning activity for 
MutS. This is based on the observation that bent molecules are seen for both homo- and 
heteroduplex DNA [80]. Upon recognition of a mismatch, a conformational swich in the 
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protein causes kinking of the DNA. Finally, MutSα undergoes a second conformational 
change in which the DNA is unbent with the mismatched base possibly flipped out [81]. 
This final, unbending step, is perhaps a precaution before proceeding with the repair 
reaction. 
3.2.2.4 Overall importance of mismatch repair and role in other metabolic 
pathways 
Defects in mismatch repair predisposes to tumors of the colon, endometrium and other 
organs [82], and confers a mutator phenotype known as microsatellite instability (MSI) 
which is caused by the faulty repair of insertion/deletion loops during replication. One 
such MSI-displaying cancer is human-non-polyposis-colon-cancer (HNPCC), or Lynch 
syndrome, a cancer of the digestive tract. The first hint of this correlation was provided in 
the 1990s when germ-line mutations in MSH2 were observed in HNPCC families [83-
86]). To date, mutations and epigenetic silencing in MSH2, MLH1, PMS1, MSH6 and 
PMS2 have been linked to this disease (although the latter three are rarely found) and 
account to 40-50% of these cancers [82, 86-88]. Germline mutations in MSH3 have not 
yet been identified in this context. As was expected from the known MMR functions, 
mouse knockout models for Msh2, Msh3, Msh6, Mlh1, Mlh3, Pms1, Pms2 and Exo1 [49, 
89, 90] showed mice that were cancer-prone due to a mutator phenotype that became 
evident when analyzed for MSI. Table 2. summarizes these phenotypes. 
Aside from its replicative function, mismatch repair proteins are also involved in other 
processes such as meiotic and mitotic recombination, immunoglobulin class-switching, 
somatic hypermutation, the stability of trinucleotide repeats, the repair of interstrand 
crosslinks and the DNA damage response [50, 83, 91-95].  
Recent years have provided further insight into this intriguing pathway. Despite an 
evident methyl-directed strand discrimination signal in E. coli a parental-strand/daughter 
strand discriminating signal in eukaryotes remained a puzzle. Recently, an elevated 
incorporation of ribonucleotides (rNMPs) into the leading strand was reported [96, 97]. 
Biochemical work by this lab [98] provided evidence that repair of these rNMPs could act 
as entry points for MMR. This observation has sparked interest as to whether hijacking of 
other such lesions by the MMR machinery during replication could be the strand 
discrimination signal in eukaryotes.  
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Table 2. Phenotype of MMR deficient knockout-mice. Taken from [99]. 
Work linking MMR with epigenetic remodelling of chromatin has also surfaced in recent 
years. It appears that permissive chromatin is not only needed for transcription-related 
events, but also for MMR [100-103]. Also thought-provoking, a specific histone 
modification has been proposed to participate in recruitment of MMR to the chromatin 
during replication [104]. It is also likely that MMR proteins are themselves post-
translationally modified. In fact, phosphorylation of MSH6 and MSH2 has been reported, 
even though its precise role is not well understood [105, 106]. Possible modification of 
both proteins by ADP-ribosylation, mainly MSH6, has also been observed in vitro [107, 
108]. These observations add a further layer of complexity to all protein-protein 
interactions published regarding when, where and how these modifications could occur 
on MMR proteins and how they are linked to intact MMR function in cells. 
  
Gene MSI Tumor Fertility 
MSH2 YES LYMPHOMA, G1, SKIN, 
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YES 
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3.2.3 Base excision repair  
The base excision repair (BER) pathway removes damaged bases from our DNA that 
are generated by several endogenous and exogenous chemical alterations in the cellular 
environment [109]. It begins with recognition of the damaged base by a DNA 
glycosylase, of which there are 11 known in humans (see Table 3) [110, 111]. The 
glycosylase removes the damaged nitrogenous base by flipping it out of  the DNA and 
cleaving the N-glycosidic bond. The DNA backbone remains intact, but this activity 
creates an apurinic/apyrimidinic (AP) site which is then targeted by an 
apurinic/apyrimidinic (AP) endonuclease such as (APE1). The phosphodiester bond is 
then cleaved 5' to the AP site, generating a nick or single-strand break (SSB) in the DNA. 
Monofunctional glycosylases lack lyase activity and depend on polymerase β to remove 
the 5'-deoxyribose phosphate and proceed to insert a new, undamaged nucleotide to the 
3' end of the nick [112]. A bifunctional glycosylase has both glycosylase and AP lyase 
activity that removes the base and cleaves the phosphodiester bond 3' to the AP site. 
Repair is completed by the X-ray repair cross-complementing protein 1 (XRCC1)-DNA 
ligase IIIα complex [113, 114], which seals the nick. This would be a classical short-patch 
BER reaction. 
A variation of this is long-patch BER [115], which occurs when processing of the damage 
by the glycosylase leads to SSBs that cannot be sealed. Polymerase β then inserts a 
nucleotide into the nick, and proteins such as polymerase δ, PCNA and RFC displace the 
strand further, creating a 2-12 nucleotide flap. Flap endonuclease 1 (FEN1) removes this 
structure and the final nick is sealed by DNA ligase I [116]. 
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Table 3. Overview of human DNA glycosylases. Glycosylases are listed as 
monofunctional or bifunctional. MPG, 3-methyladenine DNA glycosylase; UNG, uracil 
DNA glycosylase; OGG1, 8-oxoguanine glycosylase; NTH1; Neil1/2/3, Nei-like 
glycosylase; SMUG1, single-strand selective monofunctional uracil DNA glycosylase; 
TDG, Thymine DNA glycosylase; MBD4, methyl-CpG binding domain 4; 3-meA (3-
methyladenine), 8-oxoG (8-oxoguanine), Tg (thymine glycol), hoU (5-hydroxyuracil), hoC 
(5-hydroxycytosine), FapyG/FapyA (formamidopyrimidine derivatives of guanine or 
adenine), hmU (5-hydroxymethyluracil), fU (5-formyluracil). Adapted from [111].  
 
 
Human 
glycosylase 
Type Substrates 
MPG monofunctional 3-meA, hypoxanthine 
UNG monofunctional uracil 
OGG1 bifunctional 8-oxoG, FapyG 
NTH1 bifunctional Tg, hoU, hoC, urea, FapyG 
NEIL1 bifunctional Tg, hoU, hoC, urea, FapyG, FapyA 
NEIL2 bifunctional AP site, hoU 
NEIL3 bifunctional unknown 
MYH monofunctional A:8-oxoG 
SMUG1 monofunctional hoU, hmU, fU 
TDG monofunctional T:G mispair 
MBD4 monofunctional T:G mispair 
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Fig. 5. Schematic overview 
of base excision repair 
(short-patch). The first step 
is the recognition of a 
damaged base (blue) by a 
DNA glycosylase. This 
enzyme flips the base out of 
the DNA and cleaves the N-
glycosidic bond, creating an 
AP site (pink). The sugar-
phosphate backbone is then 
cleaved by an AP 
endonuclease, which creates 
a nick in the DNA. Then DNA 
polymerase β fills in the gap 
with the correct nucleotide 
and the XRCC1/ligaseIIIα 
complex seals the nick. 
Adapted from [117].  
 
3.2.4 Nucleotide excision repair 
The term nucleotide excision repair (NER) is ascribed to a repair pathway that senses 
distortion in the DNA rather than a specific substrate. It is of vital importance, since it 
adresses adducts generated by dietary mutagens (nitrosamines, aflatoxin), through 
exposure to pollutants in the air (benzo(a)pyrenes) and, last but not least, sunlight (UV-
induced cyclobutane pyrimidine dimers or (6-4)pyrimidine-pyrimidine photoproducts).  
NER also repairs lesions induced by crosslinking agents. These can either covalently 
bond DNA on the same strand (intrastrand crosslink) or across both strands (interstrand 
crosslink) (Nouspikel, 2009). The latter is repaired by a combination of NER together with 
other pathways, and it is recognized as a type of repair on its own, namely, interstrand 
crosslink repair (see 3.2.7). An important subset of NER, transcription-coupled repair 
(TCR), is coupled to transcription and was first documented in 1985. This study showed 
that removal of pyrimidine dimers (CPDs) was very efficient in an expressed gene [118]. 
RNA polymerase II stalled at a lesion is the sensor in this sub-pathway [119].  
polymerase !"
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Fig. 6. Schematic overview of nucleotide excision repair (NER). Left, global genome 
repair (GGR) removes lesions such as UV-induced pyrimidine dimers throughout the 
genome. Lesions are recognized by the XPE and XPC complexes. Subsequently, other 
proteins are recruited to the site for further verification and dual incision by structure 
specific endonucleases XPG and XPF/ERCC1 enables the removal of the damage-
containing oligonucleotide. The repair patch is then filled in and sealed by replicative 
polymerases and ligases I and III. Right, transcription-coupled repair (TCR), a sub-
pathway that repairs actively-transcribed genes upon RNA polymerase II stalling. The 
two pathways converge after damage recognition. Here, recognition is mediated by the 
Cockayne syndrome group A (CSA) complex when the lesion stalls RNA polymerase II. 
Adapted from [120].   
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All other NER in the cell is known as global genome repair (GGR).  The principal disease 
associated with defects in this repair pathway is Xeroderma pigmentosum, which can be 
caused by mutations in seven proteins of this pathway (XPA-XPG) and is characterized 
by sensitivity to sunlight accompanied by cancer predisposition [121]. In fact, the name of 
several NER players stems from their involvement in the disease. For example, the 
Xeroderma pigmentosum complementation group C protein is known as XPC.  
Sensoring of the bulky DNA lesion is pivotal in this pathway and is the first repair step 
[122] (see Fig. 6). Distorted, chemically-modified DNA can be recognized by  
XPC/HR23B/Centrin2 [123]. Of the three, XPC is believed to perceive the distortion 
[124], Centrin2 improves its efficiency and HR23B might play a role in XPC ubiquitination 
[125], which in turn, increases affinity for the damaged DNA. Another complex involved in 
lesion recognition is the DNA damage binding protein (DDB) complex, a heterodimer 
consisting of DDB1 and DDB2(XPE) [126]. This particular complex can exist as a 
component of a Cul4/RBX1-based multisubunit E3 ubiquitin ligase not only for GGR, but 
also within TCR. In this repair scenario, however, it  acts within a Cockayne syndrome 
group A (CSA)/CSB complex [127, 128]. A striking difference of the two paths of 
recognition is that in TCR, a substrate, CSB, is targeted for degradation via 
ubiquitination, whereas in the other, the ubiquitin ligase activity leads to XPC 
polyubiquitination but not to its degradation [129]. The role of the TFIIH complex, which is 
comprised of 10 subunits (ERCC2(XPD), ERCC3(XPB), p62(TFIIH1), p52(TFIIH4), 
p44(TFIIH2), p34(TFIIH3), TTDA, CDK7, MAT1, and Cyclin H), is to ensure the formation 
of a denaturation bubble spanning the lesion [130]. Althought the precise function of all of 
these subunits is not known, the XPD and XPB helicases play an important function in 
opening up the DNA [131], although in the case of XPB it is its ATPase, rather that its 
helicase function, which is required [132].   
A further gap in knowledge is provided by the involvement of XPA [133]. It is associated 
with RPA [134], absolutely required for the repair and it might aid in discriminating the 
lesion-containing strand from the intact DNA strand, but this possibility has not been 
conclusively explored. The next step requires incision on either side of the denatured 
bubble so that a damage-containing fragment of 25-30 nucleotides in length can be 
excised. XPG cuts 3' to the lesion and XPF/ERCC1 5' to the lesion [135, 136]. The 
penultimate step requires filling of the generated gap by replicative DNA polymerases 
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such as pol δ and ε (Popanda & Thielmann, 1992). The repair is completed upon ligation 
of the nicked DNA. Previously, it was believed that ligase I carried out this task. More 
recent data identified ligase III together with its partner XRCC1 as the main ligase 
involved [137]. 
3.2.5 Double-strand break repair 
Double-strand breaks (DSBs) are breaks in DNA that arise throughout the cell cycle and 
can be successfully repaired in error-prone as well as error-free ways. They are 
generated upon cell irradiation (γ radiation and X-rays) for example, or treatment with 
clastogenic agents, and are also features of replication [138]. Repair of unwanted 
double-strand breaks is distinct from the metabolism of programmed DSBs that are 
required for e.g. lymphocyte development [139], meiotic recombination [140], or 
pathways that mask structures that could resemble DSBs, such as telomere ends [141]. 
Two main pathways of this repair type can be recognized: non-homologous end-joining 
(NHEJ) and homologous recombination (HR) (see Fig. 7). 
3.2.5.1 Non-homologous end joining 
NHEJ can take place throughout the cell cycle, whereas HR can only occur after 
genomic replication when a sister chromatid guides DSB repair [142]. As its name 
implies, NHEJ relies on direct ligation of the broken ends, which is quite inaccurate since 
it can process altered or improper ends. Another form of NHEJ is micro-homology 
mediated end joining (MMEJ), which uses small homologous regions on the two sides of 
the DSB to align the broken strands before joining [143]. NHEJ is an error-prone mode of 
repair, since sequence information is lost . NHEJ is associated with local activation of the 
DNA dependent protein kinase (DNA-PK) which is triggered by the binding of the broken 
ends by the Ku70/Ku80 heterodimer [144]. Often, processing of the ends is required 
before Ku binding. This can be mediated by the protein Artemis for example, a 5'-3' 
exonuclease which acquires endonuclease activity upon phosphorylation by DNA-PK 
and relieves the formation of hairpins within the two strands of the DSB [145]. End-
ligation is performed by DNA ligase IV, together with X-ray cross-complementation group 
4 (XRCC4) and XRCC4-like factor (XLF) [146, 147].  
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3.2.5.2 Homologous recombination 
In HR, 5'-3' resection of the broken ends creates two single-stranded DNA regions. This 
is mediated by the MRN complex meiotic recombination 11 homolog (Mre11)/Nijmegen 
breakage syndrome 1 (Nbs1)/Rad50, Exo1, Dna2, CtBP-interacting protein (CtIP) and 
possibly the Bloom (BLM) helicase [148-151]. This, in turn, leads to recruitment and 
activation of ATM (see 3.4.1). ATM phosphorylates a set of substrates including H2AX, 
creating the DSB marker γH2AX [152]. This phosphorylation signal helps amplify a 
ubiquitination signal in response to DSB and other proteins, for example 53BP1 and 
breast cancer 1 (BRCA1) are recruited to the site [153]. The free 3' ends are then coated 
by RPA, which leads to parallel activation of the ATR kinase in response to DSBs [154]. 
RPA is then displaced by Rad51 and associated factors to form so-called synaptic 
filaments in a BRCA2-mediated manner and this filament can then invade a homologous 
neighbouring sister chromatid and perform a homology search [155, 156]. This creates a 
specific structure, a D-loop, as well as an X-shaped structure called a Holliday junction 
(HJ) [157] and synthesis from the invading 3' strand can occur. In vitro studies have 
implicated pol η in this extension [158]. 
From this point onwards several possibilites are available, depending on the type of 
break and proteins involved. The most prevalent repair type is synthesis-dependent 
strand annealing (SDSA) where regulator of telomere length 1 (RTEL1) reverses the D-
loop and thus prevents an exchange of genetic material beween the homologous 
chromosomes (non-crossover repair). Conversely, realignment or capture of the newly- 
synthesized end forms a double Holliday junction (HJ) [159] structure that can be 
adressed via crossover or non-crossover operations. A complex formed by the Bloom 
helicase (BLM) and TOPOIIIα can dissolve this structure into a non-crossover, the 
structure specific Mus81/EME1 endonuclease can resolve this structure into a crossover 
and HJ resolvases such as GEN1 can resolve the structure in ways that can result in a 
crossover or not [160-162]. Finally, it should be mentioned the HR has a role in 
replication fork restart after stalling due to interstrand crosslinks, for example. 
When it comes to pathway choice, not only do CDKs play an important role in asserting 
activity of pathway players during the cell cycle [163], but this year, a report focusing on 
53BP1 and BRCA1 has shed further light into this matter. These two proteins are 
seemingly antagonistic: 53BP1 promotes NHEJ and BRCA1 promotes HR, yet, they are  
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Fig. 7. Schematic overview of the two main double-strand break repair pathways, 
non-homologous end joining (NHEJ) and homologous recombination (HR). Left, 
NHEJ pathway. The Ku70/Ku80 heterodimer senses the double-strand break (red), 
stabilises the two ends and recruits DNA-PK. DNA-PK phosphorylates and activates a 
complex consisting of ligase IV, XRCC4 and XLF, which religates the broken DNA. Right, 
HR pathway. The MRN complex (Mre11/Rad50/Nbs1) recruits ATM to the damaged site. 
This leads to ATM activation and phosphorylation of multiple substrates. The broken 
ends are resected by the action of proteins such as Mre11, CtIP and Exo1, and Rad51 
coats the ends and then nucleoprotein filaments then invade the undamaged sister 
strand forming Holliday junction (HJ) structures. DNA synthesis and the activity of HJ 
resolvases, structure specific endonucleases or helicases proceed to complete the 
repair. Adapted from [164]. 
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both recruited to DSBs. It was unclear how their accumulation at DSB could set up 
pathway choice. It was reported by the Durocher group that in G1, even though  
expressed, BRCA1 does not form foci due to the recruitment of the Rap1 interacting 
factor 1 (RIF1) to the DSB. This recruitment is somehow mediated by the 
phosphorylation of 53BP1 by ATM. Alternatively, accumulation of RIF1 at DSBs during S 
ahd G2 phases can be inhibited by BRCA1 and CtIP, thus promoting HR. Remarkably, 
depletion of RIF1 can restore DSB repair to resection and Rad51 loading in BRCA1-
depleted cells [165]. 
3.2.6 DNA damage bypass 
DNA damage bypass refers to a tolerance mechanism evolved to aid genome 
replication, albeit at the expense of genome instability by using error-prone translesion 
synthesis (TLS) polymerases that allow circumventing lesions instead of stalling and/or 
slowing down of replication forks. TLS polymerases have a more flexible catalytic pocket 
that allows replication across and past damaged templates at the expense of 
processivity. Examples of TLS polymerases (see Table 4) include pol λ, pol η, pol ι, pol 
κ, pol ζ and REV1 (the latter is believed to act as a scaffold in recruiting other TLS 
polymerases and is a deoxycytidyl transferase rather than a polymerase) [166]. 
Bypass of lesions in this manner is largely regulated by two small proteins, ubiquitin (76 
amino acids) and SUMOs 1-4 (ca. 100 amino acids). At the centre of this is PCNA, which 
acts as a molecular switch for post-translational modification with these proteins mainly 
via its K164 residue. Both ubiquitination and SUMOylation require an E1 conjugating 
enzyme, an E2-activating enzyme and an E3 ligase to modify PCNA, either once (e.g 
monoubiquitinated PCNA, SUMOylated PCNA) or multiple times (e.g polyubiquitinated 
PCNA). The Rad6 E2 ubiquitin conjugator and the Rad18 E3 ubiquitin ligase take over 
monoubiquitination of PCNA both in yeast and humans [167]. Rad18 binds single-
stranded DNA and could thus contribute to the recognition of the damage. 
Polyubiquitination of PCNA requires the yeast E2 Ubcl3-Mms2 and E3 Rad5 ligase but 
the precise trigger for this signal remains unknown [168]. DNA damage-dependent 
monoubiquitinated PCNA supports an error-inducible pathway involving TLS polymerase 
recruitment, whereas polyubiquitinated PCNA is believed to lead to error-free template 
switching. In general, polymerase stalling or exposure of single-stranded DNA is 
considered the trigger for activation of the TLS pathway. Many of these TLS polymerase 
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have been shown to interact directly with PCNA or monoubiquitinated PCNA. For 
example, pol η  has a higher affinity for monoubiquitinated PCNA, which would help 
target it to damage where it would then bypass thymine photodimers [169, 170]. The 
precise role of PCNA SUMOylation on the other hand, remains obscure. It might 
increase the activity of an antirecombinogenic protein, yeast Srs2, to avoid HR and 
 
       Table 4. Overview of human TLS polymerases. 
 
favor bypass. What complicates this scenario is that a human homologue has not yet 
been identified so corroborating this hypothesis will be difficult. Adding salt to injury, 
detection of PCNA SUMOylation in human cells, probably due to its transient nature and 
subtle targetting of PCNA, had not been reported until recently [171, 172]. Nevertheless, 
it should be noted that there are human proteins such as ELG1 that contain SUMO-
interacting domains [173]. This protein is being studied with regard to its possible link to 
replication and participation in HR. Thus, a role of PCNA SUMOylation in human cells 
should not be ruled out [174]. 
TLS polymerases Function 
! (eta) Bypass UV lesions 
"(iota) Bypass synthesis 
# (kappa) Bypass synthesis 
$ (lambda) BER, NHEJ 
µ (mu) NHEJ 
% (theta) DNA repair 
& (zeta) Bypass synthesis 
Rev1 Abasic sites 
' (nu) Unknown 
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3.2.7 Interstrand crosslink repair 
DNA interstrand crosslinks (ICLs) are lesions that covalently link two DNA strands. They 
are extremely cytotoxic, since they present a block for both replication and transcription. 
They are repaired by a combination of different repair pathways, in which the Fanconi 
anemia (FA) pathway takes centre stage (see Fig. 7).  
At least 15 FA gene products are known to be involved in key steps of the repair. Stalling 
of the replication fork upon encountering the ICL is recognized by the FA 
complementation group M (FANCM)/FA associated protein of 24 kDa (FAAP24) 
complex, which also participates in the activation of the ATR pathway. ATR, which is 
recruited to RPA-coated single-stranded DNA in the stalled replication fork, can then 
readily phosphorylate target FA proteins belonging to the core complex (FANCA, B, C, E, 
F, G, L, M) and the FANCI/FANCD2 complex [175, 176]. 
Monoubiquitination of FANCD2 and FANCI is crucial in fueling clear activation of the 
pathway and serves as a recognition marker for interstrand crosslink repair. The E3 
ubiquitin ligase responsible is the FANCL FA core subunit, together with the E2 ubiquitin 
conjugator UBE2T [177, 178]. The monoubiquitinated heterodimer is relocalized to the 
lesion where it coordinates downstream repair events such as the recruitment of 
nucleases like FA-associated nuclease I (FAN1), FANCP(SLX4) , MUS81/EME1 and 
XPF/ERCC1 that can create incisions on one or both sides of the ICL to allow unhooking 
of the lesion [179-181]. The unhooking of the lesion turns a collapsed replication fork into 
a double-strand break (DSB). To overcome this, translesion DNA synthesis (TLS) 
proteins are recruited to the lesion in a manner that remains unclear, and this allows 
bypass of the unhooked crosslinked oligonucleotides and restoration of a nascent strand. 
The homologous recombination (HR) pathway with the aid of downstream FA proteins 
such as FANCD1/BRCA2, FANCJ, FANCN and FANCO, repairs the DSB and NER 
excises the remaining unhooked oligonucleotide. The gap which is left behind is filled in 
by DNA polymerases. 
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Fig. 7. Schematic representation of interstrand crosslink repair. Replication fork 
stalling upon encountering an interstrand crosslink leads to phosphorylation of several 
subunits of the Fanconi anemia (FA) core complex (FANCA, B, C, E, F, G) by ATR and 
recruitment to the lesion by FANCM/FAAP24. The E3 ubiquitin ligase FANCL (a) 
monoubiquitylates the FANCD2/FANCI heterodimer (b), MUS81 cleaves the lesion on 
one side and XPF/ERCC1 unhooks it on the other (c and d). Translesion polymerases 
then fill the gap opposite the unhooked nucleotide (e), which is released by excision 
repair (f). HR then rescues the collapsed fork with the intervention of several proteins 
(e.g. BRCA2, FANCN, likely also FANCJ (f and g)). Adapted from [179]. 
 
Mutations in the FA proteins or disruption of the repair process by, for example, failing to 
deubiquitinate the FANCD2/FANCI complex leads to hypersensitivity to crosslinking 
agents in cells [182]. Indeed, the name for the FA proteins stems from their association 
with the inherited disease Fanconi anemia (FA), a chromosomal instability disorder 
characterized by bone marrow failure,  congenital defects and a predisposition to certain 
types of cancer [183, 184]. 
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The study of this type of repair extends to ICLs occuring outside of replication, and is 
refered to as replication-independent ICL repair. Components of this pathway include 
NER proteins and translesion polymerases such as pol κ and exclude FA proteins or 
Rad51, which is imperative for formation of homologous HR intermediates during the 
replication-coupled repair [185, 186]. 
3.3 Mismatch repair lead DNA damage tolerance and clinical implications 
As previously mentioned, MMR proteins are implicated in HNPCC. It is not clear how 
these mutations arise and what precise molecular consequences play out in these 
patients, but the lack of MMR surveillance during DNA replication is most likely the root 
cause of the genomic instability observed. Ironically, MMR functions are not only 
required for stability that would prevent disease onset, but they are used in a clinical 
setting to treat certain diseases. This is due to the fact that there is a clear link between 
MMR and drug resistance.  
For example, both BER and MMR can remove 5-fluorouracil (FU) from DNA, a drug that 
is used in treatment of colon cancer [187]. MutSβ was recently described to participate in 
this recognition [188]. A MMR-dependent two-fold resistance to cisplatin can also be 
observed. It appears that cells treated with this agent accumulate defects in MMR that 
help them circumvent its toxicity [189-191]. The main adduct generated in this case is a 
1,2-intrastrand crosslink between the N7 atoms of two adjacent purines. This adduct is 
normally repaired by NER, but it was shown in vitro that MutSα could bind this type of 
crosslink [192]. Treatment with this agent induces a rapid arrest during S phase, since it 
presents a block for replicative polymerases and this in turn activates many stress-
response pathways. This response could involve, in part, an interaction between MMR 
and a transcription factor during apoptosis in these cells [193]. In accordance with this, 
induction of MSH2 expression by the p53 transcription factor might take over the repair 
of pyrimidine photodimers cause by exposure to sunlight [194] and contribute to 
resistance to UV damage [195]. Studies in yeast support the notion that there might be 
crosstalk between NER and MMR proteins [196]. 
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Figure 8. Role of MMR in the 
response to alkylators. 
Temozolomide and other SN1-type 
alkylators generate the toxic lesion 
O6-methylguanine (meG, red circle). 
MGMT (O6-methylguanine DNA 
methyltransferase) normally repairs 
this toxic adduct by direct removal of 
the methyl group in a suicide 
reaction. Inhibitors such as Patrin-2 
and O6-benzylguanine (BG) lead to 
MGMT degradation. The MMR 
machinery, which includes the 
MutSα (MSH2/MSH6) and MutLα 
(MLH1/PMS2) heterodimers then 
takes over and elicits cell death 
during a second cell cycle. Adapted 
from [197]. 
 
 
More problematic seems to be the response to agents such as 1-(2-chloroethyl)-e-
cyclohexyl-nitrosourea (CCNU), which generates interstrand crosslinks. A body of data 
report cell sensitivity towards treatment with this agent in a MMR-deficient background 
[198-200]. Since this is the only agent in which MMR defects contribute to sensitivity and 
not resistance this is certainly noteworthy. Since this sensitivity seems to involve 
MutSβ ρecognition of the lesions [201, 202] more studies are neccessary to clarify this 
scenario. 
At the opposite end of the spectrum, the most corroborated and striking MMR-associated 
tolerance to an agent is the 100-fold resistance observed towards SN1-type alkylators 
(temozolomide, MNNG, MNU) in MMR deficient cells. This is of relevance in tumors 
where O6-methylguanine-methyltransferase (MGMT) activity has been inhibited, a 
therapy approach used in the treatment of certain types of melanoma, leukemia and 
glioblastoma [203, 204]. It is generally accepted that O6-methylguanine or meG is the 
primary cytotoxic lesion, since its presence in the DNA leads to the formation of meG/C 
 meG  
MGMT
MGMT inhibitors
(Patrin-2 or BG)
Degradation
Mismatch repair
Futile cycling
MSH2
MSH6
MLH1
PMS2
Strand breaks Apoptosis
Cytotoxicity
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Table 5. Substances with cytotoxicities that are related to MMR status. Taken from 
[54]. 
 
and meG/T mispairs that activate MMR [205] but are irreparable because the meG is in the 
template strand during replication. This leads to a delayed arrest during the second cell 
cycle that is mainly ATR-dependent [206, 207] (see Fig. 8). Interestingly, the homologous 
recombination machinery is required for the damage tolerance during the first S phase 
[208]. This gave rise to speculation as to the nature of the intermediates formed upon 
MMR processing [209]. Treatment with yet another anti-cancer drug, 6-thioguanine, is 
also partially dependent on MMR status. Only a 10-fold resistance to it can be seen in 
MMR-deficient cells, however [210-213]. 
 
mismatch, will translocate along the DNA in a control-
led manner that is dependent on ATP hydrolysis. The 
DNA bending/verification model proposes that MSH 
proteins remain in the vicinity of the mismatch and 
that the communication between the mismatch and the 
strand-discrimination signal involves DNA bending 
rather than protein movement along the DNA54,55. This 
last model is based on studies in E. coli, where it was 
shown that MutH can be activated by mismatch-bound 
MutS–MutL in trans75. This has so far not been dem-
onstrated in a mammalian system. Moreover, as MMR 
excision tracts initiate at the strand-discrimination sig-
nal and proceed ~150 nucleotides past the mismatch 
site, the mismatch position must become free during 
the excision step. This requires that the mismatch recog-
nition complex leaves the mismatch site at some point. 
Indeed, although mismatch-dependent excision was 
activated in the experimental system that was developed 
by Wang and Hays, the repair process failed to proceed 
to completion54,55.
The available evidence, therefore, seems to favour the 
first and second models. As the difference between them 
lies essentially only in the mode of translation of MutS! 
from the mismatch, which does not affect the principle 
mechanisms of the process, they will be discussed as one 
(FIG. 3). An ATP- and mismatch-activated MutS! clamp 
(with or without MutL!) might travel away from the 
mi match in either direction. Clamps that encounter a 
nick that is 5" from the mismatch would first contact an 
RFC mol cule th t is bound at the 5" side of the nick. 
EXO1 could be loaded here, presumably following the 
displacement of RFC, and start the strand degradation 
in the 5"#3" direction, towards and past the mismatch 
(FIG. 3a).
Diffusion of the activated clamp in the opposite 
direction would lead to an encounter with a PCNA 
molecule bound at the 3" terminus of the strand break. 
The RFC molecule that is bound at the 5" side of the 
break would not be displaced by MutS!, and therefore 
no EXO1-mediated degradation in the direction away 
Table 2 | Substances with cytotoxicities that are dependent on the mismatch-repair status
Substance type Substance Cytotoxic metabolite Mode of action
SN1-type 
methylating agents
N-methyl-N-nitrosourea 
(MNU), N-methyl-N"-
nitro-N-nitrosoguanidine 
(MNNG), temozolomide, 
procarbazine, 
dacarbazine, 
streptozotocin
6-O-methyl-2"-deoxyguanosine
O
N
N
N
O
NH2N
O
O
CH3
MeG base pairs with T during 
replication. These lesions are 
unsuccessfully addressed 
by the MMR system, which 
results in a cell-cycle arrest 
in G2
Antimetabolites 6-Thioguanine 6-S-methylthio-2"-deoxyguanosine
O
N
N
N
S
NH2N
O
O
CH3
As above, but two replication 
cycles are required, because 
6-thioguanine has to be 
incorporated into DNA 
before being methylated
Intrastrand 
crosslinking agents
Cis-diammine-
dichloroplatinum (II) 
(CDDP; also known as 
cisplatin) NH
N
N+
S
NH2N
HN
N
N+
O
H2N N
CH3
Pt
NH2H2N This lesion is repaired 
primarily by the NER 
pathway, but if it persists 
until replication, it would 
arrest the replication fork, 
involving MMR proteins in 
the process
Intrastrand 
crosslinking agents
1-(2-chloroethyl)-3-
cyclohexyl- nitrosourea 
(lomustine, CCNU), 
mitomycin-C (MMC)
(DNA adducts of MMC are not well 
characterized)
O
N
N
N
O
NH2N
O
O
Cl
The chloroethyl group can 
react with the opposite DNA 
strand to generate a covalent 
crosslink. Some MMR-
deficient cells are more 
sensitive to these substances 
than MMR-proficient ones. 
The mechanism of MMR 
involvement is unknown
 MeG, methylguanine; MMR, mismatch repair; NER, nucleotide-excision repair;  SN1, unimolecular nucleophilic substitution.
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3.4 Signaling networks in response to DNA damage 
That mismatch repair responds to treatment with various chemotherapeutic and similarly-
acting agents is clear, but what is the nature of the signaling involved? Which main 
pathways elicit MMR-mediated toxicity and what are they activated by? 
A coordinated signaling response to several types of DNA damage is elicited by two 
main kinases which belong to the PIKK (phosphatidylinositol-3-kinase related kinases) 
[214] family: ATM (Ataxia telangiectasia mutated) and ATR (Ataxia telangiectasia and 
Rad3 related). A further PIKK member, DNA-PK, is known to stimulate repair activities 
locally, but without triggering a widespread cellular response. Activation and signal 
transduction by these two main players is mainly associated with phosphorylation events, 
although recent years have underscored the merits of SUMOylation and ubiquitylation in 
these events as well [215]. Members of the PIKK family (see Fig. 9) are large proteins 
(>300 kDa) with the following structures (see Fig. 9): a variable number of repeat 
domains at the N-terminus (HEAT domains), a FAT domain, a catalytic domain 
homologous to that of PI-3 kinase, a PIKK regulatory domain (PRD) and a FATC domain 
at the very C-terminus [216]. 
 
Fig. 9. Diagram of PIKK domain structures. Taken from [216]. 
3.4.1 ATM and ATR 
As mentioned previously, treatment of MMR-proficient cells with SN1-type alkylators 
triggers a G2/M arrest after two cell cycles that is intrinsically linked to the ATR kinase. 
Within DNA damage response networks, ATM and ATR are key regulators in 
vertebrates. They associate with DNA and preferentially phosphorylate substrates at S/T-
Q (serine/threonine/glutamate) residues [217-219]. In general, ATM is activated 
throughout the cell cycle in response to numerous DSBs whereas ATR is activated by 
C.A. Lovejoy, D. Cortez / DNA Repair 8 (2009) 1004–1008 1005
Fig. 1. Diagram of PIKK domain structures showing the locations of the kinase, PRD,
FAT, and FATC domains.
or Rictor (mTORC1 andmTORC2, respectively) [8,9]. Similar to ATR,
the stability of mTOR also depends on it forming a holo-enzyme
complex.
3. Localization
3.1. ATR and ssDNA gaps
ATR appears to be the most versatile of the PIKK family of DNA
damage-responsive kinases, being activated by a variety of DNA
lesions including base adducts, cross-links, DSBs, and compounds
that directly promote replication stress such as hydroxyurea and
aphidicolin. In addition to responding to environmental mutagens
that induce replication stress, ATR is essential for the viability of
replicating cells [7,10]. ATR is activated during every cell cycle to
regulate replication origin firing and repair damaged replication
forks. Disruption of ATR results in an accumulation of DSBs during
S phase, cell cycle arrest or apoptosis, and early embryonic lethality
in mice [7,11].
ATR-activating DNA lesions have in common the ability to
expose single-stranded DNA (ssDNA), often as a consequence of
stalling the replicative polymerases. The relative insensitivity of
the replicative helicase to these lesions causes an uncoupling of
polymerase and helicase activities resulting in ssDNA gaps [12]. The
ssDNA is a common ATR-activating signal [13,14].
ssDNA is rapidly coated by the heterotrimeric ssDNA binding
protein RPA [15]. Several observations have highlighted the impor-
tance of RPA-coated ssDNA in ATR activation. The extent of ssDNA
generated by a lesion influences the amount of DDR activation
observed,with larger regions producing greater ATR activation [12].
Additionally, S. cerevisiae ATR (Mec1) activation is compromised
by mutations in RPA, and knockdown of RPA in mammalian cells
impairs ATR activation [14,16,17]. These defects may be partially
reflective of the important role that RPA has in the recruitment of
ATR to DNA lesions in eukaryotic organisms. ATR–ATRIP recruit-
ment to ssDNA gaps is dependent on both ATR and ATRIP [7,14]. An
evolutionarily conserved RPA binding surface called the checkpoint
protein recruitment domain (CRD) binds an N-terminal domain of
RPA70 [18]. Deletion of the ATRIP CRD severely compromises the
localization of ATR–ATRIP to DNA lesions, although it has only mild
effects on ATR signaling [18,19]. The lack of strong phenotype may
be explained by additional RPA interactions, alternative mecha-
nisms of ATR–ATRIP recruitment, or possibly ATR activation with
only transient localization to ssDNA gaps.
The interaction with RPA-coated ssDNA may be sufficient for
the recruitment of ATR–ATRIP to DNA lesions, but it is not suf-
ficient to activate ATR. Co-localization of the RAD9-RAD1-HUS1
(9-1-1) complex to ssDNA gaps is also required. The 9-1-1 het-
erotrimeric ring is similar to the replicative sliding clamp PCNA,
and is loaded onto ssDNA–dsDNA junctions by the RAD17-RFC2-5
clamp loader [20–23]. In vitro, the 9-1-1 complex is preferentially
loaded at ssDNA gaps at the free 5′ DNA end [20], and a 5′ primer
end appears to be the relevant checkpoint activating structure
[24]. A ssDNA gap with a 5′ primer end can be found at resected
DSBs, unprotected telomeres, duringnucleotide excision repair, and
at stalled replication forks. Thus, all of these structures can acti-
vate ATR. RPA directs the recruitment of the 9-1-1 complex to the
5′ primer ends, effectively placing the components of the check-
point activating structure in close proximity [20,21]. A checkpoint
recruitment domain on RAD9with sequence similarity to the ATRIP
CRD binds the same RPA70N binding surface as ATRIP and may
help direct 9-1-1 loading or retain it at the 5′ junction [25]. Thus,
multiple RPA-checkpoint protein interactions promote assembly of
two checkpoint complexes (ATR–ATRIP and 9-1-1) at ssDNA gaps
formed as a consequence of many types of DNA lesions.
3.2. ATM, DNA-PK, and DNA double strand breaks
ATMandDNA-PKcsarealso recruited toDNAlesionsites through
their accessory binding proteins NBS1 and Ku70/80. In the case of
DNA-PKcs, it is clear that its function and activation is dependent
on Ku70/80-dependent localization [26,27]. Ku70/80 form a ring
shaped molecule with high affinity for DNA ends [28]. Binding of
Ku70/80 toDNAends provides a scaffold for the association of DNA-
PKcs and other proteins involved in non-homologous end joining.
DNA-PKcs activation requires both the Ku proteins and DNA.
Whether ATM must be recruited to a double strand break to
be activated is less clear. ATM autophosphorylates (a measure of
activation) when cells are treated with agents like chloroquine
or placed in hypotonic conditions, which reportedly do not cause
DNA strand breaks [29]. In these conditions, ATM activation may
depend on a protein, ATMIN, that is dispensable for DSB-induced
ATM activation [30]. It is unclear what physiological stimulus these
treatments mimic.
Considerable data indicate that recruitment to the damage site
is important for ATM activation in response to DNA damage. Dis-
ruption ofMRN function throughmutation or viral infection causes
defects in ATM localization and activation [31–33]. The MRN com-
plex directly binds DNA through DNA binding domains in Mre11,
and Nbs1 contains a region with sequence similarity to both ATRIP
and Ku70/80 that binds ATM and is important for ATM signaling
[6,34]. Thus, the MRN complex bridges ATM with the DNA end.
Controversy remains, however, about where the initial activa-
tion of ATMoccurs in response to aDSB. The chloroquine/hypotonic
ATM activation data and chromatin immunoprecipitation experi-
ments indicating that kinase activity andATMautophosphorylation
are important for ATM localization [35] have been interpreted as
evidence that chromatin structure changes initiate ATM activa-
tion. In this model, the recruitment of an already active ATM to
DSBs by Nbs1 amplifies ATM activity and allows it to phosphory-
late additional proteins on chromatin. The alternativemodel is that
the initial ATM activation happens at the DSB site. Support for this
idea includesexperiments inXenopuseggextracts thatdemonstrate
both the DSB end and the flanking chromatin provide a platform for
ATMautophosphorylation and activation [36]. Both ATMautophos-
phorylation and substrate phosphorylation depended on the DNA
end in this system. While further experiments will be needed to
distinguish between these ideas, bothmodels agree that amplifica-
tion of ATM signaling and phosphorylation of most ATM substrates
requires the concentration/localization of ATM at the DSB site.
3.3. mTOR, endomembranes, SMG1, and mRNA
Other PIKKs are also regulated by dynamic changes in cellu-
lar localization. Amino acid stimulation causes mTOR to localize
to distinct perinuclear, endomembrane compartments using a
Raptor- and Rag GTPase-dependent mechanism [37]. This local-
ization is important for mTOR activation because it co-localizes
mTOR and its protein activator, Rheb (see below). SMG1 binds
to protein complexes at premature termination codons and
exon-junction complexes on mRNA. This localization regulates
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ssDNA tracts formed during the S and G2 phases of the cell cycle. Like its name 
indicates, ATM is perhaps most recognized in conjunction with the hereditary disorder 
Ataxia-Telangiectasia [220]. This is a severe autosomal recessive disease characterized 
by early onset lack of voluntary coordination of muscle reflexes (cerebellar ataxia), small 
dilated blood vessels on the skin surface (telangiectasia), immunodeficiency and 
predisposition to lymphomas. 
In a way that is not completely understood, ATM activation is triggered by the recruitment 
of the MRN (MRE11/Rad50/Nbs1) complex to DSBs, caused by ionizing radiation or 
treatment with campthotecin, for example [221-223]. It is thought that ATM is an inactive 
homodimer that dissasociates and activates in response to damage, probably due to its 
autophosphorylation at serine residue 1981. This remains controversial, as it has also 
been shown that its autophosphorylation is not required for its activation in vivo [224-
226]. ATM monomers are then recruited to DSBs via interactions with the MRN sensor 
complex, which provides a platform for local ATM substrate phosphorylation [227]. These 
substrates include the histone variant H2AX, which forms the γH2AX mark [228], the 
MRN complex itself, SMC1 [229] and its downstream effector Chk2 [230]. ATM 
phosphorylates Chk2 at a specific threonine, T68, which leads to homodimerization and 
full activation of this kinase [231-233]. Once activated, Chk2 monomers disperse [234] 
and act on multiple downstream targets such as p53 [235] and Cdc25 family 
phosphatases [236], 53BP1 [224] and the BRCA1 tumor suppressor [237], amongst 
others. 
In contrast to ATM, ATR is essential for cell survival. ATR and Chk1 (ATR downstream 
target) knockout mice are embryonic lethal [238, 239]. Known ATR-related diseases 
include the rare Seckel syndrome, whose symptoms include mental retardation and 
microcephaly. Patients with this disease live with very low amount of ATR protein [240]. 
Activation of ATR can be traced to several sources of DNA stress such as replication fork 
stalling, nucleotide depletion, DSB resection, etc [241]. What is ultimately recognized by 
the ATR machinery and activates it, is the appearance of ssDNA regions in the DNA. 
The molecular mechanism of ATR activation is well understood: ATR and ATRIP, its 
interaction partner, recognize ssDNA regions coated by RPA [242]. Rad17 and the 9-1-1 
(Rad9-Hus1-Rad1) complex are independently recruited to the chromatin by the same 
structure [243]. This, in turn, is required for TopBP1 (Topoisomerase binding protein 1) 
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recruitment to these sites, where it acts as an ATR activator [244, 245]. Recently, the 
proteins Timeless and Tipin (Timeless-interacting protein) were implicated in ATR-Chk1 
activation [246]. Another mediator is Claspin, which is also shown to associate with 
ssDNA and mediate activation of ATR and downstream phosphorylation of Chk1 [247, 
248]. ATR phosphorylates Chk1 within the C-terminal regulatory domain, primarily on 
serine 345 (S345), although phosphorylation on serine 317 (S317) can also be observed. 
Activated Chk1 substrates include positive and negative regulators of Cdk inhibitory 
phosphorylation such as Cdc25A [249] and Cdc25C [250]. In addition to the DNA 
damage response, ATR functions in both S and M cell cycle phases to monitor 
replication origin firing, elongation, replication fork restart and centrosome instability 
[251-253]. 
Although ATM and ATR have distinct substrate specificities, it is becoming increasingly 
clear that these two pathways are interconnected and complementary [254]. In 2006 it 
was unveiled that ATM-dependent processing of DSBs, which is mediated by Mre11, 
forms ssDNA regions that then activate ATR [163]. Further studies have also provided 
support for the dual rual of ATM and ATR in DSB repair [154, 255]. Importantly, it was 
also shown that ATR can activate ATM in response to ssDNA [256]. 
3.4.2 DNA damage checkpoints 
All three kinases involved in the DNA damage response are essential for  DNA damage 
checkpoints throughout the cell cycle (see Fig. 10). Activation of these checkpoints in 
response to damage is neccessary to grant the cell more time for repairing damage. 
Progression though different stages of the cell cycle is tightly regulated by cyclin-
dependent kinases or CDKs. These are activated by cyclins and inhibited by CDK 
inhibitors or inhibitory tyrosine phosphorylations [257]. CDK1 is considered a mitotic 
CDK, whereas CDK2, 4 and 6 are active during interphase. Cell transduction pathways, 
like the ATM and ATR pathways, can limit the activity of CDKs and prevent cell cycle 
progression into the next stage (G1 and G2/M checkpoints) or also slow down cell cycle 
progression (intra-S checkpoint). More specifically, the G1/S checkpoint prevents 
replication of damaged DNA and the G2/M checkpoint provides surveillance before 
proceeding into chromosome segregation [217]. ATR and ATM, via activated Chk1 or 
Chk2, can induce the phosphorylation of the CDK1 and CDK2 inhibitor CDC25a during S 
phase, for example, which leads to the degradation of the Cyclin E/CDK2 complex. This 
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effectively hampers replication initiation [258]. Another example of this regulation 
involves the phosphorylation of p53 by ATM, ATR, Chk1 and Chk2. Many targets of this 
transcription factor are involved in cell cycle progression. An important target is the 
cyclin-dependent kinase inhibitor (CKI) p21CIP1 which is involved in the G1/S checkpoint 
by inhibiting CDK2 and CDK4. Likewise, phosphorylation of Cdc25c by Chk1 or Chk2 
prevents mitotic entry of damaged cells. This occurs because Cdc25c phosphorylation 
prevents it from targeting its substrate CDk1/CDC2-Cyclin B for dephosphorylation, thus 
preventing mitotic entry.  
 
Fig. 10. Checkpoint responses in cells. DNA damage that delays entry in S phase 
causes a G1 checkpoint. An intra-S checkpoint occurs when replication is slowed down 
and replication forks need to be stabilised and/or suppressed until the damage is 
overcome and the G2 checkpoint prevents entry into mitosis when damage is persistent. 
  
G1 S G2 M
G1
checkpoint
G2
checkpoint
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checkpoint
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This part of the thesis ends with an overview of DNA repair protein defects associated 
with cancer. 
Table 6. DNA repair genes and checkpoint genes implicated in cancer by pathway.  
  
Table 2 | Synthetic lethal interactions of DNA repair and cell cycle checkpoint genes implicated in cancer by pathway
Protein Syndrome Primary cancers Biomarker SLIs S. cerevisiae 
homologue
SLIs in S. 
cerevisiae (n)
HR
BRCA1, BRCA2 – Breast, ovarian112, 135  – PARP1 (REFS 78,79) – –
RAD54B – NHL, colon cancer113 – PARP1 (REF. 87) rdh54 –
RAD51B (RAD51L1) – Lipoma, uterine 
leiomyoma114
– PARP1 (REF. 87) rad51 31
CtIP (RBBP8) – Colorectal cancer115 – – sae2 5
NHEJ
MRE11 Ataxia 
telangiectasia-
like disorder 
Colorectal cancer108 IR sensitivity – mre11 40
LIG4 LIG4 Leukaemia116 IR sensitivity – lig4 –
Artemis (DCLRE1C) Omenn Lymphoma117 – – pso2 –
MMR
MSH2, MLH1, MSH6, 
PMS1, PMS2, MLH3
– Hereditary nonpolyposis 
colorectal cancer118–120
Microsatellite 
instability 
– msh2, mlh1, 
msh6, pms1, mlh3
3
RecQ 
BLM Bloom Various121 Increased SCE – sgs1 43
WRN Werner Various122 Increased 
telomeric SCE
– sgs1 43
RECQL4 Rothmund–
Thomson
Skin basal and sqamous 
cell, osteosarcoma122
– – sgs1 43
Damage signalling
ATM Ataxia-
telangiectasia 
Leukaemia123 IR sensitivity PARP1 
(REFS 124,125), 
FANC89
tel1 2
NBS1 Nijmegen 
breakage 
Various126 IR sensitivity – xrs2 30
p53 Li–Fraumeni Various127 – – - –
CHK2 Li–Fraumeni Various128 – – dun1/rad53 37
NER
XPA, XPC, DDB1, 
ERCC4, ERCC5, POLH
XP Skin cancers129 UV sensitivity  – rad14, rad4, 
rad1, rad2, rad30
11
ERCC2, ERCC3 XP, Cockayne, 
trichothio-
dystrophy
Skin cancers129 – – rad25, rad3 8
ERCC1 Cerebro-oculo-
facio-skeletal
Squamous cell carcinoma, 
head and neck130
– – rad10 6
FA
FANCA, FANCC, 
FANCD2, FANCE, 
FANCG
Fanconi 
anaemia
Various131 Impaired FANCD2 
ubiqutination131
ATM89 – –
FANCB, FANCF, FANCL Fanconi 
anaemia
Various131 Impaired FANCD2 
ubiqutination131
– – –
BRIP1 Fanconi 
anaemia
Various131 – – – –
FANCM Fanconi 
anaemia
Various131 Impaired FANCD2 
ubiqutination131
– mph1 1
BER
POLB – Various132 – – pol4 –
FEN1 – Various133 – – rad27 104
Synthetic lethalities observed in mammalian cells and the number of synthetic lethal interactions (SLIs) for their Saccharomyces cervisiae homologues are shown. 
The genes showing SLIs with DNA repair genes can potentially be used as targets for novel drugs that then may selectively kill cancer cells in monotherapy.  
A complete list of the SLIs in S. cervisiae can be found in Supplementary information S1 (table). ATM, ataxia telangiectasia mutated; BER, base-excision repair; 
CHK, checkpoint kinase; ERCC, excision repair cross-complementation; FA, Fanconi anaemia-mediated repair; FANC, Fanconi anemia, complementation group; 
FEN1, flap structure-specific endonuclease 1; HR, homologous recombination; IR, infrared; MLH, mutL homologue; MMR, mismatch repair; MSH, mutS 
homologue; NER, nucleotide-excision repair; NHEJ, non-homologous end joining; PARP, poly(ADP-ribose) polymerase; RecQ, RecQ-mediated repair; SCE, sister 
chromatid exchange; UV, ultraviolet; XP, xeroderma pigmentosum.
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3.5 The Xenopus laevis egg extract system as a model for replication and 
replication-tethered DNA damage responses 
South African clawed toad (Xenopus laevis) egg extracts have proven to be an 
indispensable tool for gaining mechanistic insights into DNA replication and the 
molecular machinery required for maintenance of our genome during S phase. Their 
potential as a model for replication was first recognized in a series of publications in the 
1980s, which started with the observation that simian virus (SV40) chromatin could be 
replicated in protein extracts from Xenopus laevis eggs [259]. The same laboratory 
reported the use of single-stranded M13-DNA as a replicative template in this in vitro 
system a while later [260]. Meanwhile, Lohka and Masui [261, 262] showed that low-
speed supernatants made from activated eggs induce chromatin decondensation and 
nuclear envelope formation in demembranated sperm nuclei and in 1986 it was 
demonstrated that these extracts can complete a single round of semiconservative DNA 
replication of sperm nuclei and plasmid DNA [263]. What followed was a multitude of 
publications investigating not only the sequence of events in replication initiation and 
elongation with the aid of this tool, but also providing novel insights into known replicative 
proteins as well as identifying new replication factors. Almost concomitantly, DNA repair 
of damaged DNA templates in the extracts was described [264-266]. 
But what characteristics do these eggs possess that make them so useful in biochemical 
experiments? 
First and foremost, Xenopus proteins show a good homology with their human 
counterparts. Secondly, mature Xenopus laevis oocytes are large cells. Their diameter is 
about 106 times that of a somatic cell and the protein content of a single oocyte is the 
equivalent of 25 µg of cytoplasmic protein. They are arrested in metaphase of meiosis II 
by cytostatic factor (CSF), which is responsible for maintaining high intra-cellular levels of 
Cdk1/Cyclin B, ready for ovulation and fertilisation [267]. 
When fertilisation occurs, an increase in calcium channels the degradation of CSF and 
Cyclin B, which releases the G2-arrest so that the egg can transit from metaphase, 
through anaphase, to interphase. The fusion of male and female pronuclei paves the way 
for replication of the zygotic genome, mitosis and 11 subsequent and alternating S and M 
phases of the cell cycle. Following this, the embryo progresses through the midblastula 
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transistion (MBT), which is characterised by elongation of the cell cycle and zygotic 
transcription. 
Extracts obtained from unfertilised oocytes recapitulate DNA replication in a way similar 
to the pre-MBT stages observed, where of course all the proteins neccessary for 
replication of DNA are to be found. 
 
Figure 11. Schematic representation of the preparation of Xenopus egg extracts. A) 
Variants of crude cytoplasmic extracts (Low speed supernatant, LSS) that replicate upon 
sperm chromatin addition. Eggs are crushed in the presence of cycloheximide to impede 
Cyclin B resynthesis (I, Interphase extract), no additives (II, Cycling extract) or the 
calcium chelator EGTA (III, CSF-arrested). The graph indicates Cyclin B activity (red) 
and  template replication (black.) B) Left arrow: High speed supernatant is harversted 
from crude cytoplasm (Low speed supernatant, LSS). This is used for pre-RC assembly. 
Right arrow: sperm chromatin is replicated in LSS to induce nuclei rich in protein content 
that is the fractionated into nucleoplasmid extract (NPE). This extract is added in excess 
to the reaction to initiate replication. Taken from [268]. 
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Depending on the protocol used there are several ways to make extracts from these 
eggs [269, 270] (see Fig. 11). An LSS (low speed supernatant) extract is perhaps the 
simplest, obtained by crushing the unfertilised eggs in the presence of cycloheximide. 
Crushing leads to release of calcium, which mimicks sperm entry into the egg, 
degradation of Cyclin B and entry into interphase [271]. These extracts have been shown 
to replicate plasmid DNA to a certain extent [272, 273] but are mainly used for replication 
of demembranated sperm chromatin. 
Replication of the chromatin involves formation of a transport competent nuclear 
envelope or "pseudo-nucleus" that accumulates high concentration of components 
required for replication. Traditionally, LSS can be further fractionated into a high speed 
supernatant (HSS) and a fraction of nuclear membrane vesicles, which allows separation 
of pre-RC assembly from replication initiation. Within the scope of this thesis, however, 
what is refered to as "S phase extract" is a variant of the HSS extract that does not 
require external nuclear membrane particles. As is the case for other Xenopus egg 
extracts, only a single round of semi-conservative replication is completed due to the 
presence of Geminin and degradation of Cdt1 [274]. Omision of cycloheximide during 
extract preparation is the protocol used for cycling extracts which can re-synthesize 
Cyclin B and can therefore re-enter alternating mitosis and S phase cycles up to 5 times. 
Another possibility is to add EGTA to the crushed eggs. The lack of calcium release 
means these CSF-arrested extracts are trapped in metaphase of meiosis II with high 
Cyclin B activity in a highly condensed state characteristic of meiosis. 
Another form of extract is comprised by a combination of HSS extract and an enriched 
fraction obtained by harvesting replicating nuclei from LSS. This is known as NPE [275]. 
This system is particularly useful for the replication of small plasmid molecules (see Fig. 
12) 
A powerful way in which these extracts are employed is by depleting a protein of interest 
from the extract and measuring the effect on replication. This, combined with 
synchronicity of the reaction and the ease of adding chemicals or damaged templates 
that may interfere with extract activity emphasizes their value for biochemical studies on 
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Figure 12. Schematic representation of DNA plasmid replication in NPE. The 
flowchart depicts a plasmid replication using NPE for 3 different time points. Plasmid is 
added to the HSS aliquot for pre-RC assembly. Only upon addition of 2 volumes of NPE 
to the reaction does replication begin. Taken from [276]. 
 
different aspects of DNA replication. The role of MCM7 and Cdc45 in origin unwinding 
during replication was studied this way, for example [277]. Similarly, recent studies have 
uncovered and supported replicative tasks for proteins such as the Tipin/Tim/And1 
complex [278], Treslin, a novel TopBP1 interactor [279], and Rad51 [280-282]. 
This modus operandi extends to the role of DNA repair proteins in the context of 
replication, in particular proteins involved in crosslink- and double-strand break repair 
[186, 283] [284-286], as well as the coordination and activation of the DNA damage 
response in these extracts. Noteworthy with regards to this thesis is the fact the these 
extracts have been shown to be proficient in ATR dependent Chk1 activation in response 
to different types of damage [245, 287] [288-290]. Because of this, we postulated that it 
would be a valuable tool in studying MMR-dependent responses to alkylating damage in 
DNA. 
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4 Aims of this study 
This introduction has elaborated on eukaryotic DNA replication and the varied DNA 
repair pathways that are key to maintaining genome stability by counteracting various 
sources of endogenous and exogenous DNA damage. Also described are the main 
signaling networks involved in halting and coordinating cell cycle progression in cases 
when the damage-induced stress proves to be too severe for a cell. Particular attention 
was paid to mismatch repair and its role in the DNA damage response to several 
cytotoxic agents as well as to the tool used in this study, the Xenopus egg extract 
system.  
The aim of this PhD thesis was to gain insights into the mechanism of mismatch repair 
(MMR) dependent DNA damage signaling caused by genotoxic agents and 
chemotherapeutics such as SN1-type methylating agents. Conflicting hypotheses as to 
the nature of the lesion recognition by the MMR machinery exist. The question as to 
whether it is directly involved in recruitment of the ATR pathway evidenced the need for a 
biochemical analysis of MMR protein dynamics during replication of undamaged and 
alkylation-damaged DNA. To date, both models addressing this, the direct signaling 
hypothesis and the futile cycling hypothesis, have reached a non-mutually exclusive 
impasse, so we aimed to clarify some open questions. The approach we took was to use 
the Xenopus egg extract (XEE) technique, permissive for the in vitro replication of DNA 
templates and hence recapitulates an in vivo replication scenario to a great extent. A 
limitation of this system was the lack of comercially available antibodies against Xenopus 
mismatch repair proteins so we first undertook the generation of a set of antibodies 
against several Xenopus MMR proteins. Namely, Msh2, Msh6, Mlh1 and Exo1. The 
second, and main aim of this thesis, was to analyze MMR activity on alkylation-
generated O6-methylguanine (meG) lesions both in sperm chromatin and lesion-specific 
plasmids during a single-round of synchronised DNA replication. This, with focus on  
possible parallel activation of the ATR checkpoint machinery in response to O6-
methylguanine (meG) recognition. 
 We also wanted to confirm the formation of MMR-associated gapped intermediates 
towards the end of replication and use them for a second round of replication. To our 
knowledge, ours is the only system that can monitor the replication of meG-containing 
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substrates and therefore also the associated formation of new meG mismatches. 
Collectively, these observations would finally pinpoint the importance of MMR 
intermediates in the G2 arrest during the second cell cycle following treatment with SN1-
type alkylators. Fully understanding the mode of action of these agents and how and why 
they bring about cell death should be a required platform for the continued use of these 
agents in chemotherapy and also the development of new cytotoxic drugs. 
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5 Results 
5.1 Mismatch repair dependent processing of O6-methylguanine adducts 
in Xenopus egg extracts 
 
Maite Olivera Harris, Mariela Artola Boran, Vincenzo Costanzo, Milica Enoiu and Josef 
Jiricny* 
 
This manuscript describes the contribution of meG towards the toxicity of alkylating agents 
such as MNNG and MNU, which is associated with a MMR-dependent replication 
checkpoint. To study this phenomenon, we utilized extracts of Xenopus laevis eggs, a 
naturally synchronous in vitro replication system that not only allows replication of 
damaged chromatin, but also permits the study of the fate of meG-containing  substrates 
during replication in the absence of other lesions. There is some dispute as to why meG 
adducts in DNA ultimately lead to cell death during a second cell cycle and not during the 
first. We found that replication of alkylated chromatin or of meG-containing substrates did 
not lead to recruitment of proteins in the ATR pathway and to activation of a meG-specific 
checkpoint. More importantly, we were able to detect single-stranded gaps in DNA 
caused by the presence of a single meG after replication completion. These would hinder 
a second round of replication in a way that the presence of the mismatches alone would 
not. 
 
I contributed to this study by designing, performing and quantifying the research under 
the guidance and supervision of Josef Jiricny, as well as by drafting the manuscript. 
 
  
RESULTS 
 
 
 
46 
 
Mismatch repair dependent processing of O6-methylguanine adducts in 
Xenopus egg extracts 
 
Maite Olivera Harris1,2, Mariela Artola Boran1, Vincenzo Costanzo3, Milica Enoiu1 and 
Josef Jiricny1,2* 
 
1Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 
CH-8057 Zurich, Switzerland 
 
2Department of biology, Swiss Federal Institute of Technology (ETH),  University of 
Zurich, Wolfgang-Pauli-Str. 27 CH-8093 Zurich, Switzerland 
 
3London Research Institute, Clare Hall Laboratories,  South Mimms, Hertfordshire, UK 
 
 
 
 
 
 
 
 
Keywords: Mismatch repair, SN1-type alkylators, DNA damage signaling, DNA 
replication 
 
 
 
Running title: The response to SN1-type alkylators in XEE 
 
 
 
Abstract:  100 words 
 
 
 
*Correspondence to jiricny@imcr.uzh.ch 
  
RESULTS 
 
 
 
47 
 
Abstract 
 
Cytotoxicity by SN1-type alkylators is largely meG dependent and catalyzed by 
MMR. Whether processing of the adducts during replication underlies the 
cytotoxicity remains unresolved. Here, we show that recruitment of the ATR 
checkpoint machinery to sites of alkylation damage does not coincide with that of 
MMR proteins in XEE. Furthermore, an accumulation of meG/T mispairs at the end 
of replication, a preferred MMR substrate, is not enough to trigger prolongued 
checkpoint activation. Also, meG-dependent gaps arise during replication and 
hinder re-replication in the extract. This suggests that the main cytotoxic trigger 
would be the attempt to replicate meG-containing gapped DNA.  
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Introduction 
The mismatch repair system is assigned to eliminate mutations that might perturb 
genome stability [1]. As such, it recognizes mismatches and short insertion/deletion 
loops (IDLs) [2] formed during replication and directs its excision and resynthesis efforts 
to the nascent strand, in order to restore the correct coding information in our DNA. This 
task is mainly carried out by MutSα and MutLα (heterodimers of MSH2/MSH6 and 
MLH1/PMS2, respectively), EXO1, PCNA, RPA, RFC and polymerase δ [3] . From a 
clinical standpoint, it is also involved in checkpoint and apoptotic responses to 
chemotherapeutics such as SN1-type methylating agents [4]. meG residues generated by 
these agents are normally detoxified by the suicide enzyme O6-methylguanine 
methyltransferase (MGMT) via direct removal of the methyl group from the guanine. 
When MGMT is absent, however, MMR-proficiency renders cells up to 100-fold more 
sensitive to SN1-type methylators [5]. This methylation-biased phenomenon is 
characterized by MMR-dependent activation of the ATR and ATM checkpoint 
machineries, arrest and cell death in G2 of the second cell cycle [6, 7]. At the basis of 
this lies MMR recognition of meG/C and meG/T mispairs formed upon incorporation of a C 
or a T opposite meG by replicative polymerases. They are both bound by the MutSα 
heterodimer and it could be shown that removal of meG mispairs before entry into the 
second cell cycle is sufficient to disable the arrest [8, 9]. To date, two plausible 
explanations for how MMR machinery could address this damage exist. Since meG 
persists in the template strand, ongoing recognition and processing attempts by MMR 
behind the replication fork would create intermediates that, encountered during a second 
S phase, would prompt replication stalling. This is known as the futile cycling hypothesis 
[10, 11]. In accordance with this, a full complement of MutLα, which is downstream of 
mispair recognition by MutSα and which fine-tunes EXO1-catalyzed degradation of the 
error-containing strand, is needed for the methylation-induced arrest [12]. An alternate 
view, the direct signaling model, regards MutSα as a damage sensor and mediator of 
ATR activation [13], and suggests that mismatch recognition upon treatment with an SN1-
type alkylator is accountable for the observed toxicity. In support of this, interactions 
between MMR proteins and proteins of the ATR checkpoint machinery have been 
reported in co-immunoprecipitation studies and also in vitro using recombinant proteins 
[14, 15]. Nevertheless, it still remains unclear why repercussions of MMR recognition of 
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the meG-containing mismatches during the first S phase should unfold only during the 
second round of replication.  
Recent reports from the Constanzo and Cimprich laboratories demonstrated the 
usefulness of the Xenopus laevis egg extract (XEE) in the study of replication-dependent 
DNA damage signaling [16, 17]. We therefore set out to use this system to study the 
response to SN1-type alkylators during in vitro DNA replication. We report here that 
recruitment of MMR proteins to alkylation-damaged chromatin does not coincide with 
recruitment of the ATR checkpoint machinery. Furthermore, a closer examination of 
replication of methylated substrates revealed the presence of persistent single-stranded 
gaps opposite meG. Such gaps would cause the collapse of the replication forks during a 
subsequent S phase. Our data thus provide support for the futile processing hypothesis. 
Results and discussion  
MMR activity during replication in XEE was explored by generating a set of antibodies 
against the MMR proteins Msh2, Msh6, Mlh1 and Exo1 (Fig. S1A, B, C). Since MMR is 
believed to be closely associated with the replication fork [18], we first monitored 
replication-dependent recruitment of MMR proteins to undamaged sperm chromatin in S 
phase extracts (Fig. 1A). As shown in Fig. 1B, recruitment of Msh2, Msh6 and Exo1 was 
similar to that of the leading strand polymerase, pol ε. Interestingly, the residence time of 
Mlh1 in chromatin was substantially longer, which corresponds with reports that this 
protein has additional functions, particularly in recombination [19]. Since we were 
interested in studying damage response to SN1-type alkylators in the extract, we then 
examined the effect of treating sperm chromatin with MNU, and monitoring both the 
recruitment of MMR proteins to the chromatin (Fig. 1A, C), as well as the replication 
products (Fig. 1D). MMR proteins could be seen to be recruited to chromatin in a meG-
dependent fashion, as shown by increased amounts of these proteins in chromatin 
samples incubated with extracts pre-treated with Patrin-2, which inhibits Mgmt and thus 
ensures that meG persists in the DNA (Fig. 1C). As shown in Fig. 1D, MNU doses ranging 
from 0.5 to 4 mM did not visibly affect replication. Similar experiments with MNNG-
treated chromatin (Fig. S2A, B, D), confirmed that, at doses which do not affect 
replication, MMR proteins are recruited to the chromatin together with replicative proteins 
such as pol ε and persist because of meG presence in the DNA.  
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Recently, MMR proteins were described as possible DNA damage sensors that can 
directly interact with the ATR checkpoint machinery upon meG recognition [13, 14]. These 
studies proposed a non-canonical activation of ATR and CHK1 in response to the lesion, 
which can occur independently of RPA or 9-1-1 complex recruitment. Since it would 
imply parallel recruitment of MMR and checkpoint machinery during replication, we used 
the naturally synchronous XEE as a platform for monitoring such recruitment during a 
single round of replication. To this end, sperm chromatin treated with increasing doses of 
MNU was replicated in extracts where Mgmt had been inhibited with Patrin-2. Treatment 
with MMS, which is known to elicit a checkpoint response in the extract, strongly recruits 
both MMR proteins as well as ATR machinery proteins. Contrary to this, there was no 
obvious recruitment of any ATR checkpoint proteins to the chromatin in response to 
MNU, even at doses that led to similar MMR recruitment as seen with MMS. This 
underscored even further that recognition of the meG throughout replication, as evidenced 
by the persistence of MMR proteins in the chromatin at later replication time points, does 
not necessarily trigger a checkpoint response. In accordance with this, no clear 
checkpoint activation (p-CHK1) could be detected at doses up to 4 mM MNU, i.e. at 
concentrations that do not affect replication (Fig. 2B). The treatment can trigger 
activation of CHK1, but only at high doses of MNU (80-500 mM) and in a manner that is 
independent of MMR (Fig. 2B, D).  
One hypothesis explaining MMR-dependent cytotoxicity upon treatment with SN1-type 
alkylators posits that formation of meG/T mismatches, arising through incorporation of a T 
opposite meG by the replicative polymerases, underlies the recruitment and activation of 
checkpoint responses. This agrees with reports that meG/T is a better MMR substrate 
than meG/C [20, 21], as also confirmed by us in Xenopus MMR assays which showed a 
MutSα-dependent MMR activity on the substrates (Fig. 3A, B, C).  Of course, separating 
the effects of meG/C and meG/T in DNA during replication or even attempting to monitor 
generation of meG/T mismatches is not possible in cells. Fortunately, the XEE system 
offers the possibility of replicating plasmids containing single lesions of interest. We 
made use of this and switched to the HSS+NPE system for plasmid replication in XEE, 
where incubation of a substrate in two different extracts replicates it with high efficiency. 
We therefore decided to first replicate all MMR substrates (T/G, meG/C and meG/T) as well 
as a C/G control substrate in the extract. As can be seen in Fig. 3D, replication was 
complete already after 60 min and its efficiency was similar for all substrates and was 
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unaffected by the presence of the mismatches in the DNA. The presence of meG in the 
DNA substrates after replication was confirmed by dot blot with an antibody against meG.  
Since our previous observations concerning the possible activation of CHK1 in response 
to meG was performed with MNU-treated sperm chromatin, we wanted to have a closer 
look at a possible checkpoint response  during replication of a plasmid containing a 
single meG. Interestingly, we could observe transient meG-dependent checkpoint 
activation, but, as in the case of the MNU-treated sperm chromatin, this initial recognition 
was not tantamount to a prolonged checkpoint response (Fig. 4A). We cannot rule out 
that this transient activation was due to communication of MMR with the checkpoint 
machinery. In fact, recent work also showed that meG/T recognition can lead to activation 
of signaling in vivo [22]. This, however, was not enough to sensitize cells to killing by the 
methylating agent and the downregulation of the effector protein involved had no effect 
on the MMR-dependent G2/M arrest, which would strongly argue in favor of a scenario 
where the meG/T mismatch needs to be processed to impart cytotoxicity. 
Because there seemed to be no major involvement of the ATR checkpoint machinery in 
the response to meG, we wondered whether something structural in the DNA, 
independent of checkpoint signaling, could arise from replication of meG containing DNA. 
Although gaps present behind the replication fork in MNNG treated cells have been 
previously reported [9], a formal proof of meG lesions directly leading to gapped DNA was 
missing. We wondered whether the difference between the response during the first and 
second cell cycle in cells damaged with SN1-type alkylators could be attributable to 
transient gaps formed by MMR futile cycling behind the replication fork that would be 
encountered during a second S phase. We performed a gap-filling assay post-
replicatively (Fig. 4B). That is, we replicated the C/G and meG/C substrates without 
addition of a radioactive nucleotide to the reaction (a small control sample was removed 
for confirmation of replication), added a low dose of aphidicolin, a polymerase inhibitor, 
for a few minutes after replication was complete and then conducted a fill-in reaction with 
Klenow polymerase in the presence of [α-32P]dCTP. The difference between the 2 
substrates was clear: only the meG/C substrate contained gaps that could be filled-in. 
Furthermore, the majority of the radioactivity was found in the substrate fragment that 
contains the meG, indicative of post-replicative attempts by MMR to repair the lesion. This 
was substantiated by the detection of meG in the substrate after replication completion 
(Fig. 4C, Dot blot), confirming its status as an irreparable lesion. Finally, to confirm 
RESULTS 
 
 
 
52 
 
whether the presence of these meG-dependent gaps could indeed impair replication if 
present in the template to be replicated, we conducted a re-replication reaction with 
sperm chromatin in the extract. This showed us that, indeed, a significant impairment of 
re-replication could be directly linked to the presence of meG-containing template in the 
extract (Patrin-2 treated). where MMR has more access to the lesion.  
In conclusion, we were able to demonstrate that the presence of meG in DNA does not 
hinder replication, but that this modified base activates MMR. Because meG is in the 
template strand, it cannot be removed by the MMR reaction. This leads to futile attempts 
at repair/resynthesis, which leave gaps opposite the meG. These gaps do not signal to the 
checkpoint machinery, possibly due to being “masked” by RPA but they are sufficient to 
impair fork progression during a second round of replication. 
Materials and methods 
DNA substrates and Xenopus laevis MMR (xMMR) assay  
The substrates were generated as described previously [23]. Briefly, the hetero- and 
homoduplexes were constructed by primer extension using the oligonucleotides listed 
below as primers and the single-stranded phagemid DNA as template. 
pRichi2850topSalI (pRichi2850t SalI) and pRichi2850top (pRichi2850t) that create 5' 
substrates were used as the ssDNA template. A single mutation abrogating an AclI site 
and creating a SalI site was used to generate the pRichi2850top SalI phagemid. After 
primer extension and ligation, the desired supercoiled heteroduplex substrates were 
purified on CsCl gradients. 
Mismatch-provoked excision assays were performed as previously described [24] in the 
presence of 100 ng DNA substrate and 26 µl HSS extract in a total volume of 30 µl in a 
buffer containing 15 mM Hepes-KOH pH 7.4, 15 mM potassium glutamate and 8.75 mM 
magnesium acetate, and 2 µCi of [α-32P]dCTP. The extracts were incubated at 23°C for 
45 min. The reaction was stopped by adding 70 µl STOP solution containing 1 mM 
EDTA, 3% SDS and 5 mg/ml proteinase K (Roche). The samples were incubated at 
37°C ON, purified on Mini-Clean columns (Qiagen) and subjected to restriction digests in 
the presence of RNase (5prime). The digested DNA was cleaned up again and resolved 
on 1% agarose gels stained with GelRed.  
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Primers 
All primers were obtained from Microsynth (Balgach, Switzerland). The sequences are 
indicated below. The SalI restriction site (GTCGAC) is underlined. The mispaired residue 
is highlighted in bold.  
C/G-SalI primer:  
5' CCAGACGTCTGTCGACGTTGGGAAGCTTGAG 3’ 
T/G-SalI primer:  
5' CCAGACGTCTGTTGACGTTGGGAAGCTTGAG 3’ 
meG/C and meG/T *-SalI primer: 
 5' CCAGACGTCTGTCmeGACGTTGGGAAGCTTGAG 3’ 
* pRichi2850top AclI was used for this substrate to pair a T opposite the meG  
Xenopus laevis egg extracts and chromatin isolation 
Lysolecithin-permeabilised Xenopus laevis sperm nuclei were prepared as described 
[25]. S phase extract capable of performing a single round of replication was prepared as 
previously described [26]. Briefly, eggs were dejelled, activated with calcium ionophore 
(Sigma), rinsed with S buffer (50 mM Hepes-KOH pH 7.5, 50 mM KCl, 2.5 mM MgCl2 
and 250 mM sucrose), transferred to 2 ml Eppendorf tubes and crushed by centrifugation 
for 12 min at 13 200 rpm. The cytoplasmic layer was removed and after addition of CytB 
(Sigma) cleared by centrifuging for 25 min at 70 000 rpm (TL55 swinging bucket rotor). 
Extract was supplemented with 250 µg/µl cycloheximide, 25 mM phosphocreatine and 10 
µg/ml creatine phosphokinase before use. 
To generate damaged chromatin, sperm chromatin was exposed to varying doses of 
MNU (Sigma), MNNG (Sigma) or 1% MMS (Sigma). 
Egg cytosol (HSS) and NPE were prepared as described previously [27]. To make NPE, 
unfractionated egg extract (crude S phase extract) was supplemented with nocodazole 
(3.3 µg/ml), cycloheximide (50 µg/ml), DTT (1mM), aprotinin/leupeptin (10 µg/ml each) 
and cytochalasin B (5 µg/ml), and centrifuged at 10 000 rpm for 15 min in an HB-6 rotor 
at 4°C. The dark brown layer at the top of the tube was removed by aspiration and the 
extract was decanted into a fresh Falcon tube and supplemented with an ATP 
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regeneration system and demembranated sperm chromatin to a concentration of 4000 
n/µl. The mixture was incubated at room temperature for 75-90 min. To collect nuclei, the 
reaction was centrifuged for 2 min at 10 000 rpm at 4°C in an HB-6. The clear ~4mm 
layer of nuclei was removed from the top of the tube and transferred to 5 x 20 mm 
ultracentrifuge tubes. They were then centrifuged for 30 min at 55 000 rpm in a Beckman 
TL199 ultracentrifuge using a TL55 swinging bucket rotor. After centrifugation, lipids at 
the top of the sample were aspirated and the clear nucleoplasm was harvested. 
Isolation of nuclear and chromatin fractions 
For isolation of nuclear fractions, egg extracts containing 4000 n/µl were incubated at   
23°C for 120 min unless otherwise indicated, diluted in 500 µl EB buffer (100 mM KCl, 
2.5 mM MgCl2 and 50 mM Hepes-KOH pH 7.5), overlaid on a 30% sucrose/EB buffer 
cushion and centrifuged for 5 min. The pellets were resuspended and centrifuged again. 
To isolate chromatin, sperm nuclei (4000 n/µl) were added to egg extract for the 
indicated times. For Western blotting, samples were diluted in ten volumes of EB buffer 
containing 0.25% Nonidet P-40 and centrifuged through a 30% sucrose layer at 10 000 
rpm for 5 min at 4°C using a fixed angle rotor (HB-6), washed twice with 500 µl EB buffer 
and centrifuged at 10 000 rpm for 1 min. The pellet was resuspended in Laemmli loading 
buffer, the proteins were resolved by either 4-15%, 7.5% or 10% SDS-PAGE and 
analyzed by Western blotting with specific antibodies as indicated. Unless otherwise 
indicated, Fermentas prestained marker was used as a size reference. 
DNA replication  
Replication of sperm DNA (4000 n/µl), was measured by monitoring the incorporation of 
[α-32P]dCTP for 120 min at 23°C as previously described [28]. Treatments are indicated 
in the figure legends. 5 µl aliquots were removed and combined with 15 µl of STOP mix 
(6 mM EDTA, 0.13% phosphoric acid, 10% Ficoll, 5% SDS, 0.2% Bromphenol blue and 
80 mM Tris-HCl pH 8). Proteinase K (Roche) was then added to a final concentration of 
2 µg/µl for 1 h at 37°C. Samples were then electrophoresed on a 0.8% agarose/TAE gel, 
after which the gel was dried and analyzed on a PhosphoImager with ImageQuant 
software (GE Healthcare) 
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For plasmid replication, plasmid DNA pRichi2850t was initially incubated in 6 µl HSS for 
30 min at 23°C, followed by addition of a 2-fold volume of NPE. DNA replication was 
assayed by [α-32P]dCMP (32P) incorporation as described [27]. All replication reactions 
were carried out in the presence of Patrin-2 (100-150 µM), unless otherwise indicated. 
For substrate recovery, 40 µl STOP solution (5% SDS, 80 mM Tris-HCl pH 8 and 5 
mg/ml RNase) was added for 30 min 37°C following by Proteinase K treatment (1 mg/ml) 
ON at 37°C. Samples were purified on Mini-Clean columns (Qiagen) and subjected to 
restriction digests in the presence of RNase (0.5 mg/ml, 5prime). The digested DNA was 
cleaned up again and resolved on 1% agarose gels stained with GelRed. 
Production of recombinant proteins  
Fragments of Xenopus leavis MMR proteins and full-length Xenopus laevis Mgmt were 
PCR-amplified from EST clones obtained from Imagenes using primers containing 
restriction sites for NcoI and XhoI. The PCR products were then cloned in a pET28B(+) 
vector (Novagen). 6xHis-tagged protein fragments (Msh2F1: 258-404 aa, Mlh1F1: 615-
744aa, Msh6F1: 128-249aa, Exo1F1: 344-450aa) were expressed in BL21 cells 
(Invitrogen) and purified on Ni-NTA agarose columns (Qiagen) according to the 
manufacturer’s protocol.  
Antibodies 
Rabbit Xenopus laevis Msh2, Msh6, Mlh1 and Exo1 were generated in a facility 
belonging to the Institute of Laboratory Animal Science (University of Zurich) against 
recombinant 6xHis-tagged protein fragments expressed in bacteria. On average, two 
rabbits per fragment were injected. Immunoglobulins specific for the Xenopus laevis 
MMR proteins were affinity-purified using Hitrap NHS-activated HP (GE healthcare) 
according to standard protocols. Only Msh6 and Exo1 sera worked for 
immunodepletions.  
Rabbit polyclonal antibodies against Xenopus laevis TopBP1, Atr, Rad9, Rad1, Hus1, 
Rad17, Orc2 and Pol ε were a gift from Julian Blow (Dundee University, Dundee, UK),  
Howard Lindsay (Lancaster University, Lancaster, England, UK), Shou Waga (Osaka 
University, Osaka, Japan), William Dunphy (Stanford University, Stanford, CA) and 
Karlene Cimprich (Stanford University, Stanford, CA). Antibodies against human PCNA 
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(Santa Cruz), MCM7 (Sigma), CHK1 (Santa Cruz) and RPA32 subunit (Abcam), which 
also recognize the Xenopus proteins, were obtained commercially. The antibody that 
recognizes phospho-S345 of Xenopus laevis p-CHK1 was purchased from Cell Signaling 
Technology. Anti-meG (EM2-3) antibody was a kind gift of Juergen Thomale (Duisburg-
Essen University, Germany) 
Western blot procedures were performed using ECL or ECL advanced (GE Healthcare). 
Antibodies for Western blots were used at 1:1000 dilutions, unless otherwise specified. 
Dot blots 
The dot blot procedure was described previously in Technologies for detection of DNA 
damage and mutations (G.P. Pfeifer, 1996 edition). Briefly, 200 ng of pRichi2850t SalI 
substrates were heat-denatured at 100°C for 10 min. 2 M Ammonium acetate was added 
to a final concentration of 1 M and the samples were blotted onto pre-wetted 
nitrocellulose. The membrane was rinsed in 5 x SSC (0.75 M sodium chloride and 75 
mM trisodium citrate) and blocked for 1 h in PBS/0.5% Casein/0.1% deoxycholate for 1 h 
at RT. Anti-meG antibody (EM2-3) was used at 1:10 000 dilution for 1 h at RT in the same 
solution. Membranes were washed with PBS/160 mM NaCl/0.1% Triton X-100 3 x 5 min, 
incubated with a secondary anti-mouse antibody, washed further 3 times and developed. 
Band shift assay 
The oligonucleotide heteroduplexes were created by annealing 5' labelled 
oligonucleotides (see meG/C and meG/T *-SalI primer for oligonucleotide sequences) with 
complementary oligonucleotides containing a C or a T opposite the meG. Where 
indicated, annealed substrates were treated with Mgmt prior to band shift. The binding 
reaction mixtures (50mM Hepes pH 7.5, 0.5mM EDTA, 10% glycerol, 0.5mM DTT, 
0.5mg/ml BSA and 20 ng polydI-C) contained 40 fmol oligonucleotide duplex meG/C or 
meG/T and human MSH2/MSH6 (250 ng). Protein-bound substrates were separated from 
free probes by electrophoresis on a 6% native polyacrylamide gel eluted with TAE. 
 
Xenopus laevis MSH6 immunodepletion 
To prepare Msh6 depleted extracts, 100 µl extract were incubated 3 times for 30 min with 
33 µl protein A-Sepharose beads 4B fast flow (Sigma) coupled to 100 µl of anti-Msh6 
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serum. Mock depletion was performed using beads coupled to pre-immune serum. The 
coupling to the beads was performed without diluting the serum ON at 4°C. After the 
coupling reaction, the beads were washed extensively with EB buffer. The extract was 
reconstituted with 1000 ng hMutSα where indicated. 
Figure legends  
Figure 1. Recruitment of Xenopus MMR proteins to sites of MNU-induced 
alkylation damage. A) Schematic representation of the chromatin association assay. B) 
Western blot showing a time course of recruitment of the indicated replication and MMR 
proteins to chromatin. C) Recruitment of the indicated proteins to chromatin of 
undamaged or MNU-treated (1.5 mM) sperm nuclei (4000 n/µl), incubated with the 
extracts for 120 min in the absence or presence of the Mgmt inhibitor Patrin-2 (150 µM). 
and then subjected to Western blotting. D) Efficiency of replication of MNU-treated sperm 
chromatin in S phase extract. Chromatin replication was monitored by supplementing the 
extracts with [α-32P]dCTP (32P) and incubation for 120 min with the MNU-treated nuclei 
(4000 n/µl). Left panel: Autoradiograph of a 0.8% agarose gel. Right panel: Column 
graph of data from three independent experiments, with error bars representing standard 
deviation from the mean. 
Figure 2. Role of the ATR checkpoint machinery in replication of alkylation-
damaged chromatin bound Xenopus MMR proteins. A) Western blot showing binding 
of mismatch repair proteins Msh2 and Mlh1 as well as Atr, Atrip, TopBP1, Rad17 and 
Hus1 to chromatin in response to a range of MNU-induced damage. MNU-treated sperm 
chromatin (4000 n/µl) was replicated in S phase extract and samples were removed 120 
min post nuclei addition. Orc2 blotting was used as a loading control. Chromatin treated 
with MMS (1%) was replicated as a positive control for Atr activation. B) Phosphorylation 
of CHK1 (S345) in S phase extract in response to MNU. Nuclei were isolated at 120 min 
and probed for p-CHK1 (S345) and CHK1. C) MMR-independent phosphorylation of 
CHK1 (S345) in S phase extract in response to MNU. Nuclei were isolated at 120 min 
and probed for p-CHK1 (S345) and CHK1. 
Figure 3. MMR activity on pRichie2850t substrates and their replication in XEE. A) 
Left: Schematic representation of a pRichi2850t substrate digested with HindIII/DraI 
(H/D). All substrates contain a HindIII restriction site (AAGCTT, green) in close proximity 
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to the mismatch. B) xMMR assay with C/G, T/G, meG/C and meG/T pRichi2850t 
substrates. Substrates were incubated in HSS extract (See Methods) for 30 min at 22°C 
prior to HindIII/DraI digestion. Top: Digested samples analyzed on a 1% agarose gel and 
stained with GelRed. Restriction fragments are indicated by a*+b* (2484bp), a* (1336bp), 
b* (1148) and c* (694bp). Bottom: Autoradiograph (32P) of the agarose gel. Right: Data 
from three independent MMR assays are plotted, with error bars representing standard 
deviation from the mean. C) xMMR assay in HSS extract. Mock- and Msh6-depleted 
extract were incubated with meG/C pRichi2850t SalI substrate (see Materials and 
methods) and loaded on a 1% agarose gel after SalI/DraI digestion. Restoration of MMR 
activity in Msh6-depleted extract was shown by the addition of recombinant human 
MutSα. Top: Digested samples analyzed on a 1% agarose gel and stained with GelRed. 
Restriction fragments are indicated by a*+b* (2484bp), a* (1336bp), b* (1148) and c* 
(694bp). Bottom: Autoradiograph (32P) of the agarose gel. Right: Western blot showing 
depletion of Msh6 in the extract. D) Kinetic analysis of the substrate replication in 
HSS+NPE. The plasmids were incubated in HSS for 30 min for pre-RC formation, 
followed by addition of 2 vol. of NPE for initiation of replication (see Supplemental 
Information for details). Samples were taken from the reaction at the indicated time 
points, analyzed on a 0.8% agarose gel and autoradiographed (32P). Lower panel: Dot 
blot against meG with the respective replicated substrates. 
Figure 4. Replication of meG adducts in XEE leads to gapped-replication products 
that escape checkpoint monitoring and affect further replication. A) Kinetic analysis 
of checkpoint activation (p-CHK1) during substrate replication. Indicated substrates (C/G, 
meG/C and MMS-treated C/G) were replicated in HSS+NPE, samples were removed at 
the indicated times, resolved on a 7.5% SDS-PAGE and probed for p-CHK1 (S345) and 
CHK1. Time point 0 indicates addition of NPE to the HSS+DNA mix. B) Schematic 
representation ofa pRichi2850t substrate digestion with DrdI. C) Post-replivative fill-in of 
a control substrate (C/G) and a meG-containing substrate. Substrates were replicated 
without addition of radioactive nucleotide (control sample was spiked with [α-32P]dCTP). 
Aphidicolin (7.5 µM) was added for 5 min after replication was complete, the substrate 
was isolated and a fill-in reaction with Klenow polymerase was performed in the 
presence of [α-32P]dCTP. Substrates were then digested with DrdI (Dr)  and the samples 
were run on a 1% GelRed-stained agarose gel. Bottom: autoradiograph (32P) and dot blot 
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against meG of the replicated substrates. D) Effect of meG presence on re-replication of 
undamaged and MNU-damaged sperm chromatin as indicated by autoradiograph (32P). 
Damaged or undamaged samples were replicated in 1st extract (DMSO-treated or 
Patrin-2 treated), isolated and introduced into 2nd extract (Patrin-2 treated). One sample 
was treated with ExoIII after 1st extract replication as a positive control for impaired re-
replication. 
Fig. S1. Generation of antibodies specific for Xenopus laevis MMR proteins. A) 
BLAST search showing conservation between Homo sapiens and Xenopus laevis MMR 
proteins of interest. B) Coomasie-stained 6xHis-tagged xMMR protein fragments 
resolved on a 15% SDS-PAGE. Each lane was loaded with 1 µl of purified fragment F1 
(Msh2F1: 1.5 µg/µl, Msh6F1: 1.5 µg/µl, Mlh1F1: 3 µg/µl, Exo1F1: 1.2 µg/µl). M, size 
marker in kDa. C) Western blot of Xenopus laevis egg extract (NPE, 1µl) with the affinity-
purified xMMR antibodies using the following dilutions (Msh2: 1:5000, Msh6: 1:5000, 
Mlh1: 1:500, Exo1: 1:1000). 
Fig. S2. Recruitment of Xenopus MMR proteins to sites of MNNG-induced 
alkylation damage in S phase extracts. A) Kinetic analysis of the replication of 
undamaged and MNNG-damaged sperm chromatin. Binding of Msh2 and Pol-ε to the 
chromatin was monitored by western blotting. B) meG-dependent recruitment of xMMR 
proteins to chromatin. Binding of mismatch repair proteins Msh2, Msh6 and Mlh1 to 
undamaged or MNNG-damaged chromatin in the absence or presence of the Mgmt 
inhibitor Patrin-2 samples was assayed at 120 min. E: extract. C) Monitoring checkpoint 
activation in XEE in response to MNNG (1.5 mM). Undamaged or MNNG-damaged 
sperm chromatin was replicated in S phase extract in the absence or presence of Patrin-
2. Nuclei were isolated from this experiment at 120 min and probed for p-CHK1 (S345) 
and CHK1.  
Figure S3. Purification of recombinant Xenopus Mgmt and quality control of meG-
containing substrates in XEE. A) Coomassie staining showing the purification of full-
length 6xHis-tagged Mgmt (25kDa). 15 µl of each fraction were resolved on a 15% SDS-
PAGE. C, Whole-cell lysate from IPTG-induced BL21 cells carrying the xMMR 
constructs; FT, flow-through fraction of the nickel chelated affinity chromatography; W, 
wash fraction; Mgmt, fractions obtained after eluting with imidazole. B) Band shift assay 
with hMutSα for meG/C and meG/T substrates used in replication and repair assays. 
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Presence of a meG/C or meG/T mismatch was confirmed by Mgmt treatment prior to band 
shift reaction. C) Overview of pRichi2850t substrates depicting the position of the 
respective mismatches (T/G, meG/C and meG/T) with respect to the restriction sites used 
in this study (GTCGAC, SalI, TTCGAA, HindIII). D) Schematic representation of a 
pRichi2850t substrate digested with SalI/DraI (S/D). E) SalI/DraI cleavage of pRichi2850t 
substrates C/G, T/G, meG/C and meG/T. Presence of a meG/C or meG/T mismatch was 
confirmed by Mgmt treatment prior to digestion. * indicates unspecific cleavage of meG/C 
substrate by SalI which can be seen in a higher exposure of the Gelred-stained agarose 
gel. 
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Figure 1. Recruitment of Xenopus MMR proteins to sites of MNU-induced 
alkylation damage. A) Schematic representation of the chromatin association assay. B) 
Western blot showing a time course of recruitment of the indicated replication and MMR 
proteins to chromatin. C) Recruitment of the indicated proteins to chromatin of 
undamaged or MNU-treated (1.5 mM) sperm nuclei (4000 n/µl), incubated with the 
extracts for 120 min in the absence or presence of the Mgmt inhibitor Patrin-2 (150 µM). 
and then subjected to Western blotting. D) Efficiency of replication of MNU-treated sperm 
chromatin in S phase extract. Chromatin replication was monitored by supplementing the 
extracts with [α-32P]dCTP (32P) and incubation for 120 min with the MNU-treated nuclei 
(4000 n/µl). Left panel: Autoradiograph of a 0.8% agarose gel. Right panel: Column 
graph of data from three independent experiments, with error bars representing standard 
deviation from the mean. 
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Figure 2. Role of the ATR checkpoint machinery in replication of alkylation-
damaged chromatin bound Xenopus MMR proteins. A) Western blot showing binding 
of mismatch repair proteins Msh2 and Mlh1 as well as Atr, Atrip, TopBP1, Rad17 and 
Hus1 to chromatin in response to a range of MNU-induced damage. MNU-treated sperm 
chromatin (4000 n/µl) was replicated in S phase extract and samples were removed 120 
min post nuclei addition. Orc2 blotting was used as a loading control. Chromatin treated 
with MMS (1%) was replicated as a positive control for Atr activation. B) Phosphorylation 
of CHK1 (S345) in S phase extract in response to MNU. Nuclei were isolated at 120 min 
and probed for p-CHK1 (S345) and CHK1. C) MMR-independent phosphorylation of 
CHK1 (S345) in S phase extract in response to MNU. Nuclei were isolated at 120 min 
and probed for p-CHK1 (S345) and CHK1. 
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Figure 3. MMR activity on pRichie2850t substrates and their replication in XEE. A) 
Left: Schematic representation of a pRichi2850t substrate digested with HindIII/DraI 
(H/D). All substrates contain a HindIII restriction site (AAGCTT, green) in close proximity 
to the mismatch. B) xMMR assay with C/G, T/G, meG/C and meG/T pRichi2850t 
substrates. Substrates were incubated in HSS extract (See Methods) for 30 min at 22°C 
prior to HindIII/DraI digestion. Top: Digested samples analyzed on a 1% agarose gel and 
stained with GelRed. Restriction fragments are indicated by a*+b* (2484bp), a* (1336bp), 
b* (1148) and c* (694bp). Bottom: Autoradiograph (32P) of the agarose gel. Right: Data 
from three independent MMR assays are plotted, with error bars representing standard 
deviation from the mean. C) xMMR assay in HSS extract. Mock- and Msh6-depleted 
extract were incubated with meG/C pRichi2850t SalI substrate (see Materials and 
methods) and loaded on a 1% agarose gel after SalI/DraI digestion. Restoration of MMR 
activity in Msh6-depleted extract was shown by the addition of recombinant human 
MutSα. Top: Digested samples analyzed on a 1% agarose gel and stained with GelRed. 
Restriction fragments are indicated by a*+b* (2484bp), a* (1336bp), b* (1148) and c* 
(694bp). Bottom: Autoradiograph (32P) of the agarose gel. Right: Western blot showing 
depletion of Msh6 in the extract. D) Kinetic analysis of the substrate replication in 
HSS+NPE. The plasmids were incubated in HSS for 30 min for pre-RC formation, 
followed by addition of 2 vol. of NPE for initiation of replication (see Supplemental 
Information for details). Samples were taken from the reaction at the indicated time 
points, analyzed on a 0.8% agarose gel and autoradiographed (32P). Lower panel: Dot 
blot against meG with the respective replicated substrates. 
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Figure 4. Replication of meG adducts in XEE leads to gapped-replication products 
that escape checkpoint monitoring and affect further replication. A) Kinetic analysis 
of checkpoint activation (p-CHK1) during substrate replication. Indicated substrates (C/G, 
meG/C and MMS-treated C/G) were replicated in HSS+NPE, samples were removed at 
the indicated times, resolved on a 7.5% SDS-PAGE and probed for p-CHK1 (S345) and 
CHK1. Time point 0 indicates addition of NPE to the HSS+DNA mix. B) Schematic 
representation ofa pRichi2850t substrate digestion with DrdI. C) Post-replivative fill-in of 
a control substrate (C/G) and a meG-containing substrate. Substrates were replicated 
without addition of radioactive nucleotide (control sample was spiked with [α-32P]dCTP). 
Aphidicolin (7.5 µM) was added for 5 min after replication was complete, the substrate 
was isolated and a fill-in reaction with Klenow polymerase was performed in the 
presence of [α-32P]dCTP. Substrates were then digested with DrdI (Dr)  and the samples 
were run on a 1% GelRed-stained agarose gel. Bottom: autoradiograph (32P) and dot blot 
against meG of the replicated substrates. D) Effect of meG presence on re-replication of 
undamaged and MNU-damaged sperm chromatin as indicated by autoradiograph (32P). 
Damaged or undamaged samples were replicated in 1st extract (DMSO-treated or 
Patrin-2 treated), isolated and introduced into 2nd extract (Patrin-2 treated). One sample 
was treated with ExoIII after 1st extract replication as a positive control for impaired re-
replication. 
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Fig. S1. Generation of antibodies specific for Xenopus laevis MMR proteins. A) 
BLAST search showing conservation between Homo sapiens and Xenopus laevis MMR 
proteins of interest. B) Coomasie-stained 6xHis-tagged xMMR protein fragments 
resolved on a 15% SDS-PAGE. Each lane was loaded with 1 µl of purified fragment F1 
(Msh2F1: 1.5 µg/µl, Msh6F1: 1.5 µg/µl, Mlh1F1: 3 µg/µl, Exo1F1: 1.2 µg/µl). M, size 
marker in kDa. C) Western blot of Xenopus laevis egg extract (NPE, 1µl) with the affinity-
purified xMMR antibodies using the following dilutions (Msh2: 1:5000, Msh6: 1:5000, 
Mlh1: 1:500, Exo1: 1:1000). 
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Fig. S2. Recruitment of Xenopus MMR proteins to sites of MNNG-induced 
alkylation damage in S phase extracts. A) Kinetic analysis of the replication of 
undamaged and MNNG-damaged sperm chromatin. Binding of Msh2 and Pol-ε to the 
chromatin was monitored by western blotting. B) meG-dependent recruitment of xMMR 
proteins to chromatin. Binding of mismatch repair proteins Msh2, Msh6 and Mlh1 to 
undamaged or MNNG-damaged chromatin in the absence or presence of the Mgmt 
inhibitor Patrin-2 samples was assayed at 120 min. E: extract. C) Monitoring checkpoint 
activation in XEE in response to MNNG (1.5 mM). Undamaged or MNNG-damaged 
sperm chromatin was replicated in S phase extract in the absence or presence of Patrin-
2. Nuclei were isolated from this experiment at 120 min and probed for p-CHK1 (S345) 
and CHK1.  
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Figure S3. Purification of recombinant Xenopus Mgmt and quality control of meG-
containing substrates in XEE. A) Coomassie staining showing the purification of full-
length 6xHis-tagged Mgmt (25kDa). 15 µl of each fraction were resolved on a 15% SDS-
PAGE. C, Whole-cell lysate from IPTG-induced BL21 cells carrying the xMMR 
constructs; FT, flow-through fraction of the nickel chelated affinity chromatography; W, 
wash fraction; Mgmt, fractions obtained after eluting with imidazole. B) Band shift assay 
with hMutSα for meG/C and meG/T substrates used in replication and repair assays. 
Presence of a meG/C or meG/T mismatch was confirmed by Mgmt treatment prior to band 
shift reaction. C) Overview of pRichi2850t substrates depicting the position of the 
respective mismatches (T/G, meG/C and meG/T) with respect to the restriction sites used 
in this study (GTCGAC, SalI, TTCGAA, HindIII). D) Schematic representation of a 
pRichi2850t substrate digested with SalI/DraI (S/D). E) SalI/DraI cleavage of pRichi2850t 
substrates C/G, T/G, meG/C and meG/T. Presence of a meG/C or meG/T mismatch was 
confirmed by Mgmt treatment prior to digestion. * indicates unspecific cleavage of meG/C 
substrate by SalI which can be seen in a higher exposure of the Gelred-stained agarose 
gel. 
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5.2 Tools generated to facilitate the study of mismatch repair in Xenopus 
laevis egg extracts 
At the start of this PhD thesis, the main concern was establishing the Xenopus laevis 
facility in our institute. We had some problems with the maintenance of the frogs and this 
lead to difficulties with egg production. This, however, was overcome in due time with a 
stepwise reorganization of several factors crucial to the frogs well-being, e.g food and 
light source. Despite this unfortunate delay, we proceeded with the generation of 
antibodies specific for Xenopus MMR proteins. This step is a crucial and often 
overlooked requirement in working with Xenopus egg extracts (XEE). Many proteins of 
interest are expressed in the extract, but due to variations in homology between human 
and Xenopus proteins, commercially-available antibodies often do not recognize the 
Xenopus orthologs. Once this has been verified, as in our case where several antibodies 
failed to recognize the Xenopus proteins (data not shown), it is neccessary to generate 
your own set of antibodies.  
In order to conduct a speedy and effective expression and purification of the proteins, 
small fragments of Xenopus MMR genes were first cloned into the pET28b(+) expression 
vector. Available cDNAs (partial Msh2 and full-length Msh6, Mlh1 and Exo1; Msh3 is 
unfortunately not anotated) had been previously purchased from Imagenes. This vector 
was chosen because of the possibility of tagging the fragments with a 6xHis-tag, which is 
known to be poorly immunogenic. The cloned Xenopus MMR fragments were then 
expressed in E. coli and, depending on their expression and solubility, a large scale 
expression was conducted, either under non-denaturing (Fig. 13A, B and D) or 
denaturing conditions (Fig. 13C). In the end, one fragment (F1) from each Xenopus 
protein (Msh2, Msh6, Mlh1 and Exo1) was selected for rabbit immunisation. Sufficient 
amounts of each antigen were obtained for rabbit immunisations, since less the 1 mg 
total protein is neccesary for the procedure and the immunisation was carried out in a 
nearby facility on the University of Zurich Campus.  
Antiserum from an immunised animal can be used for certain applications, for 
immunodepletion in the XEE for example, which we could indeed use for succesful 
immunodepletion of Msh6 and Exo1 from the extract (Fig. 14A, B). For more specific 
detection methods, however, isolation of the antibody is useful. We therefore conducted 
antibody purifications for each MMR protein (Fig. 15A, B, C and D) with the final bleeds 
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of the rabbit sera. We used purified antigens as baits to capture antigen-specific 
immunoglobulins from the serum. This was done to avoid the drawback of Protein G/A-  
 
Fig 13. Purification of Xenopus MMR protein fragments expressed in E. coli (BL21). 
Coomasie staining showing samples obtained during the Ni-NTA affinity purification of 
6xHis-tagged protein fragments resolved on a 15% SDS-PAGE.  C, whole-cell lysate 
from IPTG-induced BL21 cells carrying the Xenopus MMR construct; FT, flow-through 
fraction of the nickel chelated affinity chromatography; W1/W2, washes; black triangle, 
elution fragments (Imidazole) obtained that were pooled and dialysed against 20 mM 
MOPS/100 mM NaCl prior to rabbit immunisation. M, size marker in kDa (Biorad broad 
range protein marker). A) Purification of Msh2, fragment 1 (258aa-404aa). B) Purification 
of Msh6, fragment 1 (128aa-249aa). C) Purification of Mlh1, fragment 1 (62aa-172aa). 
Denaturing conditions, see material and methods for details. D) Purification of Exo1, 
fragment 1 (344aa-450aa). 
 
based purification methods, were the final preparation contains host IgG as well as the 
specific antibodies.  
Once these purifications were standardised, a similar expression and purification 
protocol was followed to purify recombinant Geminin and p27 (Fig. 16A, B), two proteins 
which inhibit replication in the Xenopus extract. Geminin acts by preventing loading of 
the MCM complex onto chromatin and p27 is a CDK inhibitor. Activity of the proteins was 
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confirmed in an in vitro replication assay in the extract (Fig. 16C) and they were then 
used in preliminary experiments. These results confirmed that MMR proteins could be 
recruited to chromatin outside of replication (Fig. 17A) and that, in general, ubiquitination 
of PCNA could be detected in the extract during replication, but more persistantly upon 
induction of exogenous damage (Fig. 17B, C). 
Preliminary experiments conducted in the XEE show that replication of not only meG-
containing substrates but also of a T/G mismatch can lead to transient checkpoint 
activation (Fig. 18) and would be interesting to investigate further with regard to what 
checkpoint machinery proteins are recruited to the meG together with MMR. This could be 
achieved by replicating biotinylated substrates in the extract and attempting to chip 
proteins specifically bound to the meG lesion with the use of streptavidin beads. 
Replication of the biotinylates substrates in HSS+NPE extract does not affect replication 
to a great extent when compared to a non-biotinylated substrate (Fig. 19). 
 
 
Fig. 14. Immunodepletion of Msh6 and Exo1 from S phase extracts. A) Mock- 
depleted (Mock) and Msh6-depleted (Msh6) extract after the first (1st), second (2nd) and 
third (3rd) round of immunodepletion using Msh6 serum prebound to protein A 
Sepharose beads. B) Mock-depleted (Mock) and Exo1-depleted (Exo1) extract after the 
first (1st) and second (2nd) round of immunodepletion using Exo1 serum prebound to 
protein A-Sepharose beads. Samples were blotted with the indicated antibodies. 
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Fig. 15. Purification of rabbit antibodies raised against Xenopus MMR proteins. 
Coomassie staining showing samples taken during the purification of Xenopus MMR 
antibodies resolved on 12% SDS-PAGE. > 3 mg of protein fragments were coupled to Hi-
trap NHS-activated HP and used as bait to capture specific immunoglobulins from the 
rabbit serum. RS, immunised rabbit serum diluted 1:10; FT, flowthrough obtained after 
binding of the serum to the "baited" column; IgG, 2 µg of reference antibody; black 
triangle, elution fraction obtained during the purification. H, IgG heavy chain, 55 kDa; L; 
IgG light chain, 25 kDa. M, size marker in kDa (Biorad broad range protein marker). A) 
Purification of anti-Msh2. B) Purification of anti-Msh6. C) Purification of anti-Mlh1. D) 
Purification of anti-Exo1. 
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Fig. 16. Purification of replication inhibitors for the Xenopus egg extract system. A, 
B) Ni-NTA purified full-length human Geminin (25 kDa) and p27 (27 kDa). Constructs 
were cloned in pET28 and pET21, respectively. C) Inhibition of replication in XEE by 
recombinant Geminin (G) and p27 (P27) used at 500 nM. Replication products were 
visualized by incorporation of radioactive [α-32P]dCTP (32P). Constructs were a gift from 
the Costanzo Lab. 
  
 
BA
Coomassie 
C
M 
116
97
66
45
31
21.5
14.5
Coomassie 
6.5
200
M 
116
97
66
45
31
21.5
14.5
6.5
200
F
T
W
1
W
2
GEMININ 
C F
T
W
1
W
2
P27 
45 60 45 60
32P 
min
DMSO G + P27
C
RESULTS 
 
 
 
74 
 
 
Fig. 17. Non-canonical MMR in S phase extract. A) Recruitment of xMMR proteins to 
damaged chromatin outside of replication as seen by addition of replication inhibitors 
Geminin and p27 to the reaction. B) Isolation of nuclei and chromatin-bound proteins 
during replication with different damaged templates (DMSO, undamaged control) shows 
that Msh6 recruitment to MNNG-damaged sperm chromatin is accompanied by 
ubiquitination of PCNA in the extract (*). C) Time course of replication of damaged 
(MNNG) and undamaged sperm chromatin shows persistent PCNA-Ub after replication 
of the damaged template.  
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Fig. 18. Kinetic analysis of checkpoint activation (p-CHK1) during substrate 
replication. Indicated substrates (C/G, T/G, meG/C and meG/T) were replicated in 
HSS+NPE, samples were removed at the indicated times, resolved on a 7.5% SDS-
PAGE and probed for p-CHK1 (S345) and CHK1. Time point 0 indicates addition of NPE 
to the HSS+DNA mix. 
 
 
Fig. 19. Replication of biotinylated xMMR substrates. pRichi2850t substrates 
containing a single biotin-dT (see Materials and Methods for primer sequence) were 
replicated in HSS+NPE alongside a T/G substrate in the presence of [α-32P]dCTP (32P). 
Samples were removed 120 min after replication start, run on a 0.8% agarose gel and 
analyzed by autoradiography. 
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5.2.1 Materials and methods 
Production of recombinant proteins for rabbit immunisation and for antibody 
purification 
Fragments of Xenopus MMR proteins and full-length xMGMT were PCR amplified from 
EST clones obtained from Imagenes, using primers containing restriction sites for Nco1 
and Xho1. The PCR products were then cloned in a pET28b(+) vector (Novagen). 6xHis-
tagged protein fragments (Msh2F1: 258-404aa, Mlh1F1: 615-744aa, Msh6F1: 128-
249aa, Exo1F1: 344-450 aa) were expressed in BL21 cells (Invitrogen) and purified on 
Ni-NTA agarose columns (Qiagen). Briefly, protein expression was induced with 0.5 mM 
IPTG in cells grown at 37°C. The cell pellets were resuspended in 20 mM Tris-HCl pH 8, 
300 mM KCl, 10% glycerol, 1 mM β-mercaptoethanol, 0.1% NP40 and PMSF for lysis. 
After cell disruption and centrifugation of cell debris and membranes, the soluble fraction 
containing 40 mM imidazole was loaded onto a nickel chelating column. Washing was 
done with 25 mM imidazole and elution with 150 mM-1 M imidazole. Fractions were 
pooled and dialysed against either 20 mM MOPS/100 mM NaCl pH 7.9 for immunisation 
or coupling buffer for antibody purification. 100-200 µg of protein were used per round of 
rabbit immunisation.  
hGeminin-pET28 and hp27-pET21 constructs were a kind gift of Yoshi 
Hashimoto/Vincenzo Costanzo (Clare Hall Laboratories, UK). The proteins were 
expressed as above. 
For denaturing conditions (neccessary for Mlh1F1 fragment), pellets were induced as 
described above, resuspended in lysis buffer and centrifuged for 15 min 4°C. The pellet 
containing insoluble Mlh1F1 was resuspended in denaturing buffer containing 6 M urea, 
100 mM NaH2PO4 and 10 mM Tris-HCl and incubated for 1 h. The beads were 
equilibrated with 6 M urea-containing buffer and the solubilised fraction was loaded onto 
the nickel chelating column. Washes and elution included 6 M urea. The eluted protein 
was then dialysed against coupling buffer cotaining 4 M, 2 M, 1 M urea and finally, no 
urea. For immunisation purposes, the protein was dialysed against 20 mM MOPS/100 
mM NaCl/1 M urea. 
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Purification of Xenopus antibodies raised against MMR proteins 
Antibody purification was performed using HiTrap NHS-activated HP column for affinity 
antibody purification as per manufacturers' instructions (GE Healthcare).  This is a pre-
packed column of N-hydroxy-succinimide (NHS) cross-linked to HP Sepharose beads.  
NHS reacts with ligands containing amino groups to give a very stable amide linkage. >3 
mg of antigen (Xenopus MMR fragments) were affinity purified and coupled to the 
column overnight at 4°C in coupling buffer (200 mM NaHCO3, 500 mM NaCl). 5 ml of 
rabbit serum were diluted to 50 ml in PBS and loaded onto the same column overnight at 
4°C. The column was washed with buffer containing 10 mM Tris-HCl pH 7.5 and 500 mM 
NaCl and the antibody was eluted with 100 mM glycine pH 2.25. The pH of the fractions 
was adjusted immediately with 1 M Tris-HCl pH 8 and the antibody was concentrated 
using Amicon Ultra centrifugal filters (Millipore). Concentration was measured using 
Nanodrop. 
Primers used for biotinylated substrates 
Biotin C/G SalI primer 
5' CGCGATCbioTGATCAGATCCAGACGTCTGTCGACGTTGGGAAGC 3' 
Biotin meG/C and meG/T*-SalI primer 
5' CGCGATCbioTGATCAGATCCAGACGTCTGTCmeGACGTTGGGAAGC 3' 
 * pRichi2850top AclI was used for this substrate to pair a T opposite the meG  
   bioT stands for biotinylated T 
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5.3 Additional observations 
5.3.1 Role of MutSβ in O6-methylguanine (meG)  recognition 
The MutSβ heterodimer is composed of MSH2 and MSH3 and is believed to be present 
in cells in a ratio of 10:1 with regard to MutSα [320]. Its role in MMR is in the repair of 
insertion/deletion loops larger than 2 nucleotides but it has also been shown to bind to 
ICLs generated by cisplatin and psoralen and as a protein that participates in the 
cytotoxic response to 5-fluorouracil [188, 202, 321]. The possibility of it playing a role in 
meG recognition first presented itself when Xenopus MMR assays showed that 
immunodepletion of Msh6 from the extract did not completely abrogate repair activity on 
the meG/T containing substrate as it did with the meG/C substrate (Fig. 19). This result was 
perplexing since, to our knowledge, there is no description in literature of a protein other 
than MutSα that recognizes meG-containing mismatches. What had been previously 
reported is that both MutS heterodimers can have functional overlap in certain contexts 
[322]. The immunodepletion showed that Msh6 depletion did not completely deplete the 
extract of Msh2 so the possibility that residual MutSβ could potentially recognize meG/T 
was therefore explored further. 
 
Fig 19. Recognition of meG substrates in Xenopus egg extract in Mock- and Msh6-
depleted extract. Mock- and Msh6-depleted extracts were incubated with C/G, meG/C 
and meG/T pRichi2850t substrates for 30 min at 23°C under Xenopus MMR conditions 
(see 5.1, Materials and methods) and loaded on a 1% agarose gel after HindIII/DraI 
digestion. Top: Digested samples analyzed on a 1% agarose gel and stained with 
GelRed. Restriction fragments are indicated by a*+b* (2484bp), a* (1336bp), b* (1148bp) 
and c* (694bp). Bottom: Autoradiograph (32P) of the same agarose gel. Right, extract 
samples (Mock- and Msh6-depleted extract) were removed and subjected to blotting with 
the indicated antibodies. 
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In order to work with an in vitro system with previously characterized MMR deficiencies, 
we began working with nuclear extracts made from human LoVo cells, a colorectal 
cancer cell line which lacks both MSH3 and MSH6 and is therefore MMR deficient (Fig. 
22A). Since both recombinant human MutSα as well as MutSβ were available, it was 
possible to selectively restore MMR with either heterodimer in a MMR assay. As 
expected, MutSα addition to the reaction restored repair activity to the T/G substrate and 
to a lesser extent the meG/T (Fig. 21A). Surprisingly, MutSβ displayed similar recognition 
capacity for meG/T. Indeed, when we performed a band shift assay for MMR susbtrates 
with recombinant MutSβ using a TTTT-loop containing substrate as a positive 
reference (Fig. 20) we could detect weak affinity of MutSβ for the meG substrates and not 
for the T/G substrate.    
Fig 20. MutSβ  binds to meG-containing mismatches. Band shift assay with 
recombinant human MutSβ (MSH2/MSH3) and 42mer heteroduplexes containing a TTTT 
loop (+4, positive control), C/G, T/G, meG/C or meG/T in their nucleotide sequence. The 
protein/DNA complexes were analyzed on a 5% native PAA (19:1) and visualized by 
autoradiography. 
 
HCT15 is a colorectal cancer cell line where the cytotoxic response to the SN1-type 
alkylator MNU was investigated [323]. Since it lacks MSH6 (Fig. 22A), it is known as a 
MMR deficient cell line and the focus of the study was to compare it to its MMR proficient 
counterpart, the HCT15 chromosome 2 cell line, where MSH6 was reintroduced. 
Interestingly, clonogenic assays performed in this study showed only a minor difference 
in response of two cell lines response to treatment with MNU; they were both sensitive to 
killing by this agent. We therefore used nuclear extracts from the HCT15 cell line and 
tested whether the MutSβ that is still expressed could be responsible for this sensitivity in 
a MMR assay (Fig. 21B). We included a looped substrate (+4) as a positive control for 
MutSβ and analyzed repair activity on T/G, meG/C and meG/T containing substrates. Here, 
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repair activity could be observed for all but the C/G control substrate. The looped 
substrate was the prefered one, followed by T/G, meG/T and slight meG/C recognition. 
Fig. 21. MutSβ  repair activity on meG/T pRichi2850t substrate in a MMR assay. A) 
The T/G and meG/T substrates were incubated with mismatch repair-deficient LoVo 
nuclear extracts (supplemented with recombinant MutSα (MSH2/MSH6) or 
MutSβ  (MSH2/MSH3). Top, samples were loaded on a 1% GelRed-stained agarose gel 
after HindIII/DraI digestion and repair activity was monitored by incorporation of [α-
32P]dCTP (32P, bottom). B) A C/G control substrate and a substrate containing a TTTT 
loop (+4, positive control) were incubated alongside meG-containing substrates meG/C and 
meG/T in MutSα-deficient/MutSβ proficient HCT15 nuclear extracts. Top, samples were 
loaded on a 1% GelRed-stained agarose gel after HindIII/DraI digestion and repair 
activity was monitored by incorporation of [α-32P]dCTP (32P, bottom). 
 
Alltogether, there was a clear indication that MutSβ could recognize meG-mismatches in 
vitro, but we had to search for evidence that it could also do so in vivo. We turned to the 
human osteosarcoma U2OS cell line, which is widely used for a variety of cell-based 
assays, and set out to examine the effect of MSH3 downregulation in these cells and 
also ask if MutSβ is able to take over meG recognition when MSH6 is absent, using a 
chromatin binding assay. This would inform us as to whether MutSβ is recruited in vivo to 
meG lesions. We first confirmed efficient siRNA downregulation of both MSH6 and MSH3 
via western blot (Fig. 22B). Both appeared fully downregulated. Unfortunately, MSH6 
downregulation led to significant co-downregulation of MSH2, which could of course 
accentuate and mask the phenotype of only downregulating MSH6.  
The chromatin binding assay in Fig. 22C shows recruitment of the proteins of interest in 
response to treatment of non-synchronised U2OS cells with 1 mM MNU. Cells were 
pretreated with O6-benzylguanine so that the recruitment shown was meG-dependent. 
Curiously, downregulation of MSH6 did not completely impair recruitment of MSH2 and 
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MLH1 to the chromatin even though it was substantially decreased as compared to the 
siLuc control samples. Whether this residual MSH2 heterodimerised with MSH3 and was 
recruited to meG is difficult to assess, since MSH3 is strongly present on the chromatin 
regardless of treatment. Interestingly, downregulation of MSH3 also led to decreased 
recruitment of MSH6 to chromatin. 
 
Fig. 22. MutSβ  recognition of meG substrates in vivo. A) MMR status of human 
adenocarcinoma cell lines LoVo (mismatch repair deficient) and HCT15 (MSH6 
deficient). 30 µg of nuclear extract were resolved on a 10% SDS-PAGE and subjected to 
western blotting with the indicated antibodies. B) MMR status of the human 
osteosarcoma cell line U2OS (mismatch repair proficient) after downregulation of MSH3 
and MSH6. Western blot showing the efficiency of MSH3 downregulation by siRNA 
Smartpool in U2OS. MSH6 was downregulated using a single siRNA against it and siLuc 
served as control. Samples were harvested 72 hours after siRNA transfection and 
resolved on a 6% SDS-PAGE. C) Western blot of total- and chromatin-bound MMR 
proteins in MNU-treated U2OS cells (1 mM treatment 3 hours prior to harvesting).  
 
These results are preliminary and conducted in this cell line only. It would be very 
interesting to see recruitment of MMR proteins in the HCT15 cell line which only 
expresses MSH3. Experiments are also currently under way to determine the right dose 
of MNU that can be used for similar chromatin binding assays as well as a clonogenic 
assay. Since it was already previously established that the HCT15 is not as resistant to 
MNU treatment as their MMR deficient cell line, it would be tempting to downregulate 
MSH3 in this cell line and observe whether that increases resistance to MNU. 
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5.3.2 Materials and methods 
Substrates, nuclear extracts and MMR assays 
The substrates and nuclear extracts were generated as described previously [316]. 
Briefly, the hetero- and homoduplexes were constructed by primer extension using the 
oligonucleotides listed below as primers and single-stranded phagemid DNA 
(pRichi2850top SalI or AclI, creates 5' nicked substrates) as template. After primer 
extension, ligation and isolation of the desired supercoiled heteroduplex substrates on 
CsCl gradients, MMR assays were carried out as described [316].  
Unless otherwise specified, the MMR reactions were carried out with 100 ng DNA 
substrate and 100 µg nuclear extracts in a total volume of 25 µl in a buffer containing 20 
mM Tris-HCl pH 7.6, 5 mM MgCl2, 110 mM KCl, 1 mM glutathione, 50 µg/µl BSA, 100 
mM dNTPs and, where indicated, 2 µCi of [α-32P]dCTP (32P). When indicated, 
recombinant human MutSα or MutSβ were added to the reaction. The extracts were 
incubated at 37°C for 40 min. The reaction was stopped by adding an equal volume of 2 
x STOP solution containing 1 mM EDTA, 3% SDS and 5 mg/ml proteinase K. The 
samples were incubated at 45°C for 30 min, purified on Mini-Clean columns (Qiagen) 
and subjected to restriction digests. The digested DNA was resolved on 1% agarose 
gels.  
Primers for substrates and the band shift assay 
C/G-SalI primer:  
5' CCAGACGTCTGTCGACGTTGGGAAGCTTGAG 3’ 
T/G-SalI primer:  
5' CCAGACGTCTGTTGACGTTGGGAAGCTTGAG 3’ 
+4-SalI primer:  
5' CCAGACGTCTGTCTTTTGACGTTGGGAAGCTTGAG 3’ 
meG/C and meG/T -SalI primer: 
 5' CCAGACGTCTGTCmeGACGTTGGGAAGCTTGAG 3’ 
* pRichi2850top AclI was used for this substrate to pair a T opposite the meG  
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Band shift assay 
This was performed essentially as described [208]. The oligonucleotide heteroduplexes 
were created by annealing 5’ radiolabelled (*) oligonucleotides (see Primers for 
substrates and the band shift assay) with unlabeled complementary oligonucleotides. 
The binding reaction mixtures contained 40 fmol heteroduplex with a +4, C/G, meG/C or 
meG/T mismatch and recombinant human MSH2/MSH3 (250 ng). Protein-bound 
substrates were separated from free probes by electrophoresis on a 5% native 
polyacrylamide gel with TAE. 
Antibodies 
Antibodies against MSH6 (BD Transduction Laboratories), MSH2 (Calbiochem), MLH1 
(BD Pharmigen), CHK1 (Santa Cruz), PCNA (Santa Cruz) and MCM7 (Sigma) were 
obtained commercially. The antibody against MSH3 was a kind gift from the IMCR. 
siRNA and knockdown experiments 
U2OS cells were transfected using 40nM siRNA against luciferase (siLuc), MSH6 
(Microsynth), MSH3 (Smartpool from Thermo Scientific) or both, using RNAiMax 
(Invitrogen) as per the manufacturer's protocol. 72 hours post-transfection, total cell 
extracts were prepared using Laemmli buffer (120 mM Tris-HCl pH 6.8, 20% glycerol, 4% 
SDS). The siRNAs used in this study were as follows: siLuc: 5’ CGU ACG CGG AAU 
ACU UCG A 3’, siMSH3.1: 5' GCA CAU AGC UAC AGA AAU U 3', siMSH3.2: 5' CCC 
GAG AGC UCA AUA UUU A 3', siMSH3.3: 5' GGA CAG GAG UUU AUG AUA G 3', 
siMSH3.4: 5' GAU UCG AAA CGU CAA AUU A 3', siMSH6: 5' CGC CAT TGT TCG AGA 
TTT A 3' 
Triton extraction for chromatin binding 
To isolate the Triton-insoluble fraction, cells were rinsed twice in cold PBS, incubated for 
10 min on ice in preextraction buffer (25 mM Hepes-KOH pH 7.4, 50 mM NaCl, 1 mM 
EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton X-100 and protease inhibitors). After 
removal of buffer and rinsing in PBS, adhering cellular material (Triton-insoluble fraction) 
was harvested by scraping the cells into Laemmli buffer (4% SDS, 20% glycerol and 120 
mM Tris-HCl pH 6.8). The enriched chromatin fraction was then heat denatured, 
fragmented by syringe and analyzed by western blotting.  
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5.4 Ribonucleotides misincorporated into DNA act as strand-
discrimination signals in eukaryotic mismatch repair 
 
Medini Manohar Ghodgaonkar, Federico Lazzaro, Maite Olivera-Pimentel, Mariela 
Artola, Petr Cejka, Martin A. Rejns, Andrew P. Jackson, Paolo Pieviani, Marco Muzi-
Falconi, and Josef Jiricny* 
 
This manuscript investigated the possibility of falsely incorporated ribonucleotides acting 
as strand discrimination signals for MMR during replication. It had recently been 
discovered that replicative polymerases, specially the leading strand polmerase pol ε, 
can misincorporate ribonucleotides into DNA and that a pathway now known as 
ribonucleotide excision repair (RER) removes these from our DNA. It is largely assumed 
that Okazaki fragments signal discontinuities in DNA that MMR uses to distinguish the 
parental strand from the daughter strand during replication. When it comes to the leading 
strand, however, how this occurs remained puzzling and it is only now that the field is 
becoming open to the possibility of MMR hijacking the repair of other lesions and using 
this as a strand discrimination signal. Ribonucleotide repair, because of its relatively 
abundant activity on the leading strand during replication, seemed a likely candidate. To 
study this, established biochemical assays for MMR activity as well as yeast reporter 
assays to confirm the hypothesis in vivo were used. These sets of experiments 
demonstrated that indeed, errors ocurring during replication of the leading strand can 
provide additional entry points for MMR, thereby increasing genome fidelity. 
 
I contributed to this study by designing the phagemid used for substrate preparation, 
extract preparation, performing the band shift with recombinant Mutsα which showed that 
it does not recognize rC/G mismatches as substrates (Fig. 1G), helping design the model 
(Fig. 4) as well as by critically reading the manuscript. 
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6 Discussion 
6.1 Studying O6-methylguanine adducts in in vitro replicating systems 
Methylating agents such as MNU, MNNG and their clinical counterpart temozolomide 
generate a broad spectrum of DNA damage in cells and sensitize them to killing, both 
alone and in combination with other damaging agents, a characteristic which is of use in 
the clinic for the treatment of melanoma, certain leukemias and glioblastoma. The finding 
that one lesion in this particular context, O6-methylguanine (meG), is accountable for most 
of the cytotoxic action of these agents has paved the way for a series of follow-up 
observations that should serve to increase the usage specificity of these agents. Given 
that, under physiological conditions, meG can be directly repaired by MGMT and that only 
when MGMT is inhibited does MMR take over and sensitize cells by a factor of 100 when 
compared to controls, the study of the exact contribution and nature of MMR recognition 
of this mutagenic, cytotoxic and carcinogenic lesion is of critical importance. 
Previous in vitro and in vivo studies have painted the following picture:  
• Treatment with SN1-type alkylators induces a G2/M arrest in the second phase of 
the cell cycle. 
• meG is the main cytotoxic lesion; it is in the template during replication. 
• This phenomenon is dependent on MMR proficiency in cells. Due to the strand 
specificity of MMR, meG is irreparable and attempted MMR will restore rather than 
repair the original mismatches.  
• Primer extension assays with recombinant replicative polymerases have shown 
that either C or T can be misincorporated opposite meG.  
• The MMR machinery includes the replicative polymerase pol δ. Also reported to 
be involved are error-prone TLS polymerases such as pol κ and pol η. 
• The second S phase post-treatment is accompanied by strong checkpoint 
activation mediated mainly by the ATR kinase. 
• Interactions between MMR proteins and checkpoint proteins such as ATR and 
Chk1 have been reported. 
 
Two non-mutually exclusive models partake in the discussion of this MMR-induced 
cytotoxicity. The direct signaling model posits that recognition of the meG mismatch is 
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sufficient to trigger cell death, since MMR can communicate directly with the ATR 
checkpoint machinery. The futile cycling hypothesis does not exclude this interaction but, 
based on the G2/M arrest ocurring after the second S phase, hypothesizes that it is 
rather the well-intended albeit futile processing of the mismatches by MMR which 
ultimately gives rise to structures that hinder replication, structures which would form 
behind the replication fork during the first replication but ahead of the second. Reports on 
both scenarios are divided. 
We established the Xenopus egg extract technique system in the laboratory, because it 
allows the single, naturally-synchronous replication of damaged templates in a contained 
in vitro setting where manipulation is more feasable. Other studies with biochemical 
emphasis worked with recombinant proteins and nuclear extracts where one can monitor 
MMR activity on a single meG, but never in the context of replication. The main questions 
we had pertained to the meG lesion itself: does MMR recognize and bind to it throughout 
replication? is there an accumulation of meG/T mismatches and does their presence elicit 
a checkpoint response? Can a single meG generate structures in DNA that could inhibit a 
second round of replication? 
An important achievement was the generation of Xenopus antibodies that recognize the 
MMR proteins in the extract. Then followed the analysis of MMR activity in response to 
methylation damage in the extract. 
In our study we could observe dynamic recruitment of main MMR players such as Msh2, 
Msh6, Mlh1 and Exo1 to the chromatin during replication in response to treatment with 
the SN1-type alkylators MNNG and MNU. This was distinct from normal recruitment to 
the chromatin during replication, in that the recruited proteins remained in the chromatin 
after replication was completed and also because it was meG-dependent. All 4 proteins 
could be detected this way, indicating that MMR proteins continue their attempts to 
process the meG lesion behind the replication fork.  
We next assessed what previous studies had implied. Namely, that meG recognition by 
MMR is accompanied by recruitment of a non-canonical ATR checkpoint machinery, 
where recruitment of proteins such as Rad17 or the 9-1-1 complex is dispensable, but 
where at least recruitment of ATR and its interaction partner ATRIP, as well as its 
activator TopBP1, should be observed. In replication reactions where increasing doses of 
the methylating agent were used, we were clearly able to detect a dose- and meG-
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dependent recruitment of MMR proteins to the chromatin, but an ATR machinery co-
dependency was not observed. Treatment with MMS, which elicits cell death through the 
generation of DSBs and is considered a radiomimetic but also generates a small amount 
of meGs, led to strong checkpoint machinery recruitment. This served to underscore that 
presence of meGs is not warranted for such a recruitment.  
We were also able to confirm that since SN1-type alkylators generate a plethora of 
different lesions, increasing the treatment dose can indeed activate a checkpoint but that 
this is MMR-independent and is most likely due to the processing of other lesions in 
close proximity to one another. 
After confirming this meG-dependent activity we switched to a different extract system, 
which allowed the replication of specific single meG-containing substrates as well as of 
control substrates. Xenopus mismatch repair assays had confirmed that meG/T was a 
better substrate for MMR than meG/C, so we were intrigued by the possibility that 
presence of either a meG/C or meG/T could trigger a response in the extract that could 
inhibit replication. This would mimic a scenario where the only difference between the 
first and second S phase was the initial presence of meG/C immediately after treatment as 
opposed to the presence of meG/T in the DNA generated during the previous S phase. 
This distinction can only be made in a replication extract with specific meG substrates and 
not with MNNG or MNU treatment as is done in cell culture work. 
Replication of all substrates was comparable. As observed by [α-32P]dCMP incorporation 
into the substrate during replication, only a slight decrease in product formation could be 
detected. When we analyzed the kinetics of checkpoint activation during this replication, 
we could detect, similarly to the experiments with the MNU or MNNG-pretreated 
chromatin, that there is no checkpoint activation at the end of replication. We could 
detect, however, a transient checkpoint activation in response to  lesion recognition. This 
was interesting, since it confirms observations made by others about MMR directly 
interacting with the ATR checkpoint machinery to signal the presence of a mismatch. The 
fact that it is short-lived and doesn't affect replication makes it hard to imagine that cell 
arrest or cell death could result from it. Also, we observed that incubation of a T/G 
substrate could also lead to a similar transient checkpoint activation as can be seen in 
Fig. 18. This result is preliminary and puzzling. Since T/Gs are more common 
physiological mismatches that can be repaired, it would indicate a general MMR 
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recognition mechanism that is not meG specific. Whether this is due to knicking of the 
DNA upon mismatch recognition or whether it causes a change in the chromatin 
environment recognized by proteins that monitor replication remains to be established. 
Recently, a report by Noonan et al. reported a related observation in cells [324]. When 
they analyzed the cell cycle profiles and checkpoint response to MNNG in TK6 cells 
(MMR proficient and MGMT deficient) and compared it to MMR deficient TK6/MMR- as 
well as MGMT proficient TK6/MGMT+  cells, they also observed weak checkpoint 
activation (ATR, Chk1, γH2AX) and transient replication slow-down during the first S 
phase. They were quick to acknowledge, however, that this damage signaling occuring 
upon initial lesion recognition is not sufficient to invoke cell death and that apoptosis can 
be observed only after cells progress into the second round of replication, where futile 
cycling presumably leads to replication fork collapse. What then is the difference 
between the first and second rounds of replication that allows survival during the first cell 
cycle but not during the second? 
Work done by Mojas et al. had previously reported that treatment of cells with MNNG 
could leave small gaps behind the replication fork. It was discussed that these could be 
the main culprit in the observed cytotoxicity. Small gaps behind the fork that are being 
repaired could probably escape checkpoint monitoring since MMR iterative repair 
attempts behind the fork would not allow prolongued exposure of ssDNA regions (RPA-
coated ssDNA regions being the assumed substrate for ATR activation). During the 
second S phase, however, the replication fork would encounter them and collide with 
MMR. It remains unclear whether MMR could recognize these lesions ahead of the fork 
and continue its repair attempts. It has been shown that MMR activity can interfere with 
chromatin assembly to access mismatches, so it remains a possibility [100, 103]. In any 
case, unwinding of the meG-containing gapped chromatin alone would lead to replication 
stress.  
Final proof that MMR activity on meG lesions leads to gaps was still missing, because the 
experimental setup in cells is not available and in non-replicating extracts distinguishing 
normal MMR activity from futile cycling is difficult, since both repair of a T/G mismatch 
and a meG-containing mismatch would incorporate new nucleotides in the excised strand 
and be detected by the use of radioactivity. In Xenopus egg extracts, gapped substrates 
have been shown to trigger a strong checkpoint response, so we asked whether 
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processing of meGs could indeed lead to gap formation after replication is complete. The 
result obtained from the replication of a meG- containing substrate in the Xenopus extract 
was clear: formation of new mismatches during replication leads to lesion recognition 
and persistent MMR activity on the meG. Isolation of the replicated substrate and a 
radioactive fill-in with Klenow polymerase revealed the presence of gaps opposite the 
meG which, as expected, was still present in the template strand after replication. With 
this final observation we were able to confirm MMR futile cycling in reponse to meG. Even 
though it is known that gapped substrates lead to checkpoint activation in the extracts, 
we wanted to confirm this during a re-replication reaction in a more physiological 
scenario with MNU-damaged sperm chromatin. This final experiment confirmed that, 
after replication of a meG-containing template is completed and the template is isolated, 
re-replication of the damaged template is severely impaired in the extract where MMR 
has taken over processing of the meG lesions and is creating gaps opposite it.  
This analysis has provided us with biochemical evidence supporting that abortive repair 
of meG lesions can extend to the formation of gapped DNA. Nevertheless, the direct 
consequence of the presence of these gapped intermediates remains open to 
discussion. That DSBs could arise upon replication forks encountering the lesions is 
evident. Whether other mechanisms, such as fork reversal, which can also activate the 
DNA damage response and which is emerging as a common ocurrence during 
replicative stress [325-327], could also play a role in activating the DNA damage 
response parallel or prior to this remains to be analyzed and would be interesting when 
thinking of possible combinational therapy.  
Studies carried out to date have assumed that whatever transpired in the DNA during the 
first S phase, such as the formation of gaps, persists during mitosis, probably due to the 
condensed nature of the chromatin and relative inaccessability of repair proteins to 
damaged DNA. Even though MutSα is expressed in G2/M, whether its activity is tightly 
regulated by post-translational modifications that inhibit it during this time is unknown. In 
general, the DNA damage response in mitotic cells remains poorly understood and MMR 
processing of the lesion in mitosis seems unlikely. What is known, is that deleterious 
lesions such as DSBs induced by IR do not hinder mitotic progression per se, but they do 
lead to H2AX phosphorylation, for example, thus priming the cell for a full-blown DNA 
damage response. Similarly, recognition of the meGs during the following G1 phase by 
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non-canonical MMR [310, 328] should not be ruled out but is also beyond the scope of 
this thesis. 
Finally, the generation of antibodies specific for Xenopus MMR proteins provides a useful 
tool in studies related to their role in replication or in the repair of other lesions, such as 
mispairs generated upon oxidative damage or ICLs. There are preliminary indications 
that the affinity-purified antibodies can also be used for immunoprecipitation, which 
would be of interest for possible protein-protein interaction studies in the XEE. 
Additionally, as seen in Fig. 19 of this thesis, it is also possible to replicate biotinylated 
substrates in the HSS+NPE extract, which provides the unique opportunity of chipping 
the susbtrate via streptavidin-bead pulldown and detecting proteins bound specifically to 
the  meG either by western blotting or mass-spectrometry. In this experimental setup, the 
Xenopus MMR antibodies could be used to detect MMR proteins binding to meG as a 
positive control. 
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6.2 Recognition of O6-methylguanine adducts by MutSβ and its possible 
implications 
Perhaps the most solid evidence in support of the direct signaling hypothesis is the 
report of separation of function mutants in mouse Msh2 and Msh6 that allow for 
nucleotide binding but not further lesion processing, and which still activate apoptosis in 
response to treatment with DNA damaging agents such as cisplatin and MNNG. In the 
case of MNNG at least, this response involves a G2/M arrest in the second cell cycle 
after treatment. This is where this model begins to contradict itself, since lesion 
recognition occurs during a first S phase and this hypothesis does not allow for an 
explanation as to why arrest and cell death occur after a second S phase. In strong 
opposition to reports supporting the direct signaling hypothesis, others have reported a 
definite requirement for downstream MMR players such as MLH1 and EXO1 in this 
apoptotic response, both of which are involved in the excision step during MMR [206, 
329]. Also noteworthy, a human cell line harboring a mutation in MSH6 that disables 
MutSα sliding along the DNA and is considered MMR deficient like the mutant MEFs, is 
resistant to MNNG [330, 331]. 
We hypothesized that the disparity between these studies could maybe be explained by 
recognition and processing of the meG lesion by a MMR player which has been reported 
to have partial redundancy with MutSα: MutSβ. Neither of the aforementioned studies 
established whether MutSβ was still active in the mouse embryonic fibroblast (MEF) 
extract they tested for MMR activity. In fact, the repair deficiency of these extracts was 
observed by using mismatches other than the most relevant meG-containing 
mismatches.   Moreover, it is interesting to note that sensitivity to one of the 
chemotherapeutic agents which was used in the studies, cisplatin, could be MutSβ− 
related, since it has been implicated in this type of repair. This was not discussed 
because, at the time, a role for MutSβ in ICL repair was considered unlikely. This 
heterodimer, composed of MSH2 and MSH3, was also recently reported to be involved in 
the cytotoxic response to 5-fluorouracil [188], a novel observation that implicated it in 
recognition of a lesion traditionally assigned to MutSα and BER [187]. 
Xenopus MMR assays first indicated that immunodepletion of Msh6 from the extract 
could abolish repair activity for all but the meG/T substrate. The fact that there was 
residual Msh2 in the extract prompted us to investigate further whether Msh2 dimerised 
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with Msh3 could still be attempting meG repair. Preliminary in vitro experiments conducted 
so far would indicate that this is indeed the case. Recombinant human MutSβ showed 
some affinity for meG-containing duplexes in an EMSA, and MMR-deficient LoVo extracts 
supplemented with either MutSα or MutSβ restored repair activity on a meG/T substrate. 
We were particularly interested in mismatch recognition in the HCT15 cell line, which 
only expresses MutSβ.  Surprisingly, it not only displayed repair activity on a meG/T 
susbtrate, but also on a T/G substrate which contradicts the results obtained by a 
different laboratory [293]. Here, a MMR assay performed with HCT15 cell extract showed 
no repair activity for T/G (meG/T recognition was not tested). 
We cannot yet assess whether MutSβ is able to recognize this lesion in vivo or whether 
this recognition would lead to canonical MMR machinery activation and recruitment. 
Reports of MutSβ involvement in ICL repair have been quick to point out that it occurs 
independently of MLH1 recruitment, for example [202]. Nevertheless, the possibility of 
MutSβ recognition of meG lesions remains intriguing.  
Our first attempt at analyzing this further has so far brought inconclusive results. We 
monitored recruitment of MMR proteins to chromatin after a 3 h treatment with MNU in 
U2OS cells but, at least in this cell line, MSH3 is strongly present on chromatin 
regardless of treatment. Whether this can be attributed to the traditional role of MSH3 in 
IDL repair, or to a possible role in the repair of other types of endogenous damage such 
as DSBs is a possibility, since MSH3 deficiency, similarly to a BRCA1 deficiency which 
impairs DSB repair, has been reported to further sensitize cells to PARP inhibition [332].  
A previous study conducted in the HCT15 cell line compared its survival to MNU 
treatment with that of the MSH6-proficient counterpart HCT15+chromosome 2 
(HCT15+Chr2) cell line [323]. This study showed only a slight difference in sensitivity 
towards MNU, not obvious resistance as is expected from a MMR deficient cell line. 
Since this cell line only expresses MutSβ, it would be interesting to investigate whether it 
is more resistant to treatment with MNU upon downregulation of MSH2 or MSH3 and 
perhaps even show a more obvious recruitment to  meG lesions. We find that this would 
be more conclusive than compairing different cells lines (HCT15 and HCT15+Chr2), 
since western blot analysis of the MMR components in the cell extracts revealed that the 
amount of MSH2 differs significantly in these two cell lines and this could be a factor 
affecting sensitivity to treatments.  
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It would be interesting to test whether this can be seen in other cell lines paired against 
each other, such as the human promyelocytic cell lines HL60 and HL60R, the former of 
which overexpress MSH3 and is considered MMR deficient [333].  
With regards to the point mutations in Msh2 or Msh6 that might uncouple damage 
signaling from repair, it would be important to see whether the said mutations also affect 
MutSβ translocation along the DNA, as it was observed for MutSα. This cannot be ruled 
out because structural studies have shown that these two heterodimers have distinct 
binding modes for their substrates and MutSβ appears to be more flexible when it comes 
to lesion recognition and binding [334, 335]. That different residues in both heterodimers 
are responsible for lesion recognition or processing can be exemplified by the fact that 
the conserved Phe-X-Glu motif that both the prokaryotic MutS homodimer and MutSα 
possess for stacking onto the mispair base is missing in both yeast and human MSH3. 
Instead, there is a lysine instead of phenylalanine and lysine or arginine instead of 
glutamate [336]. 
 Further in vitro and in vivo studies employing a MutSβ carrying the mutation in MSH2 
would be neccessary to bring clarity to the discussion about meG recognition and its 
consequences. In general, not enough is known about how MutSβ and MutSα activities 
are regulated during S phase and how their respective interactions with other proteins 
help dictate their cellular function.  
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7 Conclusions and perspectives  
The MMR machinery is a highly-conserved DNA repair mechanism that can be found in  
bacteria, plants and humans. This pathway increases the fidelity of replication by several 
orders of magnitude. It also tackles mispairs arising from treatment of cells with 
chemotherapeutic agents such as temozolomide. In this context, MMR activity sensitizes 
cells to killing by these agents at lower doses than would be neccessary for non-MMR 
mediated killing. In a clinical context, this means less harmful side-effects for patients 
treated with these agents. 
The importance of this pathway and its repair activity for maintenance of genomic 
integrity becomes evident when mutations in components such as MSH2 and MLH1 are 
correlated with susceptibility to human non-polyposis colorectal cancer (HNPCC).  
This study focused on the MMR-dependent mode of action that significantly attenuates 
tolerance to treatment with SN1-type alkylators such as MNNG, MNU or temozolomide. In 
this, more focus on the interplay between MMR, signaling activity and mismatch 
recognition during replication was of vital importance, to be able to correctly assess 
and/or develop strategies for more specificity of these treaments. This was possible with 
the use of the XEE technique and the generation of specific tools for the study of 
Xenopus MMR, which is closely related to human MMR. Parallel to this, a possible role 
for the MutSβ in meG processing which merits further investigation was uncovered. 
At a time where screening of patients for specific mutations is becoming increasingly 
common and neccessary for treatment discussion (e.g. BRCA1 and BRCA2 mutations in 
breast and ovarian cancer), where sufficient knowledge is available that one can envision 
the direct consequence of some defective DNA repair genes or DNA repair protein 
function, and where targeted delivery of DNA damage to cancerous cells is a priority, the 
pursuit of knowledge in the DNA repair field that has clinical application is vital to the 
scientific community, but should be conducted with care. Additional thorough 
investigation of the MMR pathway, its interactome, its post-translational regulation and its 
cell-cycle regulation are areas of interest that would help amass and apply knowledge in 
this field. 
  
REFERENCES 
 
 
 
105 
 
8 References 
1. Evrin, C., et al., A double-hexameric MCM2-7 complex is loaded onto origin DNA 
during licensing of eukaryotic DNA replication. Proceedings of the National 
Academy of Sciences of the United States of America, 2009. 106(48): p. 20240-5. 
2. Gambus, A., et al., MCM2-7 form double hexamers at licensed origins in 
Xenopus egg extract. The Journal of biological chemistry, 2011. 286(13): p. 
11855-64. 
3. Bell, S.P. and A. Dutta, DNA replication in eukaryotic cells. Annual review of 
biochemistry, 2002. 71: p. 333-74. 
4. Machida, Y.J., J.L. Hamlin, and A. Dutta, Right place, right time, and only once: 
replication initiation in metazoans. Cell, 2005. 123(1): p. 13-24. 
5. Piergiovanni, G. and V. Costanzo, GEMC1 is a novel TopBP1-interacting protein 
involved in chromosomal DNA replication. Cell cycle, 2010. 9(18): p. 3662-6. 
6. Balestrini, A., et al., GEMC1 is a TopBP1-interacting protein required for 
chromosomal DNA replication. Nature cell biology, 2010. 12(5): p. 484-91. 
7. Kumagai, A., A. Shevchenko, and W.G. Dunphy, Treslin collaborates with 
TopBP1 in triggering the initiation of DNA replication. Cell, 2010. 140(3): p. 349-
59. 
8. Sangrithi, M.N., et al., Initiation of DNA replication requires the RECQL4 protein 
mutated in Rothmund-Thomson syndrome. Cell, 2005. 121(6): p. 887-98. 
9. Masai, H., RecQL4: a helicase linking formation and maintenance of a replication 
fork. Journal of biochemistry, 2011. 149(6): p. 629-31. 
10. Burgers, P.M., Polymerase dynamics at the eukaryotic DNA replication fork. The 
Journal of biological chemistry, 2009. 284(7): p. 4041-5. 
11. Heller, R.C., et al., Eukaryotic origin-dependent DNA replication in vitro reveals 
sequential action of DDK and S-CDK kinases. Cell, 2011. 146(1): p. 80-91. 
12. Burke, T.W., et al., Replication factors MCM2 and ORC1 interact with the histone 
acetyltransferase HBO1. The Journal of biological chemistry, 2001. 276(18): p. 
15397-408. 
13. Kuo, A.J., et al., The BAH domain of ORC1 links H4K20me2 to DNA replication 
licensing and Meier-Gorlin syndrome. Nature, 2012. 484(7392): p. 115-9. 
14. Shen, Z. and S.G. Prasanth, Emerging players in the initiation of eukaryotic DNA 
replication. Cell division, 2012. 7(1): p. 22. 
15. Maiorano, D., et al., MCM8 is an MCM2-7-related protein that functions as a DNA 
helicase during replication elongation and not initiation. Cell, 2005. 120(3): p. 315-
28. 
16. Lutzmann, M. and M. Mechali, MCM9 binds Cdt1 and is required for the 
assembly of prereplication complexes. Molecular cell, 2008. 31(2): p. 190-200. 
17. Christov, C.P., et al., Functional requirement of noncoding Y RNAs for human 
chromosomal DNA replication. Molecular and cellular biology, 2006. 26(18): p. 
6993-7004. 
18. Nishimura, K., et al., Mcm8 and Mcm9 form a complex that functions in 
homologous recombination repair induced by DNA interstrand crosslinks. 
Molecular cell, 2012. 47(4): p. 511-22. 
19. Beranek, D.T., Distribution of methyl and ethyl adducts following alkylation with 
monofunctional alkylating agents. Mutation research, 1990. 231(1): p. 11-30. 
REFERENCES 
 
 
 
106 
 
20. Srivenugopal, K.S., et al., Ubiquitination-dependent proteolysis of O6-
methylguanine-DNA methyltransferase in human and murine tumor cells following 
inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. 
Biochemistry, 1996. 35(4): p. 1328-34. 
21. Sedgwick, B. and T. Lindahl, Recent progress on the Ada response for inducible 
repair of DNA alkylation damage. Oncogene, 2002. 21(58): p. 8886-94. 
22. Potter, P.M., et al., Characterisation and nucleotide sequence of ogt, the O6-
alkylguanine-DNA-alkyltransferase gene of E. coli. Nucleic acids research, 1987. 
15(22): p. 9177-93. 
23. Barvaux, V.A., et al., Dual repair modulation reverses Temozolomide resistance 
in vitro. Molecular cancer therapeutics, 2004. 3(2): p. 123-7. 
24. Dinglay, S., et al., Defective processing of methylated single-stranded DNA by E. 
coli AlkB mutants. Genes & development, 2000. 14(16): p. 2097-105. 
25. Aas, P.A., et al., Human and bacterial oxidative demethylases repair alkylation 
damage in both RNA and DNA. Nature, 2003. 421(6925): p. 859-63. 
26. McCulloch, S.D. and T.A. Kunkel, The fidelity of DNA synthesis by eukaryotic 
replicative and translesion synthesis polymerases. Cell research, 2008. 18(1): p. 
148-61. 
27. Jiricny, J., Mismatch repair: the praying hands of fidelity. Current biology : CB, 
2000. 10(21): p. R788-90. 
28. Loeb, L.A., Mutator phenotype may be required for multistage carcinogenesis. 
Cancer research, 1991. 51(12): p. 3075-9. 
29. Schaaper, R.M., Base selection, proofreading, and mismatch repair during DNA 
replication in Escherichia coli. The Journal of biological chemistry, 1993. 268(32): 
p. 23762-5. 
30. Fukui, K., DNA mismatch repair in eukaryotes and bacteria. Journal of nucleic 
acids, 2010. 2010. 
31. Lahue, R.S., K.G. Au, and P. Modrich, DNA mismatch correction in a defined 
system. Science, 1989. 245(4914): p. 160-4. 
32. Burdett, V., et al., In vivo requirement for RecJ, ExoVII, ExoI, and ExoX in methyl-
directed mismatch repair. Proceedings of the National Academy of Sciences of 
the United States of America, 2001. 98(12): p. 6765-70. 
33. Ban, C. and W. Yang, Crystal structure and ATPase activity of MutL: implications 
for DNA repair and mutagenesis. Cell, 1998. 95(4): p. 541-52. 
34. Langle-Rouault, F., G. Maenhaut-Michel, and M. Radman, GATC sequences, 
DNA nicks and the MutH function in Escherichia coli mismatch repair. The EMBO 
journal, 1987. 6(4): p. 1121-7. 
35. Modrich, P., Methyl-directed DNA mismatch correction. The Journal of biological 
chemistry, 1989. 264(12): p. 6597-600. 
36. Viswanathan, M., et al., Redundant exonuclease involvement in Escherichia coli 
methyl-directed mismatch repair. The Journal of biological chemistry, 2001. 
276(33): p. 31053-8. 
37. Mechanic, L.E., B.A. Frankel, and S.W. Matson, Escherichia coli MutL loads DNA 
helicase II onto DNA. The Journal of biological chemistry, 2000. 275(49): p. 
38337-46. 
38. Raschle, M., et al., Identification of hMutLbeta, a heterodimer of hMLH1 and 
hPMS1. The Journal of biological chemistry, 1999. 274(45): p. 32368-75. 
REFERENCES 
 
 
 
107 
 
39. Chen, P.C., et al., Contributions by MutL homologues Mlh3 and Pms2 to DNA 
mismatch repair and tumor suppression in the mouse. Cancer research, 2005. 
65(19): p. 8662-70. 
40. Cannavo, E., et al., Expression of the MutL homologue hMLH3 in human cells 
and its role in DNA mismatch repair. Cancer research, 2005. 65(23): p. 10759-66. 
41. Cannavo, E., et al., Characterization of the interactome of the human MutL 
homologues MLH1, PMS1, and PMS2. The Journal of biological chemistry, 2007. 
282(5): p. 2976-86. 
42. Constantin, N., et al., Human mismatch repair: reconstitution of a nick-directed 
bidirectional reaction. The Journal of biological chemistry, 2005. 280(48): p. 
39752-61. 
43. Zhang, Y., et al., Reconstitution of 5'-directed human mismatch repair in a purified 
system. Cell, 2005. 122(5): p. 693-705. 
44. Bowman, G.D., M. O'Donnell, and J. Kuriyan, Structural analysis of a eukaryotic 
sliding DNA clamp-clamp loader complex. Nature, 2004. 429(6993): p. 724-30. 
45. Pavlov, Y.I., I.M. Mian, and T.A. Kunkel, Evidence for preferential mismatch repair 
of lagging strand DNA replication errors in yeast. Current biology : CB, 2003. 
13(9): p. 744-8. 
46. McCulloch, S.D., L. Gu, and G.M. Li, Nick-dependent and -independent 
processing of large DNA loops in human cells. The Journal of biological 
chemistry, 2003. 278(50): p. 50803-9. 
47. Pluciennik, A. and P. Modrich, Protein roadblocks and helix discontinuities are 
barriers to the initiation of mismatch repair. Proceedings of the National Academy 
of Sciences of the United States of America, 2007. 104(31): p. 12709-13. 
48. Genschel, J., L.R. Bazemore, and P. Modrich, Human exonuclease I is required 
for 5' and 3' mismatch repair. The Journal of biological chemistry, 2002. 277(15): 
p. 13302-11. 
49. Wei, K., et al., Inactivation of Exonuclease 1 in mice results in DNA mismatch 
repair defects, increased cancer susceptibility, and male and female sterility. 
Genes & development, 2003. 17(5): p. 603-14. 
50. Schanz, S., et al., Interference of mismatch and base excision repair during the 
processing of adjacent U/G mispairs may play a key role in somatic 
hypermutation. Proceedings of the National Academy of Sciences of the United 
States of America, 2009. 106(14): p. 5593-8. 
51. Kadyrov, F.A., et al., Endonucleolytic function of MutLalpha in human mismatch 
repair. Cell, 2006. 126(2): p. 297-308. 
52. Kadyrov, F.A., et al., Saccharomyces cerevisiae MutLalpha is a mismatch repair 
endonuclease. The Journal of biological chemistry, 2007. 282(51): p. 37181-90. 
53. Pluciennik, A., et al., PCNA function in the activation and strand direction of 
MutLalpha endonuclease in mismatch repair. Proceedings of the National 
Academy of Sciences of the United States of America, 2010. 107(37): p. 16066-
71. 
54. Jiricny, J., The multifaceted mismatch-repair system. Nature reviews. Molecular 
cell biology, 2006. 7(5): p. 335-46. 
55. Iyer, R.R., et al., DNA mismatch repair: functions and mechanisms. Chemical 
reviews, 2006. 106(2): p. 302-23. 
56. Hsieh, P. and K. Yamane, DNA mismatch repair: molecular mechanism, cancer, 
and ageing. Mechanisms of ageing and development, 2008. 129(7-8): p. 391-
407. 
REFERENCES 
 
 
 
108 
 
57. Modrich, P., Mechanisms in eukaryotic mismatch repair. The Journal of biological 
chemistry, 2006. 281(41): p. 30305-9. 
58. Walker, J.E., et al., Distantly related sequences in the alpha- and beta-subunits of 
ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common 
nucleotide binding fold. The EMBO journal, 1982. 1(8): p. 945-51. 
59. Lamers, M.H., H.H. Winterwerp, and T.K. Sixma, The alternating ATPase 
domains of MutS control DNA mismatch repair. The EMBO journal, 2003. 22(3): 
p. 746-56. 
60. Liberti, S.E. and L.J. Rasmussen, Is hEXO1 a cancer predisposing gene? 
Molecular cancer research : MCR, 2004. 2(8): p. 427-32. 
61. Schmutte, C., et al., The interaction of DNA mismatch repair proteins with human 
exonuclease I. The Journal of biological chemistry, 2001. 276(35): p. 33011-8. 
62. Johnson, A. and M. O'Donnell, Cellular DNA replicases: components and 
dynamics at the replication fork. Annual review of biochemistry, 2005. 74: p. 283-
315. 
63. Umar, A., et al., Requirement for PCNA in DNA mismatch repair at a step 
preceding DNA resynthesis. Cell, 1996. 87(1): p. 65-73. 
64. Iyer, R.R., et al., The MutSalpha-proliferating cell nuclear antigen interaction in 
human DNA mismatch repair. The Journal of biological chemistry, 2008. 283(19): 
p. 13310-9. 
65. Kleczkowska, H.E., et al., hMSH3 and hMSH6 interact with PCNA and colocalize 
with it to replication foci. Genes & development, 2001. 15(6): p. 724-36. 
66. Clark, A.B., et al., Functional interaction of proliferating cell nuclear antigen with 
MSH2-MSH6 and MSH2-MSH3 complexes. The Journal of biological chemistry, 
2000. 275(47): p. 36498-501. 
67. Lamers, M.H., et al., The crystal structure of DNA mismatch repair protein MutS 
binding to a G x T mismatch. Nature, 2000. 407(6805): p. 711-7. 
68. Obmolova, G., et al., Crystal structures of mismatch repair protein MutS and its 
complex with a substrate DNA. Nature, 2000. 407(6805): p. 703-10. 
69. Crothers, D.M., The Kinetics of DNA Denaturation. Journal of molecular biology, 
1964. 9: p. 712-33. 
70. Radman, M., et al., Processing of mispaired and unpaired bases in heteroduplex 
DNA in E. coli. Biochimie, 1985. 67(7-8): p. 745-52. 
71. Brown, T.C. and J. Jiricny, Different base/base mispairs are corrected with 
different efficiencies and specificities in monkey kidney cells. Cell, 1988. 54(5): p. 
705-11. 
72. Natrajan, G., et al., Structures of Escherichia coli DNA mismatch repair enzyme 
MutS in complex with different mismatches: a common recognition mode for 
diverse substrates. Nucleic acids research, 2003. 31(16): p. 4814-21. 
73. Warren, J.J., et al., Structure of the human MutSalpha DNA lesion recognition 
complex. Molecular cell, 2007. 26(4): p. 579-92. 
74. Bjornson, K.P., D.J. Allen, and P. Modrich, Modulation of MutS ATP hydrolysis by 
DNA cofactors. Biochemistry, 2000. 39(11): p. 3176-83. 
75. Junop, M.S., et al., Composite active site of an ABC ATPase: MutS uses ATP to 
verify mismatch recognition and authorize DNA repair. Molecular cell, 2001. 7(1): 
p. 1-12. 
76. Gradia, S., et al., hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp 
on mismatched DNA. Molecular cell, 1999. 3(2): p. 255-61. 
REFERENCES 
 
 
 
109 
 
77. Lamers, M.H., et al., ATP increases the affinity between MutS ATPase domains. 
Implications for ATP hydrolysis and conformational changes. The Journal of 
biological chemistry, 2004. 279(42): p. 43879-85. 
78. Boland, C.R. and R. Fishel, Lynch syndrome: form, function, proteins, and 
basketball. Gastroenterology, 2005. 129(2): p. 751-5. 
79. Tessmer, I., et al., Mechanism of MutS searching for DNA mismatches and 
signaling repair. The Journal of biological chemistry, 2008. 283(52): p. 36646-54. 
80. Wang, H., et al., DNA bending and unbending by MutS govern mismatch 
recognition and specificity. Proceedings of the National Academy of Sciences of 
the United States of America, 2003. 100(25): p. 14822-7. 
81. Roberts, R.J. and X. Cheng, Base flipping. Annual review of biochemistry, 1998. 
67: p. 181-98. 
82. Peltomaki, P., Role of DNA mismatch repair defects in the pathogenesis of 
human cancer. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology, 2003. 21(6): p. 1174-9. 
83. Modrich, P. and R. Lahue, Mismatch repair in replication fidelity, genetic 
recombination, and cancer biology. Annual review of biochemistry, 1996. 65: p. 
101-33. 
84. Fishel, R., et al., The human mutator gene homolog MSH2 and its association 
with hereditary nonpolyposis colon cancer. Cell, 1993. 75(5): p. 1027-38. 
85. Leach, F.S., et al., Mutations of a mutS homolog in hereditary nonpolyposis 
colorectal cancer. Cell, 1993. 75(6): p. 1215-25. 
86. Bronner, C.E., et al., Mutation in the DNA mismatch repair gene homologue 
hMLH1 is associated with hereditary non-polyposis colon cancer. Nature, 1994. 
368(6468): p. 258-61. 
87. Jiricny, J., Replication errors: cha(lle)nging the genome. The EMBO journal, 
1998. 17(22): p. 6427-36. 
88. Papadopoulos, N. and A. Lindblom, Molecular basis of HNPCC: mutations of 
MMR genes. Human mutation, 1997. 10(2): p. 89-99. 
89. Buermeyer, A.B., et al., Mammalian DNA mismatch repair. Annual review of 
genetics, 1999. 33: p. 533-64. 
90. Prolla, T.A., et al., Tumour susceptibility and spontaneous mutation in mice 
deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nature genetics, 1998. 
18(3): p. 276-9. 
91. Harfe, B.D. and S. Jinks-Robertson, DNA mismatch repair and genetic instability. 
Annual review of genetics, 2000. 34: p. 359-399. 
92. Peng, M., et al., The FANCJ/MutLalpha interaction is required for correction of the 
cross-link response in FA-J cells. The EMBO journal, 2007. 26(13): p. 3238-49. 
93. Stavnezer, J. and C.E. Schrader, Mismatch repair converts AID-instigated nicks 
to double-strand breaks for antibody class-switch recombination. Trends in 
genetics : TIG, 2006. 22(1): p. 23-8. 
94. Chahwan, R., et al., The ATPase activity of MLH1 is required to orchestrate DNA 
double-strand breaks and end processing during class switch recombination. The 
Journal of experimental medicine, 2012. 209(4): p. 671-8. 
95. Pena-Diaz, J. and J. Jiricny, PCNA and MutLalpha: partners in crime in triplet 
repeat expansion? Proceedings of the National Academy of Sciences of the 
United States of America, 2010. 107(38): p. 16409-10. 
REFERENCES 
 
 
 
110 
 
96. Nick McElhinny, S.A., et al., Abundant ribonucleotide incorporation into DNA by 
yeast replicative polymerases. Proceedings of the National Academy of Sciences 
of the United States of America, 2010. 107(11): p. 4949-54. 
97. Nick McElhinny, S.A., et al., Genome instability due to ribonucleotide 
incorporation into DNA. Nature chemical biology, 2010. 6(10): p. 774-81. 
98. Ghodgaonkar, M.M., et al., Ribonucleotides Misincorporated into DNA Act as 
Strand-Discrimination Signals in Eukaryotic Mismatch Repair. Molecular cell, 
2013. 
99. Li, G.M., Mechanisms and functions of DNA mismatch repair. Cell research, 
2008. 18(1): p. 85-98. 
100. Schopf, B., et al., Interplay between mismatch repair and chromatin assembly. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2012. 109(6): p. 1895-900. 
101. Li, F., et al., Evidence that nucleosomes inhibit mismatch repair in eukaryotic 
cells. The Journal of biological chemistry, 2009. 284(48): p. 33056-61. 
102. Javaid, S., et al., Nucleosome remodeling by hMSH2-hMSH6. Molecular cell, 
2009. 36(6): p. 1086-94. 
103. Kadyrova, L.Y., E.R. Blanko, and F.A. Kadyrov, CAF-I-dependent control of 
degradation of the discontinuous strands during mismatch repair. Proceedings of 
the National Academy of Sciences of the United States of America, 2011. 108(7): 
p. 2753-8. 
104. Li, F., et al., The histone mark H3K36me3 regulates human DNA mismatch repair 
through its interaction with MutSalpha. Cell, 2013. 153(3): p. 590-600. 
105. Christmann, M., M.T. Tomicic, and B. Kaina, Phosphorylation of mismatch repair 
proteins MSH2 and MSH6 affecting MutSalpha mismatch-binding activity. Nucleic 
acids research, 2002. 30(9): p. 1959-66. 
106. Edelbrock, M.A., S. Kaliyaperumal, and K.J. Williams, Structural, molecular and 
cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage 
signaling and other noncanonical activities. Mutation research, 2013. 
107. Pleschke, J.M., et al., Poly(ADP-ribose) binds to specific domains in DNA 
damage checkpoint proteins. The Journal of biological chemistry, 2000. 275(52): 
p. 40974-80. 
108. Gagne, J.P., et al., Proteome-wide identification of poly(ADP-ribose) binding 
proteins and poly(ADP-ribose)-associated protein complexes. Nucleic acids 
research, 2008. 36(22): p. 6959-76. 
109. Wilson, D.M., 3rd and V.A. Bohr, The mechanics of base excision repair, and its 
relationship to aging and disease. DNA repair, 2007. 6(4): p. 544-59. 
110. Lindahl, T., DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and 
base excision-repair. Progress in nucleic acid research and molecular biology, 
1979. 22: p. 135-92. 
111. Ide, H. and M. Kotera, Human DNA glycosylases involved in the repair of 
oxidatively damaged DNA. Biological & pharmaceutical bulletin, 2004. 27(4): p. 
480-5. 
112. Matsumoto, Y. and K. Kim, Excision of deoxyribose phosphate residues by DNA 
polymerase beta during DNA repair. Science, 1995. 269(5224): p. 699-702. 
113. Kubota, Y., et al., Reconstitution of DNA base excision-repair with purified human 
proteins: interaction between DNA polymerase beta and the XRCC1 protein. The 
EMBO journal, 1996. 15(23): p. 6662-70. 
REFERENCES 
 
 
 
111 
 
114. Caldecott, K.W., et al., An interaction between the mammalian DNA repair protein 
XRCC1 and DNA ligase III. Molecular and cellular biology, 1994. 14(1): p. 68-76. 
115. Frosina, G., et al., Two pathways for base excision repair in mammalian cells. 
The Journal of biological chemistry, 1996. 271(16): p. 9573-8. 
116. Robertson, A.B., et al., DNA repair in mammalian cells: Base excision repair: the 
long and short of it. Cellular and molecular life sciences : CMLS, 2009. 66(6): p. 
981-93. 
117. Dianov, G.L. and U. Hubscher, Mammalian Base Excision Repair: the Forgotten 
Archangel. Nucleic acids research, 2013. 
118. Bohr, V.A., et al., DNA repair in an active gene: removal of pyrimidine dimers 
from the DHFR gene of CHO cells is much more efficient than in the genome 
overall. Cell, 1985. 40(2): p. 359-69. 
119. Tornaletti, S., Transcription arrest at DNA damage sites. Mutation research, 2005. 
577(1-2): p. 131-45. 
120. Wang, L., F. Sun, and T. Chen, Prioritizing functional modules mediating genetic 
perturbations and their phenotypic effects: a global strategy. Genome biology, 
2008. 9(12): p. R174. 
121. Bootsma, D., et al., Nucleotide excision repair syndromes: molecular basis and 
clinical symptoms. Philosophical transactions of the Royal Society of London. 
Series B, Biological sciences, 1995. 347(1319): p. 75-81. 
122. Sugasawa, K., et al., A multistep damage recognition mechanism for global 
genomic nucleotide excision repair. Genes & development, 2001. 15(5): p. 507-
21. 
123. Araki, M., et al., Centrosome protein centrin 2/caltractin 1 is part of the xeroderma 
pigmentosum group C complex that initiates global genome nucleotide excision 
repair. The Journal of biological chemistry, 2001. 276(22): p. 18665-72. 
124. Maillard, O., S. Solyom, and H. Naegeli, An aromatic sensor with aversion to 
damaged strands confers versatility to DNA repair. PLoS biology, 2007. 5(4): p. 
e79. 
125. Watkins, J.F., et al., The Saccharomyces cerevisiae DNA repair gene RAD23 
encodes a nuclear protein containing a ubiquitin-like domain required for 
biological function. Molecular and cellular biology, 1993. 13(12): p. 7757-65. 
126. Payne, A. and G. Chu, Xeroderma pigmentosum group E binding factor 
recognizes a broad spectrum of DNA damage. Mutation research, 1994. 310(1): 
p. 89-102. 
127. Groisman, R., et al., The ubiquitin ligase activity in the DDB2 and CSA complexes 
is differentially regulated by the COP9 signalosome in response to DNA damage. 
Cell, 2003. 113(3): p. 357-67. 
128. Groisman, R., et al., CSA-dependent degradation of CSB by the ubiquitin-
proteasome pathway establishes a link between complementation factors of the 
Cockayne syndrome. Genes & development, 2006. 20(11): p. 1429-34. 
129. Sugasawa, K., et al., UV-induced ubiquitylation of XPC protein mediated by UV-
DDB-ubiquitin ligase complex. Cell, 2005. 121(3): p. 387-400. 
130. Compe, E. and J.M. Egly, TFIIH: when transcription met DNA repair. Nature 
reviews. Molecular cell biology, 2012. 13(6): p. 343-54. 
131. Winkler, G.S., et al., TFIIH with inactive XPD helicase functions in transcription 
initiation but is defective in DNA repair. The Journal of biological chemistry, 2000. 
275(6): p. 4258-66. 
REFERENCES 
 
 
 
112 
 
132. Coin, F., V. Oksenych, and J.M. Egly, Distinct roles for the XPB/p52 and XPD/p44 
subcomplexes of TFIIH in damaged DNA opening during nucleotide excision 
repair. Molecular cell, 2007. 26(2): p. 245-56. 
133. Jones, C.J. and R.D. Wood, Preferential binding of the xeroderma pigmentosum 
group A complementing protein to damaged DNA. Biochemistry, 1993. 32(45): p. 
12096-104. 
134. Matsuda, T., et al., DNA repair protein XPA binds replication protein A (RPA). The 
Journal of biological chemistry, 1995. 270(8): p. 4152-7. 
135. O'Donovan, A., et al., XPG endonuclease makes the 3' incision in human DNA 
nucleotide excision repair. Nature, 1994. 371(6496): p. 432-5. 
136. Mu, D., D.S. Hsu, and A. Sancar, Reaction mechanism of human DNA repair 
excision nuclease. The Journal of biological chemistry, 1996. 271(14): p. 8285-
94. 
137. Moser, J., et al., Sealing of chromosomal DNA nicks during nucleotide excision 
repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. 
Molecular cell, 2007. 27(2): p. 311-23. 
138. Jackson, S.P. and J. Bartek, The DNA-damage response in human biology and 
disease. Nature, 2009. 461(7267): p. 1071-8. 
139. Dudley, D.D., et al., Mechanism and control of V(D)J recombination versus class 
switch recombination: similarities and differences. Advances in immunology, 
2005. 86: p. 43-112. 
140. Zickler, D. and N. Kleckner, The leptotene-zygotene transition of meiosis. Annual 
review of genetics, 1998. 32: p. 619-97. 
141. Bailey, S.M., et al., DNA double-strand break repair proteins are required to cap 
the ends of mammalian chromosomes. Proceedings of the National Academy of 
Sciences of the United States of America, 1999. 96(26): p. 14899-904. 
142. Mao, Z., et al., Comparison of nonhomologous end joining and homologous 
recombination in human cells. DNA repair, 2008. 7(10): p. 1765-71. 
143. McVey, M. and S.E. Lee, MMEJ repair of double-strand breaks (director's cut): 
deleted sequences and alternative endings. Trends in genetics : TIG, 2008. 
24(11): p. 529-38. 
144. Doherty, A.J. and S.P. Jackson, DNA repair: how Ku makes ends meet. Current 
biology : CB, 2001. 11(22): p. R920-4. 
145. Ma, Y., et al., Hairpin opening and overhang processing by an Artemis/DNA-
dependent protein kinase complex in nonhomologous end joining and V(D)J 
recombination. Cell, 2002. 108(6): p. 781-94. 
146. Martin, I.V. and S.A. MacNeill, ATP-dependent DNA ligases. Genome biology, 
2002. 3(4): p. REVIEWS3005. 
147. Calsou, P., et al., Coordinated assembly of Ku and p460 subunits of the DNA-
dependent protein kinase on DNA ends is necessary for XRCC4-ligase IV 
recruitment. Journal of molecular biology, 2003. 326(1): p. 93-103. 
148. de Jager, M., et al., Human Rad50/Mre11 is a flexible complex that can tether 
DNA ends. Molecular cell, 2001. 8(5): p. 1129-35. 
149. Nimonkar, A.V., et al., Human exonuclease 1 and BLM helicase interact to resect 
DNA and initiate DNA repair. Proceedings of the National Academy of Sciences 
of the United States of America, 2008. 105(44): p. 16906-11. 
150. Sartori, A.A., et al., Human CtIP promotes DNA end resection. Nature, 2007. 
450(7169): p. 509-14. 
REFERENCES 
 
 
 
113 
 
151. Nimonkar, A.V., et al., BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN 
constitute two DNA end resection machineries for human DNA break repair. 
Genes & development, 2011. 25(4): p. 350-62. 
152. Fernandez-Capetillo, O., et al., H2AX: the histone guardian of the genome. DNA 
repair, 2004. 3(8-9): p. 959-67. 
153. Doil, C., et al., RNF168 binds and amplifies ubiquitin conjugates on damaged 
chromosomes to allow accumulation of repair proteins. Cell, 2009. 136(3): p. 435-
46. 
154. Cuadrado, M., et al., ATM regulates ATR chromatin loading in response to DNA 
double-strand breaks. The Journal of experimental medicine, 2006. 203(2): p. 
297-303. 
155. Baumann, P., F.E. Benson, and S.C. West, Human Rad51 protein promotes ATP-
dependent homologous pairing and strand transfer reactions in vitro. Cell, 1996. 
87(4): p. 757-66. 
156. Tarsounas, M., D. Davies, and S.C. West, BRCA2-dependent and independent 
formation of RAD51 nuclear foci. Oncogene, 2003. 22(8): p. 1115-23. 
157. Holliday, R., The Induction of Mitotic Recombination by Mitomycin C in Ustilago 
and Saccharomyces. Genetics, 1964. 50: p. 323-35. 
158. McIlwraith, M.J., et al., Human DNA polymerase eta promotes DNA synthesis 
from strand invasion intermediates of homologous recombination. Molecular cell, 
2005. 20(5): p. 783-92. 
159. Bzymek, M., et al., Double Holliday junctions are intermediates of DNA break 
repair. Nature, 2010. 464(7290): p. 937-41. 
160. Wu, L. and I.D. Hickson, The Bloom's syndrome helicase suppresses crossing 
over during homologous recombination. Nature, 2003. 426(6968): p. 870-4. 
161. Helleday, T., et al., DNA double-strand break repair: from mechanistic 
understanding to cancer treatment. DNA repair, 2007. 6(7): p. 923-35. 
162. Ip, S.C., et al., Identification of Holliday junction resolvases from humans and 
yeast. Nature, 2008. 456(7220): p. 357-61. 
163. Jazayeri, A., et al., ATM- and cell cycle-dependent regulation of ATR in response 
to DNA double-strand breaks. Nature cell biology, 2006. 8(1): p. 37-45. 
164. Weterings, E. and D.J. Chen, The endless tale of non-homologous end-joining. 
Cell research, 2008. 18(1): p. 114-24. 
165. Escribano-Diaz, C., et al., A Cell Cycle-Dependent Regulatory Circuit Composed 
of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. 
Molecular cell, 2013. 49(5): p. 872-83. 
166. Waters, L.S., et al., Eukaryotic translesion polymerases and their roles and 
regulation in DNA damage tolerance. Microbiology and molecular biology reviews 
: MMBR, 2009. 73(1): p. 134-54. 
167. Hoege, C., et al., RAD6-dependent DNA repair is linked to modification of PCNA 
by ubiquitin and SUMO. Nature, 2002. 419(6903): p. 135-41. 
168. Branzei, D., M. Seki, and T. Enomoto, Rad18/Rad5/Mms2-mediated 
polyubiquitination of PCNA is implicated in replication completion during 
replication stress. Genes to cells : devoted to molecular & cellular mechanisms, 
2004. 9(11): p. 1031-42. 
169. Haracska, L., et al., Physical and functional interactions of human DNA 
polymerase eta with PCNA. Molecular and cellular biology, 2001. 21(21): p. 7199-
206. 
REFERENCES 
 
 
 
114 
 
170. Hishiki, A., et al., Structural basis for novel interactions between human 
translesion synthesis polymerases and proliferating cell nuclear antigen. The 
Journal of biological chemistry, 2009. 284(16): p. 10552-60. 
171. Moldovan, G.L., et al., Inhibition of homologous recombination by the PCNA-
interacting protein PARI. Molecular cell, 2012. 45(1): p. 75-86. 
172. Gali, H., et al., Role of SUMO modification of human PCNA at stalled replication 
fork. Nucleic acids research, 2012. 40(13): p. 6049-59. 
173. Parnas, O., et al., Elg1, an alternative subunit of the RFC clamp loader, 
preferentially interacts with SUMOylated PCNA. The EMBO journal, 2010. 29(15): 
p. 2611-22. 
174. Sikdar, N., et al., DNA damage responses by human ELG1 in S phase are 
important to maintain genomic integrity. Cell cycle, 2009. 8(19): p. 3199-207. 
175. Wang, W., Emergence of a DNA-damage response network consisting of Fanconi 
anaemia and BRCA proteins. Nature reviews. Genetics, 2007. 8(10): p. 735-48. 
176. Kim, H. and A.D. D'Andrea, Regulation of DNA cross-link repair by the Fanconi 
anemia/BRCA pathway. Genes & development, 2012. 26(13): p. 1393-408. 
177. Ishiai, M., et al., FANCI phosphorylation functions as a molecular switch to turn 
on the Fanconi anemia pathway. Nature structural & molecular biology, 2008. 
15(11): p. 1138-46. 
178. Cole, A.R., L.P. Lewis, and H. Walden, The structure of the catalytic subunit 
FANCL of the Fanconi anemia core complex. Nature structural & molecular 
biology, 2010. 17(3): p. 294-8. 
179. Kratz, K., et al., Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 
sensitizes cells to interstrand crosslinking agents. Cell, 2010. 142(1): p. 77-88. 
180. Crossan, G.P. and K.J. Patel, The Fanconi anaemia pathway orchestrates 
incisions at sites of crosslinked DNA. The Journal of pathology, 2012. 226(2): p. 
326-37. 
181. Ciccia, A., N. McDonald, and S.C. West, Structural and functional relationships of 
the XPF/MUS81 family of proteins. Annual review of biochemistry, 2008. 77: p. 
259-87. 
182. Nijman, S.M., et al., The deubiquitinating enzyme USP1 regulates the Fanconi 
anemia pathway. Molecular cell, 2005. 17(3): p. 331-9. 
183. Joenje, H. and K.J. Patel, The emerging genetic and molecular basis of Fanconi 
anaemia. Nature reviews. Genetics, 2001. 2(6): p. 446-57. 
184. Kennedy, R.D. and A.D. D'Andrea, The Fanconi Anemia/BRCA pathway: new 
faces in the crowd. Genes & development, 2005. 19(24): p. 2925-40. 
185. Enoiu, M., J. Jiricny, and O.D. Scharer, Repair of cisplatin-induced DNA 
interstrand crosslinks by a replication-independent pathway involving 
transcription-coupled repair and translesion synthesis. Nucleic acids research, 
2012. 40(18): p. 8953-64. 
186. Williams, H.L., M.E. Gottesman, and J. Gautier, Replication-independent repair of 
DNA interstrand crosslinks. Molecular cell, 2012. 47(1): p. 140-7. 
187. Fischer, F., K. Baerenfaller, and J. Jiricny, 5-Fluorouracil is efficiently removed 
from DNA by the base excision and mismatch repair systems. Gastroenterology, 
2007. 133(6): p. 1858-68. 
188. Tajima, A., et al., Both hMutSalpha and hMutSss DNA mismatch repair 
complexes participate in 5-fluorouracil cytotoxicity. PloS one, 2011. 6(12): p. 
e28117. 
REFERENCES 
 
 
 
115 
 
189. Aebi, S., et al., Loss of DNA mismatch repair in acquired resistance to cisplatin. 
Cancer research, 1996. 56(13): p. 3087-90. 
190. Papouli, E., P. Cejka, and J. Jiricny, Dependence of the cytotoxicity of DNA-
damaging agents on the mismatch repair status of human cells. Cancer research, 
2004. 64(10): p. 3391-4. 
191. Topping, R.P., J.C. Wilkinson, and K.D. Scarpinato, Mismatch repair protein 
deficiency compromises cisplatin-induced apoptotic signaling. The Journal of 
biological chemistry, 2009. 284(21): p. 14029-39. 
192. Duckett, D.R., et al., Human MutSalpha recognizes damaged DNA base pairs 
containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1996. 93(13): p. 6443-7. 
193. Shimodaira, H., et al., Interaction of mismatch repair protein PMS2 and the p53-
related transcription factor p73 in apoptosis response to cisplatin. Proceedings of 
the National Academy of Sciences of the United States of America, 2003. 100(5): 
p. 2420-5. 
194. Rass, K. and J. Reichrath, UV damage and DNA repair in malignant melanoma 
and nonmelanoma skin cancer. Advances in experimental medicine and biology, 
2008. 624: p. 162-78. 
195. Young, L.C., et al., DNA mismatch repair proteins promote apoptosis and 
suppress tumorigenesis in response to UVB irradiation: an in vivo study. 
Carcinogenesis, 2004. 25(10): p. 1821-7. 
196. Bertrand, P., et al., Physical interaction between components of DNA mismatch 
repair and nucleotide excision repair. Proceedings of the National Academy of 
Sciences of the United States of America, 1998. 95(24): p. 14278-83. 
197. Liu, L. and S.L. Gerson, Targeted modulation of MGMT: clinical implications. 
Clinical cancer research : an official journal of the American Association for 
Cancer Research, 2006. 12(2): p. 328-31. 
198. Fiumicino, S., et al., Sensitivity to DNA cross-linking chemotherapeutic agents in 
mismatch repair-defective cells in vitro and in xenografts. International journal of 
cancer. Journal international du cancer, 2000. 85(4): p. 590-6. 
199. Wang, Y. and J. Qin, MSH2 and ATR form a signaling module and regulate two 
branches of the damage response to DNA methylation. Proceedings of the 
National Academy of Sciences of the United States of America, 2003. 100(26): p. 
15387-92. 
200. Wu, Q., et al., Mismatch repair participates in error-free processing of DNA 
interstrand crosslinks in human cells. EMBO reports, 2005. 6(6): p. 551-7. 
201. Zhao, J., et al., Mismatch repair and nucleotide excision repair proteins cooperate 
in the recognition of DNA interstrand crosslinks. Nucleic acids research, 2009. 
37(13): p. 4420-9. 
202. Zhang, N., et al., hMutSbeta is required for the recognition and uncoupling of 
psoralen interstrand cross-links in vitro. Molecular and cellular biology, 2002. 
22(7): p. 2388-97. 
203. Yip, S., et al., MSH6 mutations arise in glioblastomas during temozolomide 
therapy and mediate temozolomide resistance. Clinical cancer research : an 
official journal of the American Association for Cancer Research, 2009. 15(14): p. 
4622-9. 
204. Quirbt, I., et al., Temozolomide for the treatment of metastatic melanoma. Current 
oncology, 2007. 14(1): p. 27-33. 
REFERENCES 
 
 
 
116 
 
205. Taira, K., et al., Binding of MutS protein to oligonucleotides containing a 
methylated or an ethylated guanine residue, and correlation with mutation 
frequency. Mutation research, 2008. 640(1-2): p. 107-12. 
206. Cejka, P., et al., Methylation-induced G(2)/M arrest requires a full complement of 
the mismatch repair protein hMLH1. The EMBO journal, 2003. 22(9): p. 2245-54. 
207. Stojic, L., et al., Mismatch repair-dependent G2 checkpoint induced by low doses 
of SN1 type methylating agents requires the ATR kinase. Genes & development, 
2004. 18(11): p. 1331-44. 
208. Cejka, P., et al., Homologous recombination rescues mismatch-repair-dependent 
cytotoxicity of S(N)1-type methylating agents in S. cerevisiae. Current biology : 
CB, 2005. 15(15): p. 1395-400. 
209. Mojas, N., M. Lopes, and J. Jiricny, Mismatch repair-dependent processing of 
methylation damage gives rise to persistent single-stranded gaps in newly 
replicated DNA. Genes & development, 2007. 21(24): p. 3342-55. 
210. Swann, P.F., et al., Role of postreplicative DNA mismatch repair in the cytotoxic 
action of thioguanine. Science, 1996. 273(5278): p. 1109-11. 
211. Waters, T.R. and P.F. Swann, Cytotoxic mechanism of 6-thioguanine: 
hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing 
S6-methylthioguanine. Biochemistry, 1997. 36(9): p. 2501-6. 
212. Yan, T., et al., CHK1 and CHK2 are differentially involved in mismatch repair-
mediated 6-thioguanine-induced cell cycle checkpoint responses. Molecular 
cancer therapeutics, 2004. 3(9): p. 1147-57. 
213. Yamane, K., K. Taylor, and T.J. Kinsella, Mismatch repair-mediated G2/M arrest 
by 6-thioguanine involves the ATR-Chk1 pathway. Biochemical and biophysical 
research communications, 2004. 318(1): p. 297-302. 
214. Shiloh, Y., ATM and related protein kinases: safeguarding genome integrity. 
Nature reviews. Cancer, 2003. 3(3): p. 155-68. 
215. Harper, J.W. and S.J. Elledge, The DNA damage response: ten years after. 
Molecular cell, 2007. 28(5): p. 739-45. 
216. Lovejoy, C.A. and D. Cortez, Common mechanisms of PIKK regulation. DNA 
repair, 2009. 8(9): p. 1004-8. 
217. Abraham, R.T., Cell cycle checkpoint signaling through the ATM and ATR 
kinases. Genes & development, 2001. 15(17): p. 2177-96. 
218. Kim, S.T., et al., Substrate specificities and identification of putative substrates of 
ATM kinase family members. The Journal of biological chemistry, 1999. 274(53): 
p. 37538-43. 
219. Matsuoka, S., et al., ATM and ATR substrate analysis reveals extensive protein 
networks responsive to DNA damage. Science, 2007. 316(5828): p. 1160-6. 
220. Savitsky, K., et al., A single ataxia telangiectasia gene with a product similar to 
PI-3 kinase. Science, 1995. 268(5218): p. 1749-53. 
221. Uziel, T., et al., Requirement of the MRN complex for ATM activation by DNA 
damage. The EMBO journal, 2003. 22(20): p. 5612-21. 
222. Banin, S., et al., Enhanced phosphorylation of p53 by ATM in response to DNA 
damage. Science, 1998. 281(5383): p. 1674-7. 
223. Canman, C.E., et al., Activation of the ATM kinase by ionizing radiation and 
phosphorylation of p53. Science, 1998. 281(5383): p. 1677-9. 
224. Lavin, M.F., Ataxia-telangiectasia: from a rare disorder to a paradigm for cell 
signalling and cancer. Nature reviews. Molecular cell biology, 2008. 9(10): p. 759-
69. 
REFERENCES 
 
 
 
117 
 
225. Bakkenist, C.J. and M.B. Kastan, DNA damage activates ATM through 
intermolecular autophosphorylation and dimer dissociation. Nature, 2003. 
421(6922): p. 499-506. 
226. Daniel, J.A., et al., Multiple autophosphorylation sites are dispensable for murine 
ATM activation in vivo. The Journal of cell biology, 2008. 183(5): p. 777-83. 
227. Lee, J.H. and T.T. Paull, Activation and regulation of ATM kinase activity in 
response to DNA double-strand breaks. Oncogene, 2007. 26(56): p. 7741-8. 
228. Fernandez-Capetillo, O., C.D. Allis, and A. Nussenzweig, Phosphorylation of 
histone H2B at DNA double-strand breaks. The Journal of experimental medicine, 
2004. 199(12): p. 1671-7. 
229. Kitagawa, R., et al., Phosphorylation of SMC1 is a critical downstream event in 
the ATM-NBS1-BRCA1 pathway. Genes & development, 2004. 18(12): p. 1423-
38. 
230. Bartek, J. and J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer. 
Cancer cell, 2003. 3(5): p. 421-9. 
231. Ahn, J.Y., et al., Threonine 68 phosphorylation by ataxia telangiectasia mutated is 
required for efficient activation of Chk2 in response to ionizing radiation. Cancer 
research, 2000. 60(21): p. 5934-6. 
232. Ahn, J.Y., et al., Phosphorylation of threonine 68 promotes oligomerization and 
autophosphorylation of the Chk2 protein kinase via the forkhead-associated 
domain. The Journal of biological chemistry, 2002. 277(22): p. 19389-95. 
233. Cai, Z., N.H. Chehab, and N.P. Pavletich, Structure and activation mechanism of 
the CHK2 DNA damage checkpoint kinase. Molecular cell, 2009. 35(6): p. 818-
29. 
234. Lukas, C., et al., Distinct spatiotemporal dynamics of mammalian checkpoint 
regulators induced by DNA damage. Nature cell biology, 2003. 5(3): p. 255-60. 
235. Chehab, N.H., et al., Chk2/hCds1 functions as a DNA damage checkpoint in G(1) 
by stabilizing p53. Genes & development, 2000. 14(3): p. 278-88. 
236. Chaturvedi, P., et al., Mammalian Chk2 is a downstream effector of the ATM-
dependent DNA damage checkpoint pathway. Oncogene, 1999. 18(28): p. 4047-
54. 
237. Lee, J.S., et al., The function of BRCA1 in DNA damage response. Cold Spring 
Harbor symposia on quantitative biology, 2000. 65: p. 547-52. 
238. Brown, E.J. and D. Baltimore, ATR disruption leads to chromosomal 
fragmentation and early embryonic lethality. Genes & development, 2000. 14(4): 
p. 397-402. 
239. Takai, H., et al., Aberrant cell cycle checkpoint function and early embryonic 
death in Chk1(-/-) mice. Genes & development, 2000. 14(12): p. 1439-47. 
240. O'Driscoll, M., et al., A splicing mutation affecting expression of ataxia-
telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nature 
genetics, 2003. 33(4): p. 497-501. 
241. Zou, L. and S.J. Elledge, Sensing DNA damage through ATRIP recognition of 
RPA-ssDNA complexes. Science, 2003. 300(5625): p. 1542-8. 
242. Cortez, D., et al., ATR and ATRIP: partners in checkpoint signaling. Science, 
2001. 294(5547): p. 1713-6. 
243. Yang, X.H. and L. Zou, Recruitment of ATR-ATRIP, Rad17, and 9-1-1 complexes 
to DNA damage. Methods in enzymology, 2006. 409: p. 118-31. 
REFERENCES 
 
 
 
118 
 
244. Lee, J., A. Kumagai, and W.G. Dunphy, The Rad9-Hus1-Rad1 checkpoint clamp 
regulates interaction of TopBP1 with ATR. The Journal of biological chemistry, 
2007. 282(38): p. 28036-44. 
245. Kumagai, A., et al., TopBP1 activates the ATR-ATRIP complex. Cell, 2006. 
124(5): p. 943-55. 
246. Kondratov, R.V., V.Y. Gorbacheva, and M.P. Antoch, The role of mammalian 
circadian proteins in normal physiology and genotoxic stress responses. Current 
topics in developmental biology, 2007. 78: p. 173-216. 
247. Liu, S., et al., Claspin operates downstream of TopBP1 to direct ATR signaling 
towards Chk1 activation. Molecular and cellular biology, 2006. 26(16): p. 6056-64. 
248. Jeong, S.Y., et al., Phosphorylated claspin interacts with a phosphate-binding site 
in the kinase domain of Chk1 during ATR-mediated activation. The Journal of 
biological chemistry, 2003. 278(47): p. 46782-8. 
249. Falck, J., et al., The DNA damage-dependent intra-S phase checkpoint is 
regulated by parallel pathways. Nature genetics, 2002. 30(3): p. 290-4. 
250. Blasina, A., et al., A human homologue of the checkpoint kinase Cds1 directly 
inhibits Cdc25 phosphatase. Current biology : CB, 1999. 9(1): p. 1-10. 
251. Shechter, D., V. Costanzo, and J. Gautier, ATR and ATM regulate the timing of 
DNA replication origin firing. Nature cell biology, 2004. 6(7): p. 648-55. 
252. Cha, R.S. and N. Kleckner, ATR homolog Mec1 promotes fork progression, thus 
averting breaks in replication slow zones. Science, 2002. 297(5581): p. 602-6. 
253. Friedel, A.M., B.L. Pike, and S.M. Gasser, ATR/Mec1: coordinating fork stability 
and repair. Current opinion in cell biology, 2009. 21(2): p. 237-44. 
254. Hurley, P.J. and F. Bunz, ATM and ATR: components of an integrated circuit. Cell 
cycle, 2007. 6(4): p. 414-7. 
255. Yoo, H.Y., et al., Ataxia-telangiectasia mutated (ATM)-dependent activation of 
ATR occurs through phosphorylation of TopBP1 by ATM. The Journal of 
biological chemistry, 2007. 282(24): p. 17501-6. 
256. Stiff, T., et al., ATR-dependent phosphorylation and activation of ATM in 
response to UV treatment or replication fork stalling. The EMBO journal, 2006. 
25(24): p. 5775-82. 
257. Guardavaccaro, D. and M. Pagano, Stabilizers and destabilizers controlling cell 
cycle oscillators. Molecular cell, 2006. 22(1): p. 1-4. 
258. Xiao, Z., et al., Chk1 mediates S and G2 arrests through Cdc25A degradation in 
response to DNA-damaging agents. The Journal of biological chemistry, 2003. 
278(24): p. 21767-73. 
259. Richter, A., B. Otto, and R. Knippers, Replication of SV40 chromatin in extracts 
from eggs of Xenopus laevis. Nucleic acids research, 1981. 9(15): p. 3793-807. 
260. Riedel, H.D., et al., Circular single stranded phage M13-DNA as a template for 
DNA synthesis in protein extracts from Xenopus laevis eggs: evidence for a 
eukaryotic DNA priming activity. Nucleic acids research, 1982. 10(18): p. 5621-
35. 
261. Lohka, M.J. and Y. Masui, Formation in vitro of sperm pronuclei and mitotic 
chromosomes induced by amphibian ooplasmic components. Science, 1983. 
220(4598): p. 719-21. 
262. Lohka, M.J. and Y. Masui, Roles of cytosol and cytoplasmic particles in nuclear 
envelope assembly and sperm pronuclear formation in cell-free preparations from 
amphibian eggs. The Journal of cell biology, 1984. 98(4): p. 1222-30. 
REFERENCES 
 
 
 
119 
 
263. Blow, J.J. and R.A. Laskey, Initiation of DNA replication in nuclei and purified 
DNA by a cell-free extract of Xenopus eggs. Cell, 1986. 47(4): p. 577-87. 
264. Brooks, P., et al., Mismatch repair involving localized DNA synthesis in extracts of 
Xenopus eggs. Proceedings of the National Academy of Sciences of the United 
States of America, 1989. 86(12): p. 4425-9. 
265. Pfeiffer, P. and W. Vielmetter, Joining of nonhomologous DNA double strand 
breaks in vitro. Nucleic acids research, 1988. 16(3): p. 907-24. 
266. Matsumoto, Y. and D.F. Bogenhagen, Repair of a synthetic abasic site in DNA in 
a Xenopus laevis oocyte extract. Molecular and cellular biology, 1989. 9(9): p. 
3750-7. 
267. Ferrell, J.E., Jr., Xenopus oocyte maturation: new lessons from a good egg. 
BioEssays : news and reviews in molecular, cellular and developmental biology, 
1999. 21(10): p. 833-42. 
268. Arias, E.E. and J.C. Walter, Initiation of DNA replication in Xenopus egg extracts. 
Frontiers in bioscience : a journal and virtual library, 2004. 9: p. 3029-45. 
269. Murray, A.W., Cell cycle extracts. Methods in cell biology, 1991. 36: p. 581-605. 
270. Smythe, C. and J.W. Newport, Systems for the study of nuclear assembly, DNA 
replication, and nuclear breakdown in Xenopus laevis egg extracts. Methods in 
cell biology, 1991. 35: p. 449-68. 
271. Lindsay, H.D., M.J. Whitaker, and C.C. Ford, Calcium requirements during mitotic 
cdc2 kinase activation and cyclin degradation in Xenopus egg extracts. Journal of 
cell science, 1995. 108 ( Pt 11): p. 3557-68. 
272. Hyrien, O. and M. Mechali, Plasmid replication in Xenopus eggs and egg extracts: 
a 2D gel electrophoretic analysis. Nucleic acids research, 1992. 20(7): p. 1463-9. 
273. Mahbubani, H.M., et al., DNA replication initiates at multiple sites on plasmid DNA 
in Xenopus egg extracts. Nucleic acids research, 1992. 20(7): p. 1457-62. 
274. Arias, E.E. and J.C. Walter, Replication-dependent destruction of Cdt1 limits DNA 
replication to a single round per cell cycle in Xenopus egg extracts. Genes & 
development, 2005. 19(1): p. 114-26. 
275. Walter, J., L. Sun, and J. Newport, Regulated chromosomal DNA replication in 
the absence of a nucleus. Molecular cell, 1998. 1(4): p. 519-29. 
276. Lebofsky, R., T. Takahashi, and J.C. Walter, DNA replication in nucleus-free 
Xenopus egg extracts. Methods in molecular biology, 2009. 521: p. 229-52. 
277. Pacek, M. and J.C. Walter, A requirement for MCM7 and Cdc45 in chromosome 
unwinding during eukaryotic DNA replication. The EMBO journal, 2004. 23(18): p. 
3667-76. 
278. Errico, A., et al., Tipin/Tim1/And1 protein complex promotes Pol alpha chromatin 
binding and sister chromatid cohesion. The EMBO journal, 2009. 28(23): p. 3681-
92. 
279. Kumagai, A., A. Shevchenko, and W.G. Dunphy, Direct regulation of Treslin by 
cyclin-dependent kinase is essential for the onset of DNA replication. The Journal 
of cell biology, 2011. 193(6): p. 995-1007. 
280. Hashimoto, Y., F. Puddu, and V. Costanzo, RAD51- and MRE11-dependent 
reassembly of uncoupled CMG helicase complex at collapsed replication forks. 
Nature structural & molecular biology, 2012. 19(1): p. 17-24. 
281. Costanzo, V., Brca2, Rad51 and Mre11: performing balancing acts on replication 
forks. DNA repair, 2011. 10(10): p. 1060-5. 
REFERENCES 
 
 
 
120 
 
282. Hashimoto, Y., et al., Rad51 protects nascent DNA from Mre11-dependent 
degradation and promotes continuous DNA synthesis. Nature structural & 
molecular biology, 2010. 17(11): p. 1305-11. 
283. You, Z., et al., CtIP links DNA double-strand break sensing to resection. 
Molecular cell, 2009. 36(6): p. 954-69. 
284. Raschle, M., et al., Mechanism of replication-coupled DNA interstrand crosslink 
repair. Cell, 2008. 134(6): p. 969-80. 
285. Long, D.T., et al., Mechanism of RAD51-dependent DNA interstrand cross-link 
repair. Science, 2011. 333(6038): p. 84-7. 
286. Sobeck, A., et al., Fanconi anemia proteins are required to prevent accumulation 
of replication-associated DNA double-strand breaks. Molecular and cellular 
biology, 2006. 26(2): p. 425-37. 
287. Lupardus, P.J., C. Van, and K.A. Cimprich, Analyzing the ATR-mediated 
checkpoint using Xenopus egg extracts. Methods, 2007. 41(2): p. 222-31. 
288. Lee, J. and W.G. Dunphy, Rad17 plays a central role in establishment of the 
interaction between TopBP1 and the Rad9-Hus1-Rad1 complex at stalled 
replication forks. Molecular biology of the cell, 2010. 21(6): p. 926-35. 
289. Costanzo, V. and J. Gautier, Single-strand DNA gaps trigger an ATR- and Cdc7-
dependent checkpoint. Cell cycle, 2003. 2(1): p. 17. 
290. Costanzo, V., et al., An ATR- and Cdc7-dependent DNA damage checkpoint that 
inhibits initiation of DNA replication. Molecular cell, 2003. 11(1): p. 203-13. 
291. Kunkel, T.A. and D.A. Erie, DNA mismatch repair. Annual review of biochemistry, 
2005. 74: p. 681-710. 
292. Palombo, F., et al., GTBP, a 160-kilodalton protein essential for mismatch-binding 
activity in human cells. Science, 1995. 268(5219): p. 1912-4. 
293. Genschel, J., et al., Isolation of MutSbeta from human cells and comparison of 
the mismatch repair specificities of MutSbeta and MutSalpha. The Journal of 
biological chemistry, 1998. 273(31): p. 19895-901. 
294. Fang, W.H. and P. Modrich, Human strand-specific mismatch repair occurs by a 
bidirectional mechanism similar to that of the bacterial reaction. The Journal of 
biological chemistry, 1993. 268(16): p. 11838-44. 
295. Jiricny, J., MutLalpha: at the cutting edge of mismatch repair. Cell, 2006. 126(2): 
p. 239-41. 
296. Adamson, A.W., et al., Methylator-induced, mismatch repair-dependent G2 arrest 
is activated through Chk1 and Chk2. Molecular biology of the cell, 2005. 16(3): p. 
1513-26. 
297. Stojic, L., R. Brun, and J. Jiricny, Mismatch repair and DNA damage signalling. 
DNA repair, 2004. 3(8-9): p. 1091-101. 
298. Pieper, R.O., Understanding and manipulating O6-methylguanine-DNA 
methyltransferase expression. Pharmacology & therapeutics, 1997. 74(3): p. 285-
97. 
299. Aquilina, G., M. Crescenzi, and M. Bignami, Mismatch repair, G(2)/M cell cycle 
arrest and lethality after DNA damage. Carcinogenesis, 1999. 20(12): p. 2317-26. 
300. Caporali, S., et al., DNA damage induced by temozolomide signals to both ATM 
and ATR: role of the mismatch repair system. Molecular pharmacology, 2004. 
66(3): p. 478-91. 
301. Hawn, M.T., et al., Evidence for a connection between the mismatch repair 
system and the G2 cell cycle checkpoint. Cancer research, 1995. 55(17): p. 3721-
5. 
REFERENCES 
 
 
 
121 
 
302. Berardini, M., A. Mazurek, and R. Fishel, The effect of O6-methylguanine DNA 
adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and 
hMSH2-hMSH3. The Journal of biological chemistry, 2000. 275(36): p. 27851-7. 
303. York, S.J. and P. Modrich, Mismatch repair-dependent iterative excision at 
irreparable O6-methylguanine lesions in human nuclear extracts. The Journal of 
biological chemistry, 2006. 281(32): p. 22674-83. 
304. Bellacosa, A., Functional interactions and signaling properties of mammalian 
DNA mismatch repair proteins. Cell death and differentiation, 2001. 8(11): p. 
1076-92. 
305. Fishel, R., Mismatch repair, molecular switches, and signal transduction. Genes & 
development, 1998. 12(14): p. 2096-101. 
306. Yang, J., et al., ATM and ATR: sensing DNA damage. World journal of 
gastroenterology : WJG, 2004. 10(2): p. 155-60. 
307. Yoshioka, K., Y. Yoshioka, and P. Hsieh, ATR kinase activation mediated by 
MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. 
Molecular cell, 2006. 22(4): p. 501-10. 
308. Liu, Y., et al., Interactions of human mismatch repair proteins MutSalpha and 
MutLalpha with proteins of the ATR-Chk1 pathway. The Journal of biological 
chemistry, 2010. 285(8): p. 5974-82. 
309. Pabla, N., et al., hMSH2 recruits ATR to DNA damage sites for activation during 
DNA damage-induced apoptosis. The Journal of biological chemistry, 2011. 
286(12): p. 10411-8. 
310. Zlatanou, A., et al., The hMsh2-hMsh6 complex acts in concert with 
monoubiquitinated PCNA and Pol eta in response to oxidative DNA damage in 
human cells. Molecular cell, 2011. 43(4): p. 649-62. 
311. Pena-Diaz, J., et al., Noncanonical mismatch repair as a source of genomic 
instability in human cells. Molecular cell, 2012. 47(5): p. 669-80. 
312. Hashimoto, Y. and V. Costanzo, Studying DNA replication fork stability in 
Xenopus egg extract. Methods in molecular biology, 2011. 745: p. 437-45. 
313. Hombauer, H., et al., Visualization of eukaryotic DNA mismatch repair reveals 
distinct recognition and repair intermediates. Cell, 2011. 147(5): p. 1040-53. 
314. Siehler, S.Y., et al., Human MutL-complexes monitor homologous recombination 
independently of mismatch repair. DNA repair, 2009. 8(2): p. 242-52. 
315. Schmitt, A.M., et al., p50 (NF-kappaB1) is an effector protein in the cytotoxic 
response to DNA methylation damage. Molecular cell, 2011. 44(5): p. 785-96. 
316. Baerenfaller, K., F. Fischer, and J. Jiricny, Characterization of the "mismatch 
repairosome" and its role in the processing of modified nucleosides in vitro. 
Methods in enzymology, 2006. 408: p. 285-303. 
317. Varlet, I., M. Radman, and P. Brooks, DNA mismatch repair in Xenopus egg 
extracts: repair efficiency and DNA repair synthesis for all single base-pair 
mismatches. Proceedings of the National Academy of Sciences of the United 
States of America, 1990. 87(20): p. 7883-7. 
318. Chong, J.P., et al., Characterization of the Xenopus replication licensing system. 
Methods in enzymology, 1997. 283: p. 549-64. 
319. Kubota, Y. and H. Takisawa, Determination of initiation of DNA replication before 
and after nuclear formation in Xenopus egg cell free extracts. The Journal of cell 
biology, 1993. 123(6 Pt 1): p. 1321-31. 
320. Drummond, J.T., et al., DHFR/MSH3 amplification in methotrexate-resistant cells 
alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base 
REFERENCES 
 
 
 
122 
 
mismatch repair. Proceedings of the National Academy of Sciences of the United 
States of America, 1997. 94(19): p. 10144-9. 
321. Palombo, F., et al., hMutSbeta, a heterodimer of hMSH2 and hMSH3, binds to 
insertion/deletion loops in DNA. Current biology : CB, 1996. 6(9): p. 1181-4. 
322. Umar, A., et al., Functional overlap in mismatch repair by human MSH3 and 
MSH6. Genetics, 1998. 148(4): p. 1637-46. 
323. Lettieri, T., et al., Effect of hMSH6 cDNA expression on the phenotype of 
mismatch repair-deficient colon cancer cell line HCT15. Carcinogenesis, 1999. 
20(3): p. 373-82. 
324. Noonan, E.M., et al., O6-Methylguanine DNA lesions induce an intra-S-phase 
arrest from which cells exit into apoptosis governed by early and late multi-
pathway signaling network activation. Integrative biology : quantitative 
biosciences from nano to macro, 2012. 4(10): p. 1237-55. 
325. Neelsen, K.J., et al., Oncogenes induce genotoxic stress by mitotic processing of 
unusual replication intermediates. The Journal of cell biology, 2013. 200(6): p. 
699-708. 
326. Follonier, C., et al., Friedreich's ataxia-associated GAA repeats induce 
replication-fork reversal and unusual molecular junctions. Nature structural & 
molecular biology, 2013. 20(4): p. 486-94. 
327. Ray Chaudhuri, A., et al., Topoisomerase I poisoning results in PARP-mediated 
replication fork reversal. Nature structural & molecular biology, 2012. 19(4): p. 
417-23. 
328. Pena-Diaz, J. and J. Jiricny, Mammalian mismatch repair: error-free or error-
prone? Trends in biochemical sciences, 2012. 37(5): p. 206-14. 
329. Klapacz, J., et al., O6-methylguanine-induced cell death involves exonuclease 1 
as well as DNA mismatch recognition in vivo. Proceedings of the National 
Academy of Sciences of the United States of America, 2009. 106(2): p. 576-81. 
330. Iaccarino, I., et al., Mutation in the magnesium binding site of hMSH6 disables the 
hMutSalpha sliding clamp from translocating along DNA. The Journal of biological 
chemistry, 2000. 275(3): p. 2080-6. 
331. Szadkowski, M., et al., Characterization of the mismatch repair defect in the 
human lymphoblastoid MT1 cells. Cancer research, 2005. 65(11): p. 4525-9. 
332. Takahashi, M., et al., MSH3 mediates sensitization of colorectal cancer cells to 
cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. The Journal of 
biological chemistry, 2011. 286(14): p. 12157-65. 
333. Pepponi, R., et al., hMSH3 overexpression and cellular response to cytotoxic 
anticancer agents. Carcinogenesis, 2001. 22(8): p. 1131-7. 
334. Gupta, S., M. Gellert, and W. Yang, Mechanism of mismatch recognition revealed 
by human MutSbeta bound to unpaired DNA loops. Nature structural & molecular 
biology, 2012. 19(1): p. 72-8. 
335. Dowen, J.M., C.D. Putnam, and R.D. Kolodner, Functional studies and homology 
modeling of Msh2-Msh3 predict that mispair recognition involves DNA bending 
and strand separation. Molecular and cellular biology, 2010. 30(13): p. 3321-8. 
336. Owen, B.A., H.L. W, and C.T. McMurray, The nucleotide binding dynamics of 
human MSH2-MSH3 are lesion dependent. Nature structural & molecular biology, 
2009. 16(5): p. 550-7. 
 
 
  
ACKNOWLEDGEMENTS 
 
 
 
123 
 
9 Acknowledgements 
This is a refrain of a Nat King Cole song which, like many of the people mentioned in my 
words of thanks, accompanies me whenever a sturdy experiment didn't work as you 
expected it to and you just need to keep going: 
 
Smile though your heart is aching  
Smile even though it's breaking  
When there are clouds in the sky, you'll get by  
If you smile through your fear and sorrow  
Smile and maybe tomorrow  
You'll see the sun come shining through for you 
 
First and foremost I would like to thank my PhD supervisor Prof. Josef Jiricny with 
heartfelt sincerity. I am extremely grateful for the constructive and encouraging learning 
environment which he provided during these past few years and believe that it has 
allowed me to understand and conduct scientific endeavours as well as provided me with 
fond memories of  the laboratory and the IMCR. I couldn't have picked a better boss for 
carrying out my PhD. 
I would also like to thank my committee members for their supportive guidance 
throughout my degree. Prof. Ulrike Kutay has been instrumental in my academic 
development and has challenged my understanding of my PhD project. Dr. Vincenzo 
Costanzo has always been very enthusiastic about my work and he has continuously 
provided a supportive voice for the project and even invited me to stay in his lab to learn 
more about the Xenopus egg extract technique. 
I owe particular thanks to all past and present members of the lab for making it a friendly 
and supportive environment to work in. In particular, Medini Ghodgaonkar, Stephanie 
Felscher, Mariela Artola, Svenja Kaden, Katja Kratz, Anja Saxer, Javier Pena Diaz and 
Milica Eniou for answering any questions I had and for providing exciting scientific 
exchanges.  
A collective thank you to so many other members of the IMCR who have also provided 
helpful suggestions and support in any way they could. Here, Arnab Chaudhuri deserves 
special thanks for always being open to suggestions and questions. 
ACKNOWLEDGEMENTS 
 
 
 
124 
 
Many thanks also to Odete Pereira for helping take care of the frogs in our facility which 
provides the eggs with which I work with. She is such a curious and observative person, I 
was lucky to have her around. 
Last but not least I am thankful to my father for introducing me to my love of learning, I 
dont think I've ever seen him without a book in his hand, writing an article or assay or 
pondering about life.  
I am also thankful for Justin Harris for  always being there for me and providing me with 
nutritious meals throught my PhD, my brother for being so insightful about life and my 
family for providing me with love and support even from far away. I don't say it often 
enough, or probably ever, but you have been missed all these years. 
I would never have known where I would end up after getting on the plane to Duesselforf 
more than 10 years ago and I am extremely grateful for the adding up of fateful decisions 
that have carried me through some of the most exciting years of my life, both personally 
and professionally. 
  
CURRICULUM VITAE 
 
 
 
125 
 
10 Curriculum vitae 
 
Curriculum Vitae Maite Olivera Harris 
 
 
RESEARCH INTERESTS 
 
DNA repair, DNA replication, Epigenetics  
 
EDUCATION & EMPLOYMENT 
 
June 2009 – Present 
PhD student, group Prof. Dr. Josef Jiricny, Institute of Molecular Cancer 
Research, University of Zurich, Switzerland. 
Research interest: DNA repair, Mismatch repair 
Thesis: Mismatch repair dependent processing of O6-methylguanine 
adducts in replicating Xenopus egg extracts. 
 
August 2008 – January 2009 
Practical training at the German Cancer Research Centre in the 
laboratory of Prof. Angel (Div. Signal-transduction) 
 
October 2002 – May 2008 
Diplom-degree in Biology at the Westfaelische Wilhelms Universitaet 
Muenster. 
Thesis: Identification of chromatin-modification factors and genes that 
play a role in the non-small-cell lung cancer metastasis process using 
ChIP-chip 
 
October 2001 – August 2002 
Studienkolleg for foreigners in Muenster, Germany  
 
January 2001 – June 2001 
Goethe Institute for the German Language in Lima, Peru 
 
1996-2000 
High school at the Colegio Peruano Britanico (Peruvian british school) in 
Lima, Peru 
 
1993-1995 
Primary at the Colegio Peruano Britanico (Peruvian british school) in 
Lima, Peru 
 
1990-1992 
Primary at Priory Infant School in Cambridge, England  
  
 
 
 
PERSONAL 
INFORMATION 
Date of Birth: 
31.01.1984  
Nationality: Peruvian  
Marital status: Married 
 
CONTACT 
INFORMATION 
Private address: 
Weinbergstrasse 68  
CH-8006, Zurich, 
Switzerland  
Tel: (+41) 789 366991 
 
Work address: 
Institute of Molecular 
Cancer Research (IMCR) 
University of Zurich 
WInterthurerstrasse 190 
CH-8057 Zurich, 
Switzerland 
Tel: (+41) 44 635 34 80 
 
REFEREES 
Prof. Dr. Josef Jiricny 
Ph. (+41) 44 635 34 50 
jiricny@imcr.uzh.ch 
 
Prof. Dr. med Carsten 
Mueller-Tidow 
Ph. (+49) 251 835 2995  
muellerc@uni-
muenster.de 
Maite Olivera Harris -- Curriculum Vitae -- 2013 
CURRICULUM VITAE 
 
 
 
126 
 
  
SCIENTIFIC EXPERTISE 
 
 Cell biology (mammalian): 
Culture and maintenance of primary and non-primary cell lines (cancerous and non-cancerous), 
experience in establishing cell lines stably expressing proteins of interest, expertise in cell 
transfection methods (including delivery of siRNAs as well as plasmids). 
 
Biochemistry: 
Profound knowledge in expression and purification of recombinant proteins (bacterial and 
mammalian expression systems), antibody purification, in vitro repair assay using heteroduplexes 
(for MMR), dot blot assays, EMSA, primer extension assays, and western blotting techniques. 
Profound knowledge of preparation and experiments done with Xenopus egg extracts.  
 
Molecular biology: 
General cloning techniques (including Gateway® cloning), site directed mutagenesis, quantitative 
RT-PCR. 
 
Transferable skills:  
Project development, organization and timely execution of projects to meet deadlines, acquisition of 
new knowledge (theoretical and technical know-how), scientific communications including Grant 
applications, presentations and scientific writing, training and supervision of team members 
(undergraduate students) 
Language skills: Spanish (mother tongue), English (native level); German (fluent); French 
(Elementary, spoken) 
 
Software/Statistical Analysis: 
Microsoft Office (Word, Excel, Power Point), DNA and protein sequence analysis (Mac Vector, 
Fasta, ClustalW), digital image processing (Photoshop, Adobe Illustrator), and statistical data 
analysis: Prism GraphPad, Endnote. 
 
GRANTS 
 
Research Grant (2010-2011): URPP Research Project Grant, University of Zurich 
(Project: Systems biology of MMR: characterization of the mismatch repair interactome).  
 
 PUBLICATIONS 
  
Maite Olivera Harris, Mariela Artola Boran, Vincenzo Costanzo, Milica Eniou and Josef Jiricny:   
Mismatch repair dependent processing of O6-methylguanine adducts in Xenopus egg extracts. 
(Manuscript in preparation)  
 
 Ghodgaonkar M.M., Olivera-Pimentel M., Artola- Borán M., Muzi-Falconi M., Cejka P., Reijns M., 
Jackson A. and Jiricny J.: Ribonucleotides in DNA can act as strand-discrimination signals during 
human mismatch repair in vitro, Mol Cell. 2013 Apr 16 
 
HOBBIES AND INTERESTS 
 
Reading fiction, historical fiction and science-fiction, movies, documentaries, competitive dance 
